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Abstract 
Survival for patients with advanced cancer has remained dismal, and there is a need for new 
treatments. In this context viral immune therapy is a promising novel strategy. Intravenous delivery 
confers advantages as it enables simultaneous treatment of primary tumour and any metastatic 
deposits but host defences limit Vaccinia virus’s (VV) ability to infect tumour after systemic 
administration.  Although Vaccinia virus can potentially be delivered systemically as it can evade 
both complement and neutralising antibodies, our investigations have revealed that VV cannot 
effectively infect tumour cells in immunocompetent mice after systemic delivery.  Strikingly, we 
observed that if macrophages were depleted in the mice using clodronate liposomes, VV infection of 
tumours was dramatically enhanced.  However, clodronate liposomes non-selectively deplete 
macrophages and potentially diminish any beneficial macrocytic activity in the tumour 
microenvironment unrelated to viral clearance. Consequently, a more clinically appropriate agent is 
needed.  
  
Macrophages recognise and ingest pathogenic microorganisms through phagocytosis, a process for 
which several lines of evidence have highlighted an important role for phosphatidylinositol 3-
kinases. Accordingly, in these investigations I have evaluated the effect of selective PI3K inhibitors 
on macrophage phagocytosis in vitro and demonstrated that IC87114 (a PI3 kinase delta inhibitor) is 
effective at reducing uptake of VV by macrophages, confirming this finding in transgenic 
macrophages with a mutant of the PI3 kinase delta isoform knocked in.  Subsequently, it was 
confirmed that IC87114 affects attachment of the virus to macrophages but plays no role in 
internalisation of the virus. In cancer cells cultured in isolation, the inhibitor has no direct cytotoxic 
effect and when combined with VV, in the same in vitro system, there is no change in the amount of 
cell death compared to VV alone treated controls.  Biodistribution studies have established that 
IC87114 combined with VV results in statistically significantly higher levels of virus detected in 
tumours compared to the groups treated with VV alone, with similarly limited off-target effects.  
Finally, three different efficacy studies have demonstrated statistically significantly superior tumour 
responses in the VV+IC87114 group. 
 
In conclusion, PI3k delta blockade is an effective strategy for enhancing systemic delivery of VV in a 
preclinical model and could be a useful adjuvant in VV clinical trials. 
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Chapter 1 
Introduction 
1.1. Background 
 
Cancer remains a major health problem and is the 5th leading cause of death worldwide [1]. There 
have been many advances in the last few decades both in surgical care and chemoradiotherapy 
regimes. Certainly this has contributed to improved survival rates for commonly occurring cancers.  
However, relapse and disease progression are still all too common occurrences in modern medical 
practice. A variety of novel adjuvant therapies have been developed over the last decade, and 
oncolytic viruses have been particularly promising members of this cohort.   
 
For longer than a century now there has been an anecdotal link between cancer regression and viral 
infection.   This was first reported by Dock et al. in 1904 [2] who observed that a patient with 
leukaemia had spontaneous regression of their disease after co-incidental infection with influenza.  
DePace also observed this phenomenon in 1912 in the context of a patient who had advanced 
cervical cancer who underwent a significant regression of her disease after receiving the live 
attenuated rabies immunisation [3].    There has been a succession of further reports detailing 
regression of mainly haematopoietic malignancies after infection with common viruses from the 
1950's onwards [4-9].  These observations formed the basis of several clinical experiments that were 
undertaken during this period [10-13].  These are not trials recognisable by modern standards as 
there were incomplete datasets and poorly defined endpoints with no generally agreed tumour 
response assessments.  Amongst the viruses investigated at this time were Adenovirus [11], West 
Nile Virus [13], Mumps [10], and (most disastrously) Hepatitis B virus [12].  The results from these 
studies were disappointing and as a result oncolytic viral therapy remained a medical curio until the 
advent of modern genetic engineering in the late 1980's.   
 
In this era, naturally occurring oncolytic viruses were identified such as Vaccinia virus (VV), Reovirus, 
and Newcastle disease virus.  These viruses preferentially infect tumour cells whilst sparing normal 
tissue.  However, with the newly available molecular techniques, other viruses that were not 
naturally oncotropic could be engineered to be so.  These included Herpes Simplex virus type 1 and 
Adenovirus, both of which were attenuated so that they infected tumour cells but not normal tissue 
[14].  In the case of Herpes Simplex virus type 1 this was achieved by the deletion of two of its 
latency genes, ICP0 & ICP4, and the removal of all but one of its virulence factors, with only γ134.5 
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remaining.  Additionally, its thymidine kinase gene was deleted so that the virus is only able to 
replicate efficiently in cells with up-regulation of the EGFR/Ras signalling pathway, a common 
occurrence in cancer [15, 16].  This strategy has been widely adopted for attenuating Vaccinia virus, 
as an extra level of safety, particularly in strains used, or destined, for clinical trials.  Adenovirus has 
also been used extensively in clinical trials and in this setting often the E1B 55K gene has been 
deleted to improve tumour specificity.  E1B 55K is involved in late viral RNA export and restricts E1B 
55K-deleted adenovirus replication in normal primary cells [17].  The purpose of all of these 
alterations is to make the oncolytic viruses more tumour-specific since the modifications do not 
affect the ability of the viruses to replicate in the dysregulated tumour cells whilst reducing the off-
target effects by sparing normal adjacent or distant tissue.   
 
Over the last decade a truly revolutionary development has occurred, and this is the ability to 
incorporate transgenes into oncolytic viruses.  This has made possible the expression of a range of 
exogenous agents in the tumour microenvironment raising the very real prospect of truly 
immmunomodulatory oncolytic viral therapy and now the discussion has moved onto which 
transgenes might be the most effective [18]. 
 
A range of delivery methods have been employed for these novel treatments, and chief amongst 
them has been intra-tumoural delivery. A wide selection of oncolytic viruses have been delivered via 
intra-tumoural injection with a measure of success in treating easily reachable solid tumours [19, 
20].   However, death from cancer is often the result of inaccessible or metastatic disease.  In this 
context, oncolytic viruses delivered intra-tumourally rely on viral replication at the tumour site and 
then systemic dissemination to the distant sites. However, this is transient and often ineffective due 
to the development of immune responses to the viral infection. 
 
Systemic delivery of oncolytic viruses (OV) affords the opportunity to treat both the primary tumour 
and any overt or undiagnosed metastatic deposits simultaneously. As a result this method of 
delivery is a very attractive option for the treatment of patients with advanced/metastatic disease or 
patients with inaccessible disease such as those with pancreatic or brain cancer due to physiological 
barriers, such as the blood-brain barrier. 
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1.2. Clinical Trials 
 
There have been many clinical trials of a variety of OV delivered systemically, as summarised in Table 
1.1.  Oncolytic Adenovirus was one of the first oncolytic viruses to be developed and licensed for 
treatment of cancer [20, 21]. The first generation of oncolytic adenovirus, ONYX-015  
(also known as dl1520, H101 in China), is a genetically modified Adenovirus with deletion of the 
55kD gene in the E1B region.  Nemunaitis et al. [22] in 2001 performed a dose escalation study using 
this agent in patients with advanced carcinoma with lung metastases. They demonstrated that 
ONYX-015 was safe to deliver systemically with no toxicity up to doses of 2x1013 particles, but the 
study was not designed to assess objective tumour responses. Also commencing in 2001, a 
succession of studies delivered ONYX-015 via hepatic artery infusion for the treatment of metastatic 
colorectal carcinoma with liver deposits [23-25].  In the first of these trials, a phase I dose escalation 
study, one patient (9%) responded after combination therapy with conventional chemotherapy and 
two patients (18%) had stable disease lasting several months [23]. In a larger phase II follow up trial 
three patients (11%) had partial responses, nine (33%) had stable disease and eleven (41%) patients 
had progressive disease [24]. A final phase II trial by this group demonstrated similar results to the 
previous studies with overall median survival of 10.7 months with two patients (8%) having a partial 
response and a further eleven (46%) having stable disease [25]. Of those with stable disease the 
median survival was prolonged to nineteen months (an advance over historical controls). In a 
different study, Small et al. [26] treated patients with hormone-refractory metastatic prostate 
cancer using a single intravenous infusion.  Unlike ONYX-015, the Adenovirus (CG7870) in this trial 
was modified so that E1A was under the control of the rat probasin promoter and E1B was under the 
control of the PSA promoter-enhancer, thus making it prostate-specific. Results from this trial were 
disappointing with no complete nor partial responses, although five patients (22%) did have a 25% 
to 49% reduction in their serum PSA values.  Finally, ColoAd1 is a modified Adenovirus that is 
currently in phase I/II clinical trials (NCT02028442) but these studies are still recruiting (Table 1.2).  
 
PV701 is a naturally attenuated Newcastle disease virus, which has been used systemically in a 
number of clinical trials between 2002 and 2007 [27-30]. Three of these trials were phase I studies in 
patients with a variety of advanced/metastatic solid tumours [28, 30, 31]. In the Pecora et al. [30] 
study in 2002, 62 patients were assessed for a tumour response and two patients (3%) had a major 
response and 14 patients (23%) had stable disease for 4-30 months. Hotte et al. [28] performed a 
small phase I study and although not designed to assess efficacy, four major (22%) and two minor 
(11%) responses to the treatment were observed.  A similarly sized trial by Laurie et al. [29] in 2006 
reported stable disease in four patients (25%) for greater than six months. Freeman et al. [27]  
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Table 1.1. Completed clinical trials using systemically delivered oncolytic viruses for the treatment of solid tumours*    
Viral 
Agent 
Virus 
Species 
Modifications Cancer Type Pt No. Treatment 
Regime 
Toxicity Results References 
ONYX-
015 
Adenovirus  E1B-55kD -ve Advanced carcinoma 
with lung metastasis 
10 Phase I, dose-
escalation study 
No dose-limiting toxicity 
was observed. 
Grade 2-3 toxicities were 
common (fever, rigors & 
fatigue) 
IV administration was well tolerated up to 2x10
13 
particles. Not designed for objective tumour responses. 
Nemunaitis et al, 
2001 [22] 
ONYX-
015 
Adenovirus  E1B-55kD -ve Liver metastases from 
gastrointestinal 
carcinoma 
11 Phase I dose-
escalation study 
Hepatic artery 
infusion 
No dose-limiting toxicity.  
Commonly mild to 
moderate fever, rigors 
and fatigue. 
Objective response with chemotherapy + virus in a 
patient who was refractory to both 5-FU and ONYX-015 
as single agents.  2 high dose patients had stable disease 
on combination therapy lasting from 7 to 17 months. 
Reid et al, 2001 [23] 
ONYX-
015 
Adenovirus  E1B-55kD -ve Metastatic liver 
deposits from 
gastrointestinal 
primaries 
27 Phase II 
Hepatic artery 
infusion in 
combination with 
5 FU and 
leucovorin 
2 patients had reversible 
grade 3/4 
hyperbilirubinemia  
1 patient had a reversible 
severe systemic 
inflammatory response 
3 patients with partial responses, 4 with minimal 
responses, 9 with stable disease and 11 with progressive 
disease.  Unclear from this study whether observed 
responses were due to viral treatment or chemotherapy 
or combination. 
Reid et al, 2002 [24] 
ONYX-
015 
Adenovirus  E1B-55kD -ve Metastatic colorectal 
cancer refractory to 
conventional therapy 
24 Phase I/II 
Hepatic artery 
infusion 
No dose-limiting toxicity 
was observed. 
 
Overall median survival 10.7 months. 2 patients had 
partial responses (tumur vol reductions of 66% & 72%).  
11 patients had stable disease after viral treatment and 
median survival in this group was 19 months.   
Reid et al, 2005 [25] 
CG7870 Adenovirus E1A under control 
of the rat 
probasin 
promoter 
E1B under control 
of the PSA 
promoter-
enhancer 
Hormone-refractory 
metastatic prostate 
cancer 
23 Phase I - single 
intravenous 
infusion 
Mostly grade 1 or 2 flulike 
symptoms were 
observed.  
There were 8 grade 3 
events (fever or fatigue).    
At higher doses 
asymptomatic grade 1 or 
2 transaminitis were 
reported. 
No partial or complete tumour responses were 
observed.  5 patients had a decrease in serum PSA of 
25% to 49% following a single treatment. 
Small et al, 2006 [26] 
PV701 Newcastle 
disease 
virus 
Naturally 
attenuated 
Advanced or 
metastatic solid 
cancers that were 
refractory to standard 
treatment 
79 Patients were 
recruited into 4 
different IV 
dosing regimes 
Grade 3 fever in 11% 
Flu like symptoms 
 
 
 
 
62 patients assessed for response, 2 major responses, 14 
had no disease progression for 4-30 months. 
Pecora et al, 2002 
[30] 
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PV701 Newcastle 
disease 
virus 
Naturally 
attenuated 
Pallitive solid tumors 16 Phase 1 No dose-limiting 
toxicities.  Mild flu-like 
symptoms were common 
Four patients had stable disease for ≥6 months. Laurie et al, 2006 [29] 
 
NDV-
HUJ 
Newcastle 
disease 
virus 
Naturally 
attenuated 
Recurrent 
glioblastoma 
multiforme 
14 Phase I/II 5 patients had grade I/II 
constitutional fever 
One patient achieved a complete response. Freeman et al, 2006 
[27] 
PV701 Newcastle 
disease 
virus 
Naturally 
attenuated 
Advanced 
chemorefractory 
cancer 
18 Phase 1 Mild or moderate in 
severity, and self-limiting 
Not design for assessment of response but 4 major and 2 
minor tumour responses were observed 
Hotte et al, 2007 [28] 
NV1020 herpes 
simplex 
virus type 1 
ICP0 & ICP4 -ve  
Only 1 copy of 
γ134.5 
Transgene 
inserted HSV-1 TK 
gene (α4)  
Hepatic colorectal 
metastases refractory 
to first-line 
chemotherapy 
12 Phase I dose-
escalation study  
Hepatic artery 
infusion 
Mild or moderate in 
severity, and self-limiting 
Tumour response assessed at 28 days after viral delivery.  
7 patients had stable disease.  2 patients had a partial 
response (tumour vol reductions of 39% & 20%) Median 
survival for this group was 25 months. 
Kemeny et al, 2006 
[32] 
Fong et al, 2009 [33] 
NV1020 herpes 
simplex 
virus type 1 
ICP0 & ICP4 -ve  
Only 1 copy of 
γ134.5 
Transgene 
inserted HSV-1 TK 
gene (α4) 
Advanced metastatic 
colorectal  
Phase  
1 = 13 
Phase 
2 = 19 
 
 
 
Phase I/II study 
Hepatic artery 
infusion 
Treatment 
followed by  
two or more 
cycles of 
conventional 
chemotherapy  
Mild to moderate febrile 
reactions after each 
NV1020 infusion. Grade 
3/4 transient 
lymphopenia in two 
patients 
After completion of NV1020 administration, 50% 
showed stable disease.  Best overall tumor control rate 
after completion of combined therapy was 68% (1 partial 
response, 14 stable disease 
Median time to progression was 6.4 months.  Median 
overall survival was 11.8 months.  One-year survival was 
47.2%.  
Geevarghese et al, 
2010 [34] 
JX-594 Vaccinia - 
Wyeth 
TK -ve 
Transgene 
inserted in TK 
region hGM-CSF 
(pE/L) and Lac-Z 
(p7.5) 
Unresectable primary 
hepatocellular 
carcinoma 
9 Phase 2 - Pilot 
Safety Study 
IV then IT 
injection followed 
by sorafenib 
treatment  
They assert viral 
treatment  was well 
tolerated and sorafenib 
side effects were 
consistent with 
previously reported 
7  out of 9 were able to be assessed for response. Of 
these  
6 achieved necrotic responses.  
5 had  stable disease and 
1 had a partial response  
http://clinicaltrials.go
v 
Jennerex 
Biotherapeutics, Inc. 
NCT01171651 
http://www.jennerex.
com/pr_091310.html 
JX-594 Vaccinia - 
Wyeth 
TK -ve 
Transgene 
inserted in TK 
region hGM-CSF 
(pE/L) and Lac-Z 
(p7.5) 
Metastatic solid 
tumour disease which 
is refractory to 
conventional therapy 
specifically: 
Melanoma 
Lung Cancer 
RCC 
SCC of H&N 
23 Phase I Dose 
Escalation Study 
No dose-limiting 
toxicities.  Mild flu-like 
symptoms were common 
Demonstrated that at the higher doses used (1x10
7
 to 
3x10
7
 PFU/kg) JX-594 can selectively infect, replicate and 
express transgene products in target tumour tissue 
whilst sparing normal tissue. 
 
Although not designed for efficacy, one patient had 
partial response.  
http://clinicaltrials.go
v 
Jennerex 
Biotherapeutics, Inc. 
NCT00625456 
 
Breitbach et al, 2011 
[35] 
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Reolysin Reovirus - 
type 3 
Dearing 
Wild-type Advanced or 
metastatic solid 
cancers that were 
refractory to standard 
treatment 
33 Phase 1 - Dose 
Escalation study 
 
No dose-limiting toxicity 
was observed. 
Grade 1-2 toxicities were 
common (fever, fatigue & 
headache) 
Antitumor activity was observed radiologically  and by 
tumor markers. 
Vidal et al, 2008 [36] 
Reolysin  Reovirus -
type 3 
Dearing 
Wild-type Phase 1 - incurable 
relapsed/metastatic 
solid tumors who 
were eligible for 
combined 
carboplatin/paclitaxel  
Phase II - incurable or 
relapsed/metastatic 
head & neck cancer 
31 Phase I/II, open-
label trial 
Phase 1 - dose-
escalating 
systemically 
delivered Reolysin 
days 1 to 5, in 
combination with 
carboplatin/paclit
axel  
 
Phase II - 3 × 10
10
 
TCID50 dose of 
Reolysin 
No dose-limiting toxicities 
during dose-escalation 
and most toxicities were  
grade I/II 
1 patient had a complete response (3.8%) 
6 patients (23.1%) had partial response 
9 patients (34.6%) had stable disease  
8 patients (30.8%) had disease progression 
Karapanagiotou et al, 
2012 [37] 
Reolysin  Reovirus -
type 3 
Dearing 
Wild-type Metastatic  
malignant melanoma 
 
21 Phase II trial, to  
assess the 
antitumor effect 
Median number 
of cycles 
administered was 
1 (range 1–4). 
Dose was 3 × 10
10
 
TCID50 on days  
1–5 for a 4-week 
cycle 
Grade 3–4 toxicities were 
fatigue (9.5%), 
lymphopenia (9.5%), and 
hyponatremia (9.5%)  
Grade 1-2 toxicities were  
fatigue (66.7%), nausea 
(57.1%),  
fever (52.4%), and 
anaemia (42.9%) 
No objective responses  
Median time to progression and survival were 45 days 
(range 13-96 days) and 165 days 
(range 15 days-15.8 months) respectively.  
 
Galanis et al, 2012 
[38] 
SVV-001 Seneca 
Valley Virus 
-replication 
competent 
picornavirus 
Wild-type Advanced 
solid tumours with 
neuroendocrine 
features 
 
30 Phase I - Dose 
escalation study.  
5 dose cohorts 
were studied, in 
log increments 
ranging from 
10
7 
to 10
11
 
vp/kg. Single 
dose. 
 
No dose limiting toxicities 
observed in any dose 
cohort. 
All subjects demonstrated viral clearance 
In small cell carcinoma there was evidence of in vivo 
intratumoral viral replication 
1 patient, who had progressive chemorefractory small 
cell lung cancer, remained progression-free for 10 
months after SVV-001 administration 
 
Rudin et al, 2011 [39] 
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Table 1.2.  Ongoing or pending clinical trials using systemically delivered oncolytic viruses for the treatment of solid tumours*  
Viral 
Agent 
Virus Species Modifications Cancer Type Patient No. Treatment Regime Status References 
 MV-NIS Oncolytic measles 
virus - Edmonston 
vaccine strain 
Transgene: thyroidal sodium 
iodide symporter 
Recurrent or 
refractory multiple 
myeloma 
Est 54 
 
Phase I trial  
Safe & dose escalation study of vaccine therapy 
when given with or without cyclophosphamide 
Recruiting http://clinicaltrials.gov 
Mayo Clinic 
NCT00450814 
 MV-NIS Oncolytic measles 
virus - Edmonston 
vaccine strain 
Transgene: thyroidal sodium 
iodide symporter 
Recurrent or 
refractory multiple 
myeloma 
Est 12 
Primary 
completion date 
Aug 2016 
Phase II Trial  
Effectiveness of MV-MIS with cyclophosphamide 
Not yet 
open 
http://clinicaltrials.gov 
University of Arkansas 
NCT02192775 
JX-594 Vaccinia - Wyeth TK -ve 
Transgene inserted in TK 
region hGM-CSF (pE/L) and 
Lac-Z (p7.5) 
Metastatic colorectal 
carcinoma refractory 
to or intolerant of 
oxaliplatin, 
irinotecan, and 
Erbitux 
Est 15  
Enrolment closed 
June 2012 
Phase 1b Dose Escalation Study  
IV injection biweekly  
(to evaluate the safety and tolerability of JX-594) 
Unknown http://clinicaltrials.gov 
Jennerex Biotherapeutics, Inc. 
NCT01380600 
JX-594 Vaccinia - Wyeth TK -ve 
Transgene inserted in TK 
region hGM-CSF (pE/L) and 
Lac-Z (p7.5) 
Patients with 
advanced 
hepatocellular 
carcinoma who have 
failed Sorafenib 
treatment 
Est 129 
Primary 
completion date 
Oct 2013 
Phase 2b Randomized Trial of JX-594 (Vaccinia 
GM-CSF / TK-deactivated Virus) Plus Best 
Supportive Care Versus Best Supportive Care in 
Patients 
Active, not 
recruiting 
http://clinicaltrials.gov 
Jennerex Biotherapeutics, Inc. 
NCT01387555 
JX-594 Vaccinia - Wyeth TK -ve 
Transgene inserted in TK 
region hGM-CSF (pE/L) and 
Lac-Z (p7.5) 
Patients with 
metastatic/refractory 
colorectal carcinoma. 
Est 52 
Primary 
completion date 
Dec 2014 
Phase 1/2a dose-escalation study.  Multiple 
intravenous infusions alone and in combination 
with Irinotecan  
Active, not 
recruiting 
http://clinicaltrials.gov 
Jennerex Biotherapeutics, Inc. 
NCT01394939 
 
JX-594 Vaccinia - Wyeth TK -ve 
Transgene inserted in TK 
region hGM-CSF (pE/L) and 
Lac-Z (p7.5) 
Patients with 
peritoneal 
carcinomatosis of 
ovarian origin that 
are not eligible for 
curative treatments. 
Est 25 
Primary 
completion date 
June 2015 
Single-arm open-label Phase 2 study  
Patients receive 5 weekly IV infusions of JX-594 
until radiographically determined progressive 
disease.  
Not yet 
open 
http://clinicaltrials.gov 
Jennerex Biotherapeutics, Inc. 
NCT02017678 
GL-ONC1 Vaccinia - Lister Transgenes inserted in F14.5L 
(Renilla luciferase-Aequorea 
green fluorescent protein 
fusion), J2R (β-galactosidase) 
and A56R (β-glucuronidase) 
Advanced solid 
cancers 
Est 60 
Primary 
completion date 
June 2014 
Phase I Study of the Safety, Tolerability,and 
Tumor-Specific Replication of the Intravenous 
Administration GL-ONC1 
Recruiting http://clinicaltrials.gov 
Genelux Corporation 
NCT00794131 
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GL-ONC1 Vaccinia - Lister Transgenes inserted in F14.5L 
(Renilla luciferase-Aequorea 
green fluorescent protein 
fusion), J2R (β-galactosidase) 
and A56R (β-glucuronidase) 
Locoregionally 
Advanced Head and 
Neck Carcinoma 
Est 24 
Primary 
completion date 
June 2014 
Phase I study of intravenously delivered GL-
ONC1 with concurrent cisplatin and 
radiotherapy  
Recruiting http://clinicaltrials.gov 
Genelux Corporation 
NCT01584284 
Reolysin Reovirus - type 3 
Dearing 
Wild-type 
 
 
 
 
Metastatic or 
recurrent SCC of H&N 
Est 280 
Enrolment closed 
Dec 2012 
Phase 3 
IV administration in combination with paclitaxel 
and carboplatin vs. chemotherapy treatment 
alone 
Completed, 
results 
pending  
http://clinicaltrials.gov 
Oncolytics Biotech 
NCT01166542 
Reolysin Reovirus - type 3 
Dearing 
Wild-type Recurrent or 
persistent ovarian, 
fallopian Tube or 
primary peritoneal 
cancer 
Est 110  
 
Phase II 
Weekly Paclitaxel Versus Weekly Paclitaxel With 
IV  Reovirus 
Recruiting http://clinicaltrials.gov 
Gynecologic Oncology Group 
NCT01199263 
Reolysin Reovirus - type 3 
Dearing 
Wild-type Recurrent or 
metastatic pancreatic 
cancer 
Est 70  
Enrolment closed 
December 2013 
Phase II 
Carboplatin, Paclitaxel Plus Reovirus vs. 
Carboplatin and Paclitaxel  
Active, not 
recruiting  
http://clinicaltrials.gov 
Arthur G. James Cancer Hospital & 
Richard J. Solove Research Institute 
NCT01280058 
Reolysin Reovirus - type 3 
Dearing 
Wild-type Patients with bone 
and soft tissue 
sarcomas metastatic 
to the lung 
Est 53 
Study completed 
April 2011 
 
Phase 2 study -  intravenous Reolysin  Completed, 
results 
pending 
http://clinicaltrials.gov 
Oncolytics Biotech 
NCT00503295 
Reolysin Reovirus - type 3 
Dearing 
Wild-type Patients with KRAS 
mutant metastatic 
colorectal cancer 
Est 20 
Primary 
completion date 
June 2015 
Multicenter Phase 1 intravenous Reolysin in 
Combination with 
Irinotecan/Fluorouracil/Leucovorin and 
Bevacizumab  
Recruiting http://clinicaltrials.gov 
Oncolytics Biotech 
NCT01274624 
Reolysin Reovirus - type 3 
Dearing 
Wild-type Patients with 
metastatic melanoma 
Est 43 
Primary 
completion date 
June 2013 
Phase 2 study -  intravenous Reolysin in 
combination with paclitaxel and carboplatin  
Active, not 
recruiting 
http://clinicaltrials.gov 
Oncolytics Biotech 
NCT00984464 
ColoAd1 Adenovirus Composite of Ad11p 
(subgroup B2) with part of its 
E2B region (pTP and DNA 
pol) from the E2B domain of 
Ad3 (subgroup B1). 
Also has a deletion in both 
the E3 and E4 regions. 
Metastatic epithelial 
solid tumours 
Est 133 
Primary 
completion date 
June 2015 
Multicentre, open-label, Phase I/II study  
ColoAd1 will be administered intravenously once 
daily as 3 consecutive injections separated by 48 
hours (hrs.) over a period of five days unless an 
unacceptable toxicity occurs. 
Recruiting http://clinicaltrials.gov 
PsiOxus Therapeutics Ltd 
NCT02028442 
*These tables were originally published in Ferguson et al. [40] they have been modified and updated for this work. 
Chapter 1 
24 
 
investigated the safety of using Newcastle disease virus in patients with recurrent glioblastoma 
multiforme and as with the other studies the treatment was well tolerated but the efficacy was 
again disappointing with only one patient (7%) having a complete response.     
 
Gene directed enzyme prodrug therapy (GDEPT) is a strategy used to effectively eradicate tumour 
cells whilst sparing normal tissue.  This is based on the principle that a gene can be delivered that 
codes for a non-toxic enzyme which converts a pro-drug into a cytotoxin in tumour cells but not 
normal tissue.  One system developed for this approach uses an attenuated Herpes Simplex virus to 
deliver it's thymidine kinase gene selectively into tumour cells in combination with the pro-drug 
ganciclovir, leading to cancer cell cytotoxicity from acyclovir.  Specifically, NV1020 is a Herpes 
Simplex virus type 1, which has been attenuated by deletions of the latency factors ICPO and ICP4, 
and contains only one copy of its virulence factor y134.5. Furthermore, the α4 promoter has been 
inserted to control the HSV-1 TK gene expression.  One phase I trial [32, 33] delivering NV1020 via 
hepatic artery infusion in patients with hepatic metastases from colorectal primaries refractory to 
first-line treatment reported seven patients (58%) with stable disease and two patients showing a 
partial response. Median survival in this group was 25 months. Another trial by Geevarghese et al. 
[34] in 2010 again delivered NV1020 by hepatic artery infusion in patients with advanced metastatic 
colorectal carcinoma but this time followed by conventional chemotherapy. After completion of the 
combined approach there was a 68% response rate, with one patient with a partial response and 
fourteen patients with stable disease.  Median survival in this study was 11.8 months. 
 
SVV-001 is a Seneca Valley Virus which is a wild-type picornavirus that has a natural tropism for 
neuroendocrine cancer cell types.  This virus has been used a phase 1 dose escalation trial in patients 
who have advanced solid tumours with neuroendocrine features [39].  The study demonstrates that 
the virus is well tolerated systemically with evidence of viral replication at the tumour sites.  
Although the trial was not designed for efficacy one patient out of thirty remained progression-free 
for 10 months after receiving a single dose. 
 
Interrogation of the various clinical trial registration sites (www.clinicaltrials.gov, WHO trials register, 
www.clinicaltrialsregister.eu, http://www.controlled-trials.com) reveals that there are no ongoing 
nor pending trials systemically delivering Newcastle disease virus, Herpes Simplex virus type 1 or 
Seneca Valley Virus. 
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Reolysin® is a type 3 Dearing Reovirus in its wild type form.  Vidal et al. [36] in 2008 reported a phase 
I dose escalation study assessing the safety of a variety of doses.  As such they observed no dose-
limiting toxicity and they further commented that anti-tumour activity was observed both 
radiologically and by tumour markers. However, no objective radiologic responses were observed in 
terms of Response Evaluation Criteria in Solid Tumours. Despite this, they did report that eight 
patients showed disease stabilisation.  Karapanagiotou et al. [37] in 2012 reported a phase 1/11 trial 
which demonstrated that Reolysin was well tolerated systemically and showed some promise in the 
treatment of advanced head and neck cancer.  As a result of this Oncolytics Biotech went on to run a 
phase III trial (NCT01166542) which has completed but not yet reported its results (Table 1.2).  
Galanis et al. [38] in 2012 reported that systemically delivered Reolysin was well tolerated for the 
treatment of advanced metastatic melanoma and there was some evidence of viral replication at the 
tumour site, however there were no objective responses.  There are six ongoing or pending trials 
investigating Reolysin at various stages of completion (Table 1.2).   
 
JX-594 (also known as Pexa-Vec) is a Vaccinia virus based on the Wyeth strain with a thymidine 
kinase (TK) deletion and the insertion of human granulocyte-macrophage colony stimulating factor 
(hGM-CSF) gene and Lac-Z into the TK-deleted region. These transgenes are under the control of 
pE/L and p7.5 promoters respectively. Jennerex Biotherapeutics Inc. has reported the results of one 
trial using this agent systemically in patients with unresectable primary hepatocelluar carcinoma. 
They performed a phase I safety study delivering JX-594 initially systemically then intra-tumourally 
with subsequent sorafenib treatment.  Seven out of nine of their patients were suitable to be 
assessed: in six patients (67%) the tumours necrosed, and of these patients five (56%) had stable 
disease and one patient (11%) had a partial response. They have recently reported the results of 
another dose escalation study using JX-594 in patients with metastatic solid tumour disease, which 
was refractory to conventional therapy. The treatment was well tolerated and at higher doses of 
virus (1x107 to 3x107 PFU/kg) they demonstrated that JX-594 can selectively infect, replicate and 
express transgene products in target tumour tissue whilst sparing normal tissue.  Although the study 
was not designed for efficacy, one patient was reported to have had a partial response [35]. 
Jennerex Biotherapeutics Inc. has two trials pending for this agent, the details of which are 
illustrated in Table 1.2.  Genelux Corporation also have two trials pending with a Lister strain of 
Vaccinia virus (Table 1.2). 
 
In general these clinical trials have shown that oncolytic viruses can be delivered systemically with 
limited toxicity and latency.  However, what they have not shown, and indeed were not powered to 
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show, is that these agents are efficacious at treating either the primary tumour or metastatic 
disease. There is a complete lack of appropriately powered phase IIb or phase III trials using OV 
delivered systemically that have been reported, however there are quite a few pending. The data 
that are available demonstrate that systemically delivered oncolytic viruses offer only modest 
improvements, if at all, over and above conventional second line therapy. Clearly if intravenously 
delivered OV are to play a part in the future treatment of advanced cancer there needs to be 
dramatic improvement.  
 
1.3. Barriers to systemic delivery of oncolytic viruses  
 
There are many obstacles to successful systemic delivery of viruses; host defences limit most 
oncolytic viruses’ ability to infect tumours after systemic administration. Blood cells, complement, 
antibodies, antiviral cytokines [41] as well as non-specific uptake by other tissues such as the lung, 
liver and spleen, tissue-resident macrophages and additionally poor virus escape from the vascular 
compartment [42] are the main barriers to systemic delivery of oncolytic viruses (Figure 1.1). Clearly, 
in order for this method to be effective, the virus must persist in the circulation without depletion or 
degradation while selectively infecting tumour cells.   
1.3.1. Neutralising antibodies  
Pre-existing immunity is a major problem for systemically delivered viruses whether this has 
developed due to the ubiquitous nature of the virus, previous immunisation or prior oncolytic viral 
therapy. Vaccinia virus was used in the worldwide immunisation program for the eradication of 
smallpox and so many people who are now developing cancer have pre-existing immunity to this OV. 
Reovirus is universally present within the environment and as a result many people have immunity 
to it [43, 44].  Furthermore, White et al. [45] have demonstrated that the antibody titre to Reovirus 
increases dramatically after systemic delivery and others have shown that the presence of these 
antibodies significantly impairs effective intravenous administration [46, 47].  One simple strategy 
for overcoming this problem has been to sequentially deliver related viruses with different serotypes 
or chimeric viruses [48].  
 
Nature has already provided several solutions when considering the significant hurdles to effective 
systemic delivery with regards to Vaccinia virus which can potentially be delivered systemically [49] 
since the Extracellular Enveloped Virus (EEV) form shrouds itself in a host cell-derived envelope and 
thus can evade both complement and neutralising antibodies [50-53]. Indeed strains of Vaccinia 
virus can be engineered that produce more of this immune-evasive form [54]. However, in the 
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Figure 1.1. Hurdles for systemic delivery of oncolytic viruses to tumour cells [40]. After intravenous injection, viruses are neutralised by pre-existing 
antibodies and complement activation. Oncolytic viruses also interact with blood cells. Sequestration into other organs and the reticuloendothelial system 
is a particular problem, often with resulting toxicities. Macrophages in the lung, liver (also known as Kupffer cells) and spleen are major players to clear 
oncolytic viruses after systemic delivery. From the bloodstream, viruses have to pass through a mixture of extracellular matrix and cells (including normal 
and immune cells) before reaching the tumour. The connective tissue of the tumour matrix is important in the regulation and creation of the tumour 
vasculature, the tumour vasculature itself and interstitial pressures are also key factors involved in the ability of the virus to penetrate the tumour mass.    
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clinical setting, it is the intracellular mature virion (IMV) form of the virus that will potentially be 
injected systemically and it is this form that must successfully reach the target tissue before any EEV 
form can be produced. IMV - unlike EEV - is highly immunogenic and is rapidly cleared from the 
organism if intravenously delivered. Clearly methods need to be developed that can overcome this 
acquired immunity. One such strategy is the so-called “Trojan Horse” technique where cells are 
taken from the model organism infected with the OV ex vivo and then re-infused. Yotnda et al. 
created transgenic cytotoxic T lymphocytes (CTL), which were transduced with adenovirus with the 
adenoviral E1 gene under the control of the cell activation-dependent CD40 ligand promoter. 
 
The CTLs were transduced ex vivo with a conditionally replicating chimera of Adenovirus 5 with the 
fibre protein of Ad35. The Ad35 fibre protein was added as it can infect cells through a coxsackie and 
adenovirus receptor (CAR)-independent method that is required as there is low expression of CAR on 
CTLs. The transgenic CTL was specifically targeted and upon binding and subsequent activation 
Adenovirus was produced. This occurred since upon activation of the CTL by its specific antigen the 
AKNA transcription factor is transiently expressed driving CD40 and E1A expression. Thus by this 
mechanism Adenovirus production is tightly linked to CTL activation by its specific tumour-
associated antigen resulting in a tumour-specific delivery of Adenovirus [55].  Work by Ilett et al. [56, 
57] has shown that dendritic cells loaded in vitro with Reovirus will “deliver” the virus successfully to 
melanoma cells in the presence of neutralising serum. Furthermore, they have shown that 
Reoviruses loaded into mature dendritric cells are able to infect tumour sites effectively in vivo 
despite pre-existing viral immunity.  Other cells have been used as potential viral carriers in pre-
clinical models such as cytokine-induced killer (CIK) cells [58], monocytes [59], endothelial cells [59], 
mesenchymal stem cells [60-62], T-cells [57, 63, 64], dendritic cells [57] and tumour cells [65-67].  
Also, stimulated peripheral blood cells, infected with oncolytic Measles virus, have successfully 
infected Raji lymphomas or hepatocellular carcinoma in the presence of neutralizing antibodies [59]. 
The “Trojan Horse” strategy may not be effective for brain tumours as some carrier cells are not able 
to pass physiological barriers, such as that between the blood and the central nervous system. 
Another interesting approach has been developed by Yotnda et al. [68] in which they encapsulated a 
conditionally replication-competent virus based on ONYX-015 in a liposome. They showed that 
despite circulating Adenovirus antibodies, the liposome-coated viruses were able to infect 
subcutaneous tumours in mice. 
 
Fontanellas et al. [69] have attempted to overcome the host immunity that develops after repeated 
administration of Adenovirus by inhibition of T cells and depletion of B-cells with anti-CD20 
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antibody. Although this study was not targeted at cancer therapy they demonstrated that this 
immunosuppressive regime was successful in facilitating gene transfer to hepatocytes despite pre-
existing Adenoviral immunity. 
 
Another immunosuppressive strategy is to use cyclophosphamide to modulate anti-viral immunity in 
combination with intravenous Reovirus. This has been evaluated in a pre-clinical murine model by 
Qiao et al. [70], in which they reported delivery of 1x107 plaque-forming units per milligram of 
tumour with this regime with only mild toxicity to the mice, whereas without cyclophosphamide 
effective seeding of the tumour was not achieved. For this particular regime, cyclophosphamide is 
often used at a lower dose and as a result would not cause significant side effects while it is 
combined with oncolytic viruses.   
1.3.2. Complement activation 
Complement activation is an important antiviral mechanism. Vaccinia virus in its EEV form 
incorporates host proteins within its membrane that may well prevent complement activation [53].  
Furthermore, it has long been established that Vaccinia virus secretes a variety of immune-
modulating molecules. One of the major secreted proteins is Vaccinia complement control Protein 
(VCP) which binds and inactivates C4b and C3b [71-73] thus inhibiting the classic and alternative 
pathways of complement activation. Furthermore, there is compelling evidence from a variety of 
viral infection models that complement activation induces various elements within the adaptive 
immune system [74-79]. Recent work has suggested that VCP dampens viral antibody responses and 
reduces the accumulation of CD4+ and CD8+ cells at the site of infection in a complement-
dependent manner [80]. This has led to at least one group using VCP to perturb complement 
activation outside the context of a Vaccinia infection [81] and raises the possibility of using it in 
combination with other OV to block complement activation.  
Herpes simplex virus type 1 has also evolved strategies to prevent complement activation. HSV-1 
secretes glycoprotein E that acts as an IgG Fc receptor and effectively blocks both IgG Fc-mediated 
complement activation and antibody-dependent cellular cytotoxicity [82]. Also HSV-1 produces 
glycoprotein C that binds C3b and is also critical in preventing C5 activation [83]. 
 
Adenovirus activates the complement system by various mechanisms but recent in vivo pre-clinical 
data suggests that this activation can be effectively reduced by shielding Adenovirus with 
polyethylene glycol [84]. Another approach to ameliorate complement activation, undertaken in 
Adenovirus, is to make the virus express soluble CD59 [85] and thus prevent deposition of the 
membrane attack complex. 
Chapter 1 
30 
 
1.3.3. Antiviral cytokines  
Viral infections stimulate a variety of cytokines to be produced (for review see Randall 2008 [86]).  
These include type 1 interferons (IFN), type 2 IFN and type 3 IFN [87, 88].  Although these molecules 
have pleiotropic functions, the main effects are to promote apoptosis in virus-infected cells and 
induce cellular resistance to viral infection in non-infected cells [89]. Additionally, they recruit 
elements of the adaptive immune system, such as dendritic cells, leading to potentially lasting 
immunity [90]. Most oncolytic viruses express proteins that block these IFNs [91-93], or their 
downstream targets, but the anti-viral response is often still sufficient to prevent intra-tumoural 
spread of the OV.   
 
As has been mentioned earlier the “Trojan horse” strategy is a potentially powerful technique for 
delivering oncolytic viruses systemically. Ahmed et al. demonstrated that mesenchymal stem cells 
infected ex vivo with Adenovirus and then subsequently re-infused had great advantages in terms of 
delivery particularly with respect to attenuating the IFN-gamma response at the tumour site since 
mesenchymal stem cells suppress activated T-cells [94].  Another strategy to overcome the antiviral 
cytokines is to pretreat with histone deacetylase inhibitors, which induce epigenetic changes that 
blunt antiviral cytokine responses at the tumour sites and have been shown to greatly improve the 
effectiveness of OV therapy [95, 96]. 
1.3.4. Non-specific uptake by other tissues such as the liver and spleen 
It is known that many viruses are either filtered or taken up by the lung, liver or spleen thus reducing 
systemic availability.  Our group has demonstrated that the spleen is pivotal in the early clearance of 
systemically delivered Vaccinia virus (James Tysome et al. (unpublished data), see page 36). 
Furthermore up to 90% of Adenovirus type 5 is sequestered from the blood by Kupffer cells [97] and 
as a result this acts as a major obstacle for the systemic delivery of Adenovirus. 
With respect to Adenovirus, several lines of investigation have developed strategies for improving its 
systemic availability. Shashkova et al. [41] demonstrated in a pre-clinical model that pre-treatment 
with warfarin followed by multiple doses of replication-defective Adenovirus successfully depleted 
Kupffer cells and prevented hepatocyte binding, thus improving the anti-tumour efficacy of a 
subsequent single dose of oncolytic Adenovirus. Another important factor involved in liver 
sequestration of Adenovirus 5 is the binding of its hexon coat protein with blood coagulation factor 
X.  Zhang et al. [48]  have developed a hexon-chimeric oncolytic Adenovirus type 5 that has 
Adenovirus type 48’s hexon which only weakly binds factor X. They have demonstrated that this 
chimera has a significantly reduced liver uptake.   
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1.3.5. Sub-optimal viral escape from the vascular compartment 
Adenovirus is known to bind to human erythrocytes [98, 99] and this reduces its therapeutic 
availability when delivered systemically. Furthermore it is well known that the neovasculature within 
solid tumours is very chaotic and abnormally leaky with often markedly raised interstitial pressures 
leading to reduced viral penetration of the tumour mass. Oncolytic viruses are known to stabilize 
tumour vasculature directly improving tumour penetrance [100].  Interestingly, other work has 
shown that the addition of anti-angiogenic agents to treatment with oncolytic viruses can further 
normalise the vasculature and improve viral delivery in preclinical models [101, 102]. There is also 
emerging evidence that blockade of the Hedgehog signalling pathway can affect tumour vasculature 
[103]. Thus a Hedgehog antagonist may prove to be an effective treatment in combination with a 
systemically delivered oncolytic virus or indeed incorporated within one as a transgene.  Another 
potential agent that could be incorporated into an OV as a transgene is histidine-rich glycoprotein 
(HRG) particularly in the context of repeated systemic administrations of OV. This protein has been 
shown to normalise tumour vasculature through its ability to polarize macrophages from M2-like 
TAM phenotype to M1-like tumour inhibitory phenotype [104].  
1.3.6. Novel methods to enhance systemic delivery 
Microbubbles have been developed as a potential method for enhancing the systemic delivery of a 
variety of agents including oncolytic viruses. They were first developed to help deliver small 
molecules to target tissues [31, 105-107]. Microbubbles are ultrasound contrast agents that contain 
high-molecular weight gases which are less soluble and do not diffuse easily, and as a result the 
microbubbles persist in the circulation for a few minutes passing through the microcirculation 
several times [105]. Ultrasound-targeted destruction of the microbubbles allows focused release of 
the oncolytic virus at the tumour site, and a secondary effect is transient and localised increased 
cellular permeability which potentially can improve viral infection of the cancer cells [108]. This 
technique has been used in vivo with Adenovirus successfully delivering the virus to the tumour site 
in mice [109, 110].  The technique has not yet been used with other oncolytic viruses. 
1.3.7. Optimal agent for systemic delivery 
All of the aforementioned viruses have the potential to be delivered systemically.  Adenovirus 
though is severely hampered by the fact it is bound by human erythrocytes [98, 99] and up to 90% is 
filtered by the liver and cleared by Kupffer cells [97].  The two viruses which are most actively being 
investigated for systemic delivery are Reovirus and Vaccinia virus (Table 1.2).  Both have 
weaknesses, as there is extensive effective immunity to Reovirus in the human population and 
Vaccinia virus can be rapidly cleared by splenic macrophages.  However, our group has focused on 
Vaccinia virus because it is able to overcome many of the barriers that reduce the efficacy of OV 
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delivered systemically.  Its EEV form is resistant to neutralising antibodies and complement, and it 
has a suite of expressed proteins designed to blunt the effects of anti-viral cytokines.  But as 
mentioned earlier the form that is injected is IMV and it is vulnerable to clearance by splenic 
macrophages.  If any effective strategy could be found to overcome this, Vaccinia virus could well be 
the best suited oncolytic virus for systemic delivery. 
1.4. Vaccinia virus  
 
Vaccinia virus (VV) is a member of the poxviridae family of double-stranded DNA viruses.  Poxviruses 
are amongst the most complex viruses known and they replicate entirely within the cytoplasm of of 
the cells of their hosts are either arthropods (Entomopoxvirinae) or vertebrates (Chordopoxvirinae).  
This family of viruses was initially of great interest because two of their members are obligate 
human pathogens, namely Variola virus and Molluscum Contagiosum virus.  Of the two, Variola 
caused by far the more clinically significant disease - smallpox.  This is a condition that after a typical 
viral prodrome caused an umbilicated vesiculo-pustular rash which preferential affected the face 
and limbs.  The condition had an overall mortality rate of about 30% with most patients dying either 
from haemorrhagic or septic shock [111].   
 
Smallpox had been a significant health problem for more than 3000 years.  The earliest description 
of disease originated in western Asia and India.  One of the first recorded victims of the virus was 
Pharaoh Ramses V who died in 1157 BC and whose mummified body shows clear evidence of 
smallpox infection [111].  Humans are the only reservoir for Variola infection and unsurprisingly 
smallpox rapidly spread wherever humans went.  So by 700 AD smallpox was a commonly fatal 
illness in Japan, China, Europe, the Far East and Northern Africa.  The first European explorers of the 
Americas brought the disease with them with devastating consequences sparking massive epidemics 
throughout the continent.  By the end of the 18th century there were reported cases of smallpox all 
over the world.     
 
In 1798 Edward Jenner observed that cow maids who had incidental cowpox infection were 
protected from smallpox.  He successfully started to inoculate people with cowpox lesion material 
and this ultimately led to immunisation with the VV.  The exact origins of Vaccinia are not clear, but 
it may well be the result of combination of cowpox with Variola.  Whatever its genesis it was the 
virus which was used in the successful eradication of smallpox by the World Health Organisation in 
1977.  As a result there have been millions of doses of Vaccinia given and it has an excellent safety 
record. 
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1.4.1. Vaccinia virus lifecycle  
Vaccinia is a member of the subfamily Chordopoxvirinae of the genus Orthopoxvirus.  As illustrated 
in Figure 1.2 it is a brick-shaped virion, roughly 350nm by 250nm, containing 200 kbp of linear 
double-stranded DNA which encodes nearly 200 proteins of which about 80 are contained within the 
mature virion [112, 113].  The virus replicates exclusively within the cytoplasm of the host cell.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.  An electron micrograph of a Vaccinia virus showing its brick-like appearance. Image 
from The Centers for Disease Control and Prevention's Public Health Image Library (PHIL), 
identification number #2143. 
 
There are various strains of VV, the most common of which are Lister, Western Reserve, 
Copenhagen, and Wyeth. Figure 1.3 illustrates the lifecycle of Vaccinia virus.  After attachment and 
internalisation (steps 1&2 in Figure 1.3), the cores are released into the cytoplasm.  These cores 
synthesize early mRNAs that are translated into growth factors, immune defence molecules, 
enzymes, intermediate transcription and viral DNA replication factors (step 3 in Figure 1.3).  After 
this the viral DNA is uncoated (step 4 in Figure 1.3) and replication occurs creating concatemeric 
DNA molecules (step 5 in Figure 1.3).  At this stage intermediate genes are transcribed which are 
translated into late transcription factors (step 6 in Figure 1.3).  Finally late genes are transcribed 
which are translated into early transcription factors, structural proteins, and enzymes (step 7 in 
Figure 1.3).  It is at this point that assembly of the progeny virion begins to occur.  The concatemeric 
molecules of DNA are resolved into viral genomes and packaged in immature virions (step 9 in Figure 
1.3).  These virions are then matured into intracellular mature virions (IMV).  This form of the virus is 
released from the cell when cell lysis occurs.  It is also the form of the virus which is responsible for 
person to person spread and it is the form given systemically in clinical trials.  However, there is 
another major form of the virus called the extracellular enveloped virion (EEV) which is formed when 
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IMV is draped in modified Golgi membranes (step 11 in Figure 1.3) and transported to the periphery 
of the cell where it acquires actin tails (step 12 in Figure 1.3) [114].  Finally fusion of this wrapped 
virion with the plasma membrane results in release of the EEV form.  As mentioned earlier EEV is 
resistant to both complement and neutralising antibodies [50-53], it has also been shown that this 
form of the virus is superior at intratumoural spread [54].   
 
 
Figure 1.3.  The lifecycle of Vaccinia Virus [115]. 
1.4.2. Vaccinia virus cell entry 
EEV and IMV forms of VV enter cells by different mechanisms [116-118], however it is IMV that is 
amenable to systemic delivery.  IMV contains twenty envelope proteins [112, 113], four of these 
proteins are known to be essential in viral attachment to cells.  H3 [119], A27 [120], and D8 [121] 
bind cell surface glycosaminoglycans whereas A26 [122] binds to the extracellular matrix protein 
laminin.  Furthermore, conditional mutant studies have demonstrated that the virus entry fusion 
complex (EFC) is essential for VV entry after the attachment stage.  The EFC is composed of twelve 
viral proteins namely A16 [123], A21 [124], A28 [125], F9 [126], G3 [127], G9 [128], H2 [129], I2 
[130], J5 [131], L1 [132], L5 [133], and O3 [134].  These are all necessary for the post-attachment 
membrane fusion step although the actual fusion mechanism remains unknown at present.  Having 
said that, it is known that VV enters the cell after attachment by either neutral pH direct plasma 
Chapter 1 
35 
 
membrane fusion [116, 135, 136] or low pH endocytosis [137, 138].  The entry method depends, in 
part, on the strain of VV [139] and the cell type being infected [140].  More recent work has 
indicated that the A26 viral protein acts as an acid-sensitive fusion suppressor, and when it is 
knocked out VV enters the cell predominantly via direct membrane fusion.  Thus A26 appears to be a 
major determinant in the endocytic entry pathway [141, 142].  IMV can enter a cell’s cytoplasm in a 
low pH-dependent manner after either macropinocytosis [117, 143-147] or dynamin-mediated fluid 
phase uptake [148].  Both these processes require dynamic actin rearrangements and cell signalling.  
Unsurprisingly therefore IMV entry is effectively blocked by cytoskeleton inhibitors, which block 
actin polymerisation (cytochalasin D) or depolymerisation (jasplakinolide), and by blebbistatin, a 
myosin II inhibitor. Furthermore dominant-negative forms of Rac1 and CDc42 Rho GTPases reduce 
viral infection.  Whereas a constitutively active mutant of Rho A, the other Rho GTPase, reduces viral 
infection [116, 144].  The subsequent step after the initial endocytosis is low pH-dependent, 
requiring a pH within the endosome of 4.5-5.0 for VV membrane fusion with the endosome 
membrane and release of the viral core into the cytoplasm.  This step is sensitive to sodium fluoride 
and cytochalasin B as well as bafilomycin, which blocks acidification of endosomes [138, 149].  
 
It also appears that VV of the same strain (in this case Western Reserve (WR)) can enter the same 
cell type by different endocytic pathways.  In HeLa cells it has been reported that VV - WR enters by 
both dynamin-dependent fluid phase endocytosis [148, 150] and dynamin-independent 
macropinocytosis induced by apoptotic mimicry [143, 151].  The exact mechanisms for the different 
entry methods in the same cell remain elusive.  More understandably, Mercer et al reported that 
two different strains can induce different forms of macropinocytosis in HeLa cells [144].  Clearly 
although the general strategies that VV employs to gain access to the cytoplasm of a cell have been 
elucidated much more work is still required.  
 
1.5. Tissue-resident macrophages 
 
To date, most pre-clinical studies examining systemic delivery of Vaccinia virus have used nude mice 
bearing xenograft tumours. It is now clear that there is a need to assess systemic delivery in an 
immunocompetent model as host immunity is a major barrier. Indeed, results from our group have 
demonstrated that while Vaccinia virus can effectively infect tumour cells in nude mice after 
systemic delivery, infection of tumour cells cannot be achieved at similar levels in the 
immunocompetent model (Figure 1.4).  When dissecting the differences between the two models by 
immunohistochemical analysis it was observed that at early time points in the immunocompetent 
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model macrophages in the red pulp of the spleen were associated with viral coat protein whereas 
this was not the case in the nude model (Figure 1.4).  This observation prompted speculation that 
maybe the key early player in the systemic clearance of Vaccinia virus was the macrophage.  
Concurrently, work in our group revealed that depletion of macrophages by clodronate liposomes 
dramatically enhanced Vaccinia virus infection of tumours in immunocompetent mice after systemic 
delivery (unpublished data generated by James Tysome et al.). This almost completely restored the 
anti-tumour potency to the level seen in nude mice, thus confirming that macrophages appear to be 
a key early cellular player in the systemic clearance of Vaccinia virus. 
 
Certainly in the immunocompetent model the macrophages appear to be clearing VV before it is 
able to reach the tumour sites.  These macrophages are effectively preventing therapeutic infection 
of the tumour cells and thus diminishing the efficacy of the treatment.  However, it is very likely that 
any successful strategy for the viral treatment of cancer will involve both viral oncolysis and immune 
modulation.  In this context macrophages both in the immediate tumour microenvironment and 
elsewhere are likely to be crucial in helping to effect the change from tumour tolerance to the 
development of anti-tumour immunity as they are both important phagocytic and antigen 
presenting cells.  The work in our group demonstrating that irreversibly depleting macrophage 
populations enhances systemic delivery (unpublished data generated by James Tysome et al.)  in the 
immunocompetent model is important as it reveals the crucial role that macrophages play in the 
early clearance of the virus.  But given that macrophages are likely to play such a beneficial role later 
in the eradication of the tumour cells an alternative strategy that only transiently perturbs 
macrophages maybe far more desirable. 
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Figure 1.4. Differences between nude and immunocompetent BALB/c mice bearing CT26 tumours 
after systemic VVL15 infection.  These data from James Tysome et al(unpublished), shows 
immunocompetent or nude BALB/c mice bearing CT26 flank tumours both of which have received 
1x108 PFU of VVL15 intravenously.  There is far greater luminescence signal from the tumours of the 
nude mice compared to the immunocompetent animals despite both groups receiving the same 
dose of VVL15.  In a separate experiment mice were treated the same as described above and then 
killed at three and eight hours after viral infection and their spleens prepared for 
immunohistochemical examination.  The micrographs show macrophages in the red pulp of the 
spleen were associated with viral coat protein in the immunocompetent mice but not the nude mice 
at these early time-points. 
 
 
 
Spleen 
                    3h                                            8h 
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1.6. The role of PI3 kinases in macrophage biology 
 
Clodronate liposomes non-selectively deplete macrophages and therefore potentially diminish any 
beneficial activity they may have in the tumour microenvironment unrelated to viral clearance. 
Consequently, this necessitates a search for a novel, more selective agent that could interfere 
transiently with macrophage function and thus enhance the systemic delivery of Vaccinia virus.  
 
In general it should be possible to perturb macrophage function at a variety of stages such as their 
development, recruitment/migration, or blocking their phagocytic function. Several lines of evidence 
have highlighted an important role for phosphatidylinositol 3-kinases (PI3K) [152-155] in 
macrophage phagocytosis.  
 
1.7. The three classes of PI3 Kinases  
 
Phosphatidylinositol 3 kinases function by phosphorylating a range of phosphatidylinositols (PtdIns).  
These phosphorylated PtdIns bind pleckstrin homology domains which are present in a wide variety 
of downstream signalling molecules (amongst others AKT, and GSK 3β) that ultimately lead to a 
whole host of cellular functions including cell growth, differentiation, motility, proliferation, survival 
and intracellular trafficking [156, 157].  They have also been implicated in a wide range of cancers 
[158].  There are three classes.  Class 1 PI3 kinases are activated by G protein-coupled and tyrosine 
kinase receptors.  In vitro they are able to phosphorylate phosphatidylinositol (4) phosphate (PtdIns 
(4)P) and phosphatidylinositol (4,5) biphosphate (PtdIns (4,5)P2). However in vivo it is likely their 
preferred substrate is PtdIns (4,5)P2.  There are four isoforms in class I, three are in class IA and these 
are α, β, δ.  They form a heterodimer composed of a catalytic subunit (p110α, p110β, or p110δ) and 
a regulatory unit p85, and they are activated by tyrosine kinase receptors and Ras.  The class 1B 
isoform is γ, which has a catalytic subunit, p110γ, and a regulatory subunit p101.  This isoform is 
activated by G protein-coupled receptors and Ras.  Both α and β isoforms are ubiquitously expressed 
whereas δ and γ are enriched in leucocytes [157].  Much less is known about the other two classes of 
PI3 kinase.  Class II includes three isoforms C2α, C2β and C2γ which phosphorylate PtdIns and PtdIns 
(4)P [159] and class III has one isoform which is formed of heterodimer of a catalytic subunit Vps34 
and regulatory subunits p150/Vps15.  Class III phosphorylates PtdIns and appears to be involved in 
cellular responses to nutrition and autophagy [160].   
 
As mentioned earlier, class I PI3 kinases have been implicated in macrophage phagocytosis [152-155] 
and these observations imply that PI3 kinase inhibitors may be potential therapeutic agents for 
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enhancement of systemic delivery of Vaccinia virus by blocking macrophage uptake/clearance of the 
viruses. One caveat to this is that therapeutic interference in the PI3K pathway may have to be 
targeted at individual or groups of PI3 kinase isoforms [161]. Mammals have eight isoforms of PI3 
kinase, but the specific isoforms of PI3 kinase involved in macrophage phagocytosis and Vaccinia 
virus uptake have yet to be elucidated.   
 
1.8. Aims  
 
1. To determine the key factors involved in the early clearance of systemically delivered VV in an 
immunocompetent preclinical model. 
 
2. To determine the effect of different isoforms of PI3 kinase on the uptake of VV by macrophages. 
 
3. To develop a therapeutic regime with enhanced systemic delivery of VV in the 
immunocompetent tumour model by use of selective PI3 kinase inhibitor. 
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Chapter 2  
Material and Methods 
2.1. Cell lines  
 
All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 5-10% fetal calf 
serum (FCS) except macrophages which were cultured in Roswell Park Memorial Institute medium 
(RPMI) with 10% FCS, 28.6μM Beta Mercaptoethanol (βMCE) and 1% streptomycin/penicillin. Dr. 
Osam Mazda (Department of Microbiology, Kyoto Prefectural University of Medicine, Japan) kindly 
provided the murine head and neck cancer cell line SCCVII. The murine colorectal carcinoma cell 
lines CMT93 and CT26, the lung cancer cell line LLC and breast cancer cell line 4T1 were all obtained 
from the Cancer Research UK cell bank. The KPC mouse-derived pancreatic carcinoma cell lines 
DT6606 and K8484 were the kind gift of Professor David A. Tuveson (Cancer Research UK Cambridge 
Research Institute, Cambridge, CB2 0RE, UK) and the African Green Monkey normal kidney cell line, 
CV1, was obtained from the American Type Culture Collection (ATCC, VA, USA).  Bone marrow-
derived macrophages from p110 delta or C2β knock-in mice were the kind gift of Professor 
Vanhaesebroeck (University College London, UK).   Cell lines were routinely tested for mycoplasma 
and were maintained at 37oC with 5% CO2 unless otherwise stated.  Similar passage numbers were 
used for all experiments.  For long term storage, cells were pelleted by centrifugation, and the cell 
pellet resuspended in DMEM containing 10% dimethyl sulphoxide (DMSO) and 10% FBS. After 
overnight storage at -80C cells were transferred to liquid nitrogen. 
 
2.2. Reagents 
 
Merck supplied PI-103 (a PI3 kinase alpha isoform inhibitor) and TGX221 (a PI3 kinase beta isoform 
inhibitor) as well as the pan-class 1 inhibitor Wortmannin.  Tocris Bioscience supplied the Rac1 
inhibitor NSC23766, cytochalasin D (an inhibitor of actin polymerisation), Y-27632 (a Rho-associated 
protein kinase inhibitor), and nocodazole (an inhibitor of polymerisation of microtubules).  Santa 
Cruz Biotechnology supplied the class 1a selective PI3 kinase alpha inhibitor A66.  Sigma-Aldrich 
supplied AS 604850, a selective class 1b PI3 kinase gamma isoform inhibitor.  Initially Symansis 
supplied IC87114, the selective class 1a p110 delta isoform inhibitor then subsequently, from March 
2012, it was obtained instead from Synkinase.  The concentrations used were PI-103 at 80nM [162-
165], TGX221 at 0.1µM [166], Wortmannin at 0.5µM [167], NSC23766 at 50µM [168], A66 at 0.5µM 
[169], Cytochalasin D at 10µM [170],  Y-27632 at 10µM [171], Nocodazole at 10µM [172] and AS 
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604850 at 1µM [167].  IC87114 was used at 1μM concentration [173] for all in vitro assays unless 
otherwise stated.  
 
The Western Blot antibodies were anti-p110δ from Santa Cruz Biotechnologies (sc-7176), and anti-
vinculin (V9131) and anti-actin (SAB2500963) from Sigma-Aldrich.  Fluorescence Activated Cell 
Sorting (FACS) antibodies were anti-mouse F4/80 APC and anti-mouse CD11b FITC, both supplied by 
eBioscience.  The Vaccinia virus antibody used for the immunohistochemical experiments was a 
rabbit anti-Vaccinia virus polyclonal antibody supplied by AbD Serotec, batch number 250906, and it 
was used diluted 1:400.  The PI3 kinase p110δ antibody used for the immunohistochemical 
experiments was a mouse monoclonal antibody supplied by Santa Cruz Biotechnology, batch 
number C1609, and it was diluted 1:500. MACs buffer was phosphate-buffered saline Dulbecco + 
2mM EDTA + 0.1% Bovine Serum Albumin (BSA).  Pronase was supplied by Roche Applied Science 
(Cat. No. 10165921001) and dissolved in phosphate-buffered saline (PBS) at 1mg ml-1 [174]. MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and PMS 
(phenazine methosulfate) were provided by Promega.  T cell culture media (TCM) was RPMI-1640, 
10% FCS, 1% streptomycin, 1% penicillin, and 1% sodium pyruvate. 
 
In vivo IC87114 was used at either 25mg kg-1, 50mg kg-1 or 75mg kg-1 by oral gavage.  Recombinant 
mouse macrophage colony stimulating factor (M-CSF) was supplied by R&D Systems, catalog no. 
415-ML.  It was used at a concentration of 30ng ml-1.  D-Luciferin was supplied by Caliper Life 
Sciences (Lot Number: 124358465) and used at 15mg ml-1.  Clodronate liposomes were supplied by 
 Dr. Nico van Rooijen (http://clodronateliposomes.org/ashwindigital.asp?docid=26), and the dose 
per mouse was 200µl delivered by intra-peritoneal injection.  Vehicle buffer, used as either a control 
or to dissolve IC87114, was made by the addition of 0.25% Tween-20 and 0.5% 
carboxymethylcellulose to PBS.   
 
2.3. Virus Production 
 
VVL15 was the kind gift of Professor Istvan Fodor (Loma Linda University Campus, Loma Linda, CA, 
USA).  It was constructed by the insertion of the firefly luciferase and the lacZ reporter genes into 
the thymidine kinase region of VVLister under the control of the early–late vaccinia p7.5 promoter 
[175].   
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2.4. Mass production of Vaccinia virus 
2.4.1. Primary Expansion 
One F175 flask was seeded with CV1 cells and left until approximately 90% confluent, when 1-2µl of 
viral stock was added.  After this infection the flasks were checked regularly.  Once there were signs 
of cytopathic effect (CPE) but the majority of cells were still adherent to the surface, the flasks were 
harvested (this usually took 1-2 days).  A cell scraper was used to detach all the cells into the 
overlying medium after which the supernatant was aspirated into a 50ml falcon tube.  The primary 
expansion was stored at -80oC prior to secondary expansion and purification.  
2.4.2. Secondary Expansion 
Between 25-50 F175s were seeded with CV1 cells and monitored until they were 80-90% confluent.  
Each flask was then infected with 300µl of primary expansion and then made up to a final volume of 
25ml with 5% DMEM.  Once there were signs of CPE, typically two days post-infection, the flasks 
were harvested.  Again a cell scraper was used to detach the cells and then the supernatant was 
aspirated.  Pooled supernatants were centrifuged at 2000rpm for 5 minutes and then resuspended 
in PBS.  The pellets from multiple flasks were combined after which the resultant pellet was 
centrifuged and resuspended twice in PBS.  Having completed this washing step the pellet was 
centrifuged, again at 2000rpm, and finally resuspended in Tris-HCl pH 9.0 buffer. 
2.4.3. Viral Purification 
Cells were disrupted by three cycles of freeze-thawing before the cell suspension was homogenised 
by 60 strokes in the Dounce homogeniser.  Following this the suspension was centrifuged at 900rpm 
for 5 minutes at 4oC, the supernatant was collected and the pellet resuspended in 3ml of 10mM Tris-
HCl pH 9.0.  The resuspended pellet was spun down again at 900rpm for 5 minutes at 4oC.  The pellet 
was discarded, the supernatants were combined and made up to a total volume of 30ml 10mM Tris-
HCl pH 9.0 after ultrasonification.  This was layered equally onto four SW27 ultracentrifuge tubes 
containing 17ml of 36% sucrose diluted in 10mM Tris-HCl pH 9.0 and centrifuged at 13,500rpm for 
80 minutes at 4C. The supernatant was aspirated and the viral pellet resuspended in 4ml of 1mM 
Tris-HCl pH 9.0.  Finally, a sucrose gradient was used to further purify the virus.  In the bottom of a 
SW27 ultracentrifuge tube 4mls of 40% sucrose (dissolved in 10mM Tris-HCl pH 9.0) was placed, 
layered on top of this was 4mls of 35% sucrose then 4mls 30% sucrose followed by 4mls of 25% 
sucrose.  10mls of viral suspension was then carefully layered on and then the entire suspension was 
centrifuged at 13,500rpm for 60 minutes at 4oC, after this the pellet was air-dried for 5 minutes and 
resuspended in 500µl of sterilised 10% glycerol in PBS with 238mM NaCl pH 7.4.  Subsequently the 
viral titre was determined by TCID50 assay. 
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2.5. DNA/RNA Extraction 
 
DNA extraction was performed using the Qiagen DNeasy Blood & Tissue Kit.  RNA was converted to 
cDNA using the superscript II RT system. 
 
2.6. Quantitative Polymerase Chain Reaction (qPCR) 
 
Quantification of viral genome copy number was achieved using the TaqMan® PCR system provided 
by Applied Biosystems as previously described [176].  For VV the primers and probe were designed 
for the Vaccinia virus late transcription factor 1 (VLTF-1) gene, forward was 5'-
AACCATAGAAGCCAACGAATCC (code SY100203462-026) and reverse was 5'-
TGAGACATACAAGGGTGGTGAAGT (code SY100203462-027) and probe sequence was 
ATTTTAGAACAGAAATACCC.   The primers were supplied by Sigma-Aldrich.  The standard was VVL15 
DNA, and 40ng of DNA was used per sample as the template.  Viral genome copy number was 
normalised by total DNA loaded and presented as such.  For p110 delta qPCR the kit was pre-
designed assay from Applied Biosystems, the code for which is Mm00435674 (gene ID: Pik3cd).  The 
standard for the delta qPCR was p110 delta plasmid provided by Professor Vanhaesebroeck.  All 
qPCR experiments were repeated a minimum of three times. 
 
2.7. Culture of bone marrow-derived macrophages 
 
The mouse's femur and tibia were dissected out.  The ends of the bone were cut, then a 2ml syringe 
filled with macrophage media was attached to a 23 gauge needle and the bone marrow was flushed 
into a clean, labelled Petri dish.  This was repeated for all bones dissected.  Homogenised bone 
marrow was flushed firstly by using a needle and then by pipetting with a 1000µl tip.  This 
homogenised suspension was transferred into a 50ml tube through a 45 μm mesh filter and then the 
remaining suspension was moved into a 15ml tube and made up to a total volume of 10ml with 
macrophage media.  It was spun down at 1300rpm for five minutes at room temperature, then the 
supernatant was poured off and the pellet resuspended in 10ml macrophage media.  The suspension 
was then spun again for five minutes at 1300rpm, then the supernatant was poured off and the 
pellet resuspended in 40ml macrophage media.  M-CSF was added to the suspension and mixed 
several times.  The cells were then plated at 10 ml/plate on 10cm Petri dishes.  Two mice were 
usually sufficient for 40ml of plating suspension.  On the second, fourth and seventh day after 
plating, the medium and M-CSF was replaced; macrophages were considered fully matured by day 
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seven and were plated for experimentation on either day seven or eight.  Confirmation of 
macrophage population was routinely undertaken by FACS using CD11b and F4/80 antibodies; the 
double-stained population was always in excess of 90% of the total population. 
 
2.8. Ex vivo infection of isolated blood cells from nude or immunocompetent 
BALB/c mice 
 
Either BALB/c wild-type or nude mice were anaesthetised and then killed by cardiac puncture with 
exsangination.  The blood from three mice was pooled and then diluted 1:1 with RPMI.  The 
blood/RPMI mix is carefully added to a falcon tube containing lymphoprep (ratio of 
lymphoprep:blood = 2:3).   This was then spun for 30mins at 2000rpm at 21oC (with 
acceleration/deceleration on 1).  Then the plasma layer was taken off and discarded, the buffy coat 
layer was also removed and placed into an Eppendorf vial filled with 1ml RPMI.  At same time the 
erythrocyte layer was collected and resuspended in 1ml RPMI.  Both the erythrocyte and buffy coat 
layers were centrifuged for 15mins at 1200rpm at 21oC. 
2.8.1. Buffy coat layer 
The supernatant was removed and the pellet resuspended in MACs buffer and then centrifuged for 
10mins at 1400rpm.  The supernatant was again removed and the pellet resuspended in: 20ul CD11b 
beads, 80ul MACs buffer per 10ml of blood started with.  The cells were then incubated with the 
beads for 30mins at 4oC.  Following which the cells were washed with 1ml MACs buffer and 
centrifuged at 1400rpm at 4oC for 10mins.  An LD column was washed with 3ml MACs buffer and 
then the supernatant was taken off the cells and the pellet was resuspended in 1ml MACs buffer and 
added to the LD column with the magnet on.  The column was washed with 3ml MACs buffer and 
the wash-through was kept as it contained lymphocytes deplete of monocytes.  Subsequently the 
magnet was removed and the LD column flushed again with 3ml of MACs buffer.  This elution 
contained the monocytes and was immediately spun at 1400rpm for 10mins and then the 
supernatant was discarded and the pellet resuspended in 1ml RPMI.  
2.8.2. Infection of Monocytes, Lymphocytes or Erythrocytes 
Monocytes, lymphocytes, or erythrocytes were infected with VVL15 at MOI 0.01.  This MOI was 
determined by taking into account the standard in vivo dose of VV of 1x108 PFU/mouse used in this 
study and then taking an estimate of the total number of blood cells / ml in a mouse (obtained from 
http://phenome.jax.org) and an assumption of a total circulating volume of 1.5ml.  The following 
formula was then used to determine the ex vivo experimental MOI. 
 
Chapter 2 
45 
 
    
 
  
 
a = standard in vivo dose of VV of  1x108 PFU/mouse 
b = total number of blood cells / ml 
c = total circulating volume (ml) 
After infection the monocytes, lymphocytes, or erythrocytes were then incubated at 37oC with 
constant agitation for 30mins.  After 30mins they were immediately placed on ice and then spun at 
1400rpm for 10mins.  The supernatant was removed and the pellet resuspended in PBS and then 
immediately frozen in dry ice.   Subsequently, DNA was extracted from all samples and qPCR 
performed to quantify the amount of viral DNA present. 
 
2.9. Viral Attachment and Internalisation Assays 
 
Cultured macrophages were seeded in 24-well plates at 105 cells per well in 500µl of macrophage 
medium.  They were seeded in duplicate for each condition tested and left to adhere overnight.  The 
next day the medium was replaced with inhibitors at required concentration for two hours (see 
section 2.2 for required concentrations).  Cells were placed in a cold room at 4oC for 20 minutes to 
cool and then infect with VVL15 at MOI 5 in 250µl of media (or mock infected if control) added to 
the media already present and then left for one hour at 4oC on very slow rocker.  After the 
appropriate incubation period, medium containing virus was aspirated and the cells were washed 
twice with cold PBS.  For the attachment assay at this stage the cells were detached and stored at -
20oC ready for subsequent DNA extraction and qPCR.   
 
There was one exception to this, in the Rho A experiment (Chapter 9) the cells were mock-infected 
or infected for 0, 3, 6, 12 and 30 minutes rather than one hour and then media containing virus was 
aspirated and the cells were washed twice with cold PBS.  After this the samples were then stored at 
-20oC ready for quantification of total Rho A and activated GTP-bound Rho A levels using 
commercially available ELISA and G-LISA kits respectively from Cytoskeleton Inc..   
 
For internalisation assays the cells were warmed by the addition of 500ul of medium containing 
inhibitors at room temperature after the removal of the virus-containing medium.  At the desired 
time-points, either 30 minutes or 60 minutes, the medium was aspirated and the cells washed with 
cold PBS.  Each well was then treated with 500µl of pronase [174] and the whole plate put on ice for 
30 minutes.  After this time period the cells were collected, washed and then frozen for subsequent 
DNA extraction and qPCR. 
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When these experiments were done using transgenic knocked-in macrophages the addition of any 
inhibitor was omitted.  
 
2.10. MTS Assay 
 
Between 1x103 to 1x104 cells per well (depending on their growth characteristics) were plated out on 
96-well plates with or without IC87114 and subsequently infected with nine serial dilutions of VVL15 
making a total volume of 90ul per well.  The cells/virus were then incubated for 6 days at 37oC in air 
supplemented with 5% CO2 in DMEM with 5% FCS.  At this stage the MTS reagents were added in a 
ratio of 20MTS to 1PMS, a total volume of 20ul per well was added, and left to incubate for two 
hours. The Optical Density (OD) reading at 490nm was obtained using an Opsys MR 96-well plate 
absorbance reader (Dynex, VA, USA).  The cell viability was determined by comparison of the treated 
cells OD reading compared to the mock-treated cells OD value once the OD value of medium alone 
had been compensated for.  Using these values a dose-response curve was created using non-linear 
regressional analysis in Prism 5.  The EC50 value, the amount of virus required to kill 50% of the cells, 
was then calculated.   
 
2.11. Viral Replication Assay (TCID50) 
 
The TCID50 assay (tissue culture inhibitory dose 50%) is a limiting dilution assay, which quantifies any 
infectious particles in the test sample. In this study the titres of viruses were determined by this 
method. Titrations were performed in duplicate. 
2.11.1. Primary Infection 
Cells were plated in six-well plates at 2x105 cells/well in 2ml of 5% DMEM.  Cells were left to adhere 
overnight and then pretreated with IC87114 or medium alone and then two hours later the 
inhibitor/medium was removed and cells infected with VVL15 at MOI 1 in 500µl of 5% DMEM.  Cells 
were then harvested at 24, 48, 72, and 96 hours after viral infection.  All the harvested cells/media 
were then freeze/thawed three times and then stored at -80oC ready for secondary infection. 
2.11.2. Secondary Infection 
Two 96-well plates of CVI cells, seeded at 104 per well in 200µl 5% DMEM, were set up per sample 
produced in the primary infection.  Cells were left to adhere overnight.  Each sample was diluted 
1:1000 (1µl in 1ml 5% DMEM) and then 20µl/well added to the top row of the 96-well plate.  Then 
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22µl was taken from the top row wells and added to the second row wells and mixed, this was 
carried on down the plate leaving the last row with no virus.  This was repeated for all samples. The 
plates were then incubated for 7 days before being read.  At this point the number of infected wells 
per row was recorded and then the TCID50 of the virus at various time-points in the primary infection 
was calculated using the Reed & Muench method [177].  When this method was used to determine 
the viral recovery from homogenised in vivo samples only the secondary infection step was used. 
2.11.3. TCID50 Calculations 
Specifically the TCID50 was calculated as follows: 
 
Log TCID50 = a - d (s – 0.5) 
 
a = Log of the highest dilution showing CPE in more than 50% of the wells 
d = Log of the dilution factor 
s = summation of the proportion of positive wells in each row. 
 
However, in this study expression of infectivity was in PFU ml-1 rather than TCID50.  Firstly Log TCID50 
was converted to TCID50 by raising Log TCID50 by the power of 10.  Then the TCID50 was converted to 
a concentration, as the volume of media per well was known (22µl), TCID50 ml-1.  Finally this was 
converted to PFU ml-1 by multiplying TCID50 ml
-1 by the coefficient factor 0.69.  This is derived from 
the following equation: 
 
         
where P(O) is the proportion of uninfected wells 
e = base of the natural logarithm 
m = is the average number of virus particles which infect a cell. 
 
The Poisson distribution determines that the proportion (P(O)) of wells not receiving infectious 
virions at all at any given dose is e-m, where m is the multiplicity of infection of the infectious viral 
particles at that dose. As TCID50 is the dose at which 50% of the wells are infected (P(O) = 0.5), 
meaning that 0.5 = e-m, therefore m = 0.69.  This statistical adjustment accounts for the proportion of 
non-infectious particles that contribute to the TCID50 value i.e., only 69% of the TCID50 titre are 
infectious particles.   
 
Finally, given that the number of cells seeded in the primary infection was known, the PFU ml-1 value 
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was converted to PFU cell-1 as this facilitated more straightforward comparison between different 
cell lines and conditions.  
 
2.12. Western Blot  
 
Cell lysates were harvested in PBS. Quantification of protein was by Bradford assay. For 
immunoblotting, 40-80 µg of protein was resolved in 8% SDS polyacrylamide gel at 80V for 30 
minutes and then at 120V for 75 minutes. Protein was transferred to nitrocellulose membrane at 
100V for 60 minutes. Blocking was performed using 5% milk for 60 minutes at room temperature 
before incubation overnight with the anti-p110δ (sc-7176) at 4oC. Membranes were washed three 
times for 10 minutes each in Tris-buffered saline Tween at room temperature and incubated with 
the secondary antibody (anti-rabbit, HRP-conjugated). Again membranes were washed three times 
with Tris-buffered saline Tween.  Subsequently the membrane was developed with ECL and exposed 
onto X-ray film.  Re-incubation with a vinculin (monoclonal anti-mouse) or actin (polyclonal anti-
goat) antibody provided a loading control.   
 
2.13. Immunohistochemistry 
 
Appropriately harvested samples from in vivo studies were immediately fixed in 4% w/v formalin 
(diluted with PBS) for 48 hours and then transferred to a 70% ethanol solution.  Samples were then 
embedded in paraffin.  Blocking, embedding and antigen retrieval were performed by Pathology 
Services, Barts Cancer Institute except in the case of the p110 delta IHC when antigen retrieval was 
undertaken by Mr Andrew Clear, Centre for Haemato-Oncology, Barts Cancer Institute. 
 
2.14. Interferon Gamma Assay 
 
Fifteen mice were subcutaneously injected in their shaved right flank with 1x106 CT26 tumour cells.  
When the tumours had reached approximately 100mm3 the mice were randomly sorted into four 
groups; Group A, B, C and D.  Mice were pretreated with either vehicle buffer (Groups A & C) or 
IC87114 at 75mg kg-1 (Groups B & D) by oral gavage three hours before receiving either an 
intravenous injection of 1x108 PFU VVL15 (Groups A & D) or PBS (Groups B & C).  The mice were then 
left for fourteen days after which they were killed.  Spleens were harvested, homogenised through 
70µm cell strainers (Becton Dickinson Falcon) and resuspended in T cell culture media (TCM) in 50 ml 
conical flasks. The splenocytes were centrifuged at 1200rpm and then left on ice for 5 minutes after 
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which they were resuspended in 5ml of RBC lysis buffer (supplied by Sigma-Aldrich). One further 
wash-centrifugation cycle was undertaken and then the splenocytes were resuspended in TCM to a 
final concentration of 5x106 cells ml-1.  
 
CT26 cells had their growth arrested by the addition of Mitomycin C (supplied by Roche).  This was 
achieved by treating 5x106 CT26 cells ml-1, suspended in 10% FCS DMEM, with 1mg ml-1 solution of 
Mitomycin C in a 50ml conical flask making a final concentration of 100µg ml-1 Mitomycin C.  The 
cells were incubated with Mitomycin C in a humidified incubator at 37°C with 5% CO2 for one hour. 
Subsequently the cells were washed twice with PBS and then resuspended in TCM at a final 
concentration of 5x105 cells ml-1. 
 
Lastly, 100µl aliquots of splenocyte suspensions from Groups A, B, C and D were co-cultured with 
100µl of Mitomycin C treated CT26 cells in duplicate in a 96 well plate. Splenocyte only control wells 
contained 5x105 splenocytes suspended in 200µl TCM. Separately, in order to assess immune 
response to VVL15 100µl aliquots of splenocyte suspensions from Groups A, B, C and D were treated 
with Vaccinia virus B8R epitope (H-2Kb/SIINFEKL, supplied by Proimmune), a strongly antigenic 
Vaccinia viral epitope at a concentration of 5µg ml-1.  
 
For 3 days the plates were incubated at 37°C with 5% CO2, following which they were centrifuged at 
1200rpm for 5 minutes. The supernatant from each of the wells was collected and the concentration 
of IFNγ was determined using a murine-specific IFNγ ELISA kit from Biolegend.    
 
The final experimental IFNγ concentration was determined after the subtraction of the IFNγ 
concentrations from the splenocyte-only wells which represented the background IFNγ release. 
 
2.15. Phagocytosis Assay 
 
Bone marrow was extracted and pooled from either two nude or wildtype BALB/c mice.  The 
macrophages were cultured ex vivo for seven days in medium containing macrophage colony 
stimulating factor until fully matured.  Cells were then plated onto 12-well plates at a concentration 
of 0.1-0.5x106 ml-1 well-1 and left overnight.  The following day the cells were then pretreated with 
either 1µM IC87114 or medium for two hours. Then cells were either stimulated with 
Lipopolysaccharide (LPS at 100ng ml-1) or left in medium for 1 hour.  Then they were placed on ice 
for 20 minutes after which 20µl (20µg ml-1) of opsonised bio-particles (from the Vybrant 
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Phagocytosis Assay Kit (V-6694) supplied by Life Technologies) were added to the wells and then the 
plates were incubated at 37oC with 5% CO2 for one hour.  Table 2.1 illustrates the treatment 
schedule.  After one hour the cells were washed three times with PBS with 0.5% BSA and then the 
cells were detached using cell scrapers. The cells were collected on ice and added to ice-cold  PBS 
with 0.5% BSA in BD Falcon FACS tubes and then they were spun down at 4oC for 5 minutes at 
1500rpm.  After which a 1:10 dilution of F4/80 APC antibody diluted in ice-cold PBS with 0.5% BSA 
was added to the cells to stain their membranes.  The cells were incubated on ice for 30 min with 
the antibody.  Then washed with PBS with 0.5% BSA and spun down at 4oC for 5 minutes at 
1500rpm.  The cells were collected immediately and 100 µL of prepared Trypan blue suspension (1 
vial in 4ml sterile water) was added to all of the wells.  The cells were then incubated for 1 minute at 
room temperature, after which they were immediately washed twice with PBS with 0.5% BSA to 
remove any excess Trypan blue.  At this point the cells were fixed with 2% paraformaldehyde in PBS 
for 10 minutes at room temperature and then washed with PBS with 0.5% BSA and spun down at 4oC 
for 5 minutes at 1500rpm.  The cells were then analysed the next day by flow cytometry.  Samples 
were read using the BD Fortessa platform. Data were analysed using the FlowJo version 7.6.5 
software. 
 
Pretreated with IC87114 
Condition  Macrophage: Nude OR Wildtype 
1 Media + No beads 
2 Media + Fluorescein-labeled Escherichia coli K-12 BioParticles 
3 Lipopolysaccharide + Fluorescein-labelled Escherichia coli K-12 BioParticles 
Pretreated with media 
Condition  Macrophage: Nude OR Wildtype 
4 Medium + No beads 
5 Medium + Fluorescein-labelled Escherichia coli K-12 BioParticles 
6 Lipopolysaccharide + Fluorescein-labelled Escherichia coli K-12 BioParticles 
Table 2.1. Treatment schedule for phagocytosis assay 
2.16. Imaging 
IVIS imaging was performed under inhalation anaesthesia 10 minutes following intra-peritoneal D-
Luciferin (15mg ml-1) injection.  Non-contrast enhanced CT was performed under inhalation 
anaesthesia. 
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2.17. Animals 
 
BALB/c and C57BL/6 mice were supplied by the Queen Mary University of London Biological Services 
Unit (BSU) at Charterhouse Square, London, EC1M 6BQ.  Except for animals used in results section 
3.1, these animals were provided by Clare Hall Service Unit.  KPC mice have the genotype LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre.  They are mice that are conditional heterozygote mutants 
for both Kras and P53 in pancreatic tissue.  The Cre recombinase is under a pancreatic-specific 
promoter and causes the expected “1LoxP” recombination events in the KPC (triple mutant) mice 
[178, 179].  These mice were bred at Charterhouse Square BSU, the original mice were the kind gift 
of Professor David A. Tuveson (Cancer Research UK Cambridge Research Institute, Cambridge, CB2 
0RE, UK). 
 
2.18. Animal studies 
 
All the animal studies that make up the results in section 3.1 were undertaken by staff at the 
Biological Resources Unit, Clare Hall, Cancer Research UK.  All subsequent animal work was 
undertaken at Charterhouse Square BSU by Mark Ferguson.  All animals were treated in accordance 
with Home Office regulations.  Animals were killed if width x length in centimetres was greater than 
1.4cm2 or any signs of ulceration or distress.  Tumour volumes were calculated according to the 
following formula:  
 
              
    
 
 
 
where w is width, l is length. 
 
In efficacy studies line graphs are used to present tumour volumes against time until the first mouse 
in the group dies (or is culled).  Similarly Kaplan Meier plots are of survival. 
2.18.1. Biological Time-point Studies - Results 3.1 
All these studies were performed at Clare Hall Cell Service Unit. CT26 cells (1x106 cells/mouse - cells 
provided by Clare Hall Cell Service Unit) were implanted subcutaneously into the right flanks of 
eight-week-old female mice, which were either wildtype BALB/c or nude BALB/c. When the tumours 
were palpable, reaching approximately 5-6 mm in diameter, VVL15 was injected intravenously via a 
tail vein.  At specified time-points after VVL15 treatment three mice, of each type, were killed.  The 
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time-points were five minutes, ten minutes, thirty minutes, and three hours.  The anaesthetised 
mice were killed by cardiac puncture, collecting each mouse’s entire circulating blood volume in an 
EDTA tube and then the blood was immediately centrifuged separating it into blood cells and plasma 
samples.  The following organs were then harvested: spleen, liver, lungs, ovaries and tumour.  All 
samples were immediately frozen and transferred to Barts Cancer Institute for DNA extraction and 
then qPCR for quantification of the amount of virus present. 
2.18.2. Biological Time-point Studies  
All these studies were performed at Charterhouse Square BSU.  CT26 cells, 2x106 cells/mouse in 
100µl PBS, were implanted subcutaneously into the shaved right flanks of thirty BALB/c eight-week-
old female mice.  When the tumours were palpable, reaching approximately 5-6 mm in diameter the 
mice were randomly sorted into two equal groups. The mice were pretreated with either IC87114 
(n=15) or vehicle buffer (n=15) and then three hours later received 1x108 PFU of VVL15 injected 
intravenously via a tail vein.  At specified time-points after VVL15 treatment, three mice in each 
group were killed.  The time-points were 3 hours, 1 day, 3 days, 5 days, and 7 days.  The mice were 
killed by cardiac puncture collecting each mouse’s entire circulating blood volume in an EDTA tube 
and then the blood was immediately centrifuged separating it into blood cells and plasma samples.  
The following organs were then harvested: brain, spleen, liver, lungs, ovaries and tumour.  All 
samples were immediately frozen.  Later, tissue samples were homogenised in DMEM medium 
added at a ratio of 500µl per 0.1g tissue.  After which these tissue homogenates were used in 
standard TCID50 assays.   
2.18.3. Clodronate liposome depletion of macrophages  
CT26 cells, 2x106 cells/mouse in 100µl PBS, were implanted subcutaneously into the shaved right 
flanks of fifteen BALB/c eight-week-old female mice.  Mice were randomly sorted into three groups 
on day 4 after CT26 injections.  Table 2.2 illustrates these groups and treatment schedules. 
 
Group  Treatment Schedule of treatments 
(after CT26 implantation)  
Number of mice 
A clodronate liposomes (CL) IP 200µl CL day 4, 7, 9 5 
B PBS +  liposomes IP 200µl Liposomes day 4, 7, 9 5 
C PBS    IP 200µl PBS day 4, 7, 9 5 
 
Table 2.2.  Groupings and treatment schedule for clodronate liposome depletion of 
macrophages.  Mice were treated according to the treatment schedule in Table 2.2 and then on 
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day 10 after CT26 implantation all mice received an intravenous injection of 1x108 PFU VVL15 in 
100µl filtered PBS via the tail vein.  The mice were then imaged using the IVIS imaging system on 
days 0, 1, 3, 5, and 7 after VVL15 injection. 
2.18.4. Dose Escalation Studies  
CT26 cells, 2x106 cells/mouse in 100µl PBS, were implanted subcutaneously into the shaved right 
flanks of twenty-four BALB/c eight-week-old female mice.  When the tumours were palpable, 
reaching approximately 5-6 mm in diameter the mice were randomly sorted into six equal groups 
(Table 2.3).   
 
Group 1 δinh (25mg/kg) + VVL15 
Group 2 δinh (50mg/kg) + VVL15 
Group 3 δinh (75mg/kg) + VVL15 
Group 4 δinh (75mg/kg) + PBS 
Group 5 Vehicle + VVl15 
Group 6 Vehicle + PBS 
Table 2.3.  Groups for the Dose Escalation Studies. 
Groups 1, 2 and 3 received IC87114 at concentrations of 25mg kg-1, 50mg kg-1, or 75mg kg-1 
respectively and then three hours later intra-venous VVL15 at 1x108 PFU/mouse in 100μl of PBS via 
tail vein. Group 4 received IC87114 at a concentration of 75mg kg-1 + intra-venous 100μl PBS via tail 
vein injection.  Group 5 received vehicle buffer + intra-venous VVL15 at 1x108 PFU/mouse in 100μl of 
PBS via tail vein.  Group 6 received vehicle buffer + intra-venous 100μl PBS via tail vein injection.  The 
mice were imaged using the IVIS imaging system on days 0, 1, 3, 5, and 7. 
2.18.5. Biodistribution of VVL15 in KPC mice after pretreatment with IC87114 or vehicle 
buffer 
Six 10-week-old, KPC mice were pretreated with either 75mg kg-1 IC87714 (n=3) or vehicle buffer 
(n=3) three hours before one intravenous injection of 1x108 PFU VVL15.  The mice were then imaged 
using the IVIS imaging system on days 0, 1, 3, 5, and 7 after VVL15 injection. 
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2.18.6. Efficacy study in BALB/c mice bearing CT26 tumours 
CT26 cells, 2x106 cells/mouse in 100µl PBS, were implanted subcutaneously into the shaved right 
flanks of forty BALB/c eight-week-old female mice.  When the tumours were palpable, reaching 
approximately 100mm3 in volume the mice were randomly sorted into four equal groups. Table 2.4 
shows the treatment schedule for each group of mice. 
 
Group  Treatment Schedule of treatments  Number of mice 
A Vehicle Buffer + VVL15 Day 0, 3, & 5 10 
B IC87114 + PBS Day 0, 3, & 5 10 
C Vehicle + PBS Day 0, 3, & 5 10 
D IC87114 + VVL15 Day 0, 3, & 5 10 
 
Table 2.4.  Treatment schedule for groups of mice.   The dose of the IC87114 used was 50mg 
kg-1, and VVL15 was delivered by intravenous injection of 1x108 PFU in 100µl filtered PBS via the tail 
vein. 
 
Mice were treated according to the schedule in Table 2.4 receiving either IC87114 or vehicle buffer 
by oral gavage three hours before either intravenous VVL15 or PBS.  The mice received this 
treatment three times on day 0, day 3, and day 5 (day 0 is the first day of treatment).  Tumours in 
each group were measured using callipers three times per week until the end of study.   
2.18.7. Optimisation of efficacy model:  BALB/c mice bearing orthotopically implanted 
4T1 cells   
4T1 cells, 5x105 cells/mouse in 50µl PBS [180-183], were implanted orthotopically into the left lower 
thoracic mammary gland of ten BALB/c 8 week old female mice.  Mice were then monitored for any 
signs of distress and culled at nine (n=3), sixteen (n=3), and twenty days (n=4) post tumour injection.  
The tumours, livers, lungs and spleen were harvested, embedded and fixed.  The samples were then 
histologically examined for the presence of tumour cells by a pathologist (Dr Yaohe Wang, Barts 
Cancer Institute, University of London, UK). 
2.18.8. Efficacy study in BALB/c mice bearing orthotopic 4T1 tumours 
4T1 cells, 1x105 cells/mouse in 50µl PBS [180-183], were injected orthotopically into the left lower 
thoracic mammary fat pad (around the nipple) of forty BALB/c eight-week-old female mice.  When 
the tumours were palpable, reaching approximately 80mm3 in volume the mice were randomly 
sorted into four equal groups. Table 2.5 shows the treatment schedule for each group of mice. 
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Group  Treatment Schedule of treatments  Number of mice 
A Vehicle Buffer + Virus Day 0, 3, & 5 10 
B IC87114 + PBS Day 0, 3, & 5 10 
C Vehicle + PBS Day 0, 3, & 5 10 
D IC87114 + Virus Day 0, 3, & 5 10 
 
Table 2.5.  Treatment schedule for groups of mice.   The dose of the IC87114 used was 75mg 
kg-1, VVL15 was delivered by intravenous injection of 1x108 PFU in 100µl filtered PBS via the tail vein. 
 
Mice were treated according to the schedule in Table 2.5 receiving either IC87114 or vehicle buffer 
by oral gavage three hours before either intravenous VVL15 or PBS.  The mice received this 
treatment three times on day 0, day 3, and day 5 (day 0 is the first day of treatment).  Tumours in 
each group were measured using callipers 3 times per week until the end of study.   
2.18.9. Efficacy study in KPC mice bearing spontaneous orthotopic pancreatic tumours 
Previous work has established that by 2.5 months old KPC mice have pancreatic tumours [178].  
Accordingly, 2.5-month-old KPC mice were pretreated with IC87114 at 75mg kg-1 by oral gavage 
three hours before receiving an intravenous injection of 1x108 PFU VVL15.  This treatment was 
performed on days 0, 3 and 5.  Mice were then monitored for signs of distress and culled if necessary 
in accordance with Home Office regulations.  Survival of all mice was recorded from the first 
treatment.  The untreated mice data were the kind gift of our collaborator Professor Thorsten 
Hagemann (Barts Cancer Institute, University of London, UK) and represents a separate experiment 
in which 15 KPC mice were monitored from 2.5 months old and their survival recorded.   
2.18.10. Optimisation of future efficacy preclinical models 
2.18.10.1 Assessment of a slower growing syngeneic flank tumour model   
 
CMT93 cells, 5x106 cells/mouse in 100µl PBS, were implanted subcutaneously into the shaved right 
flanks of four C57BL/6 eight-week-old female mice.  Tumours were measured using callipers 
regularly until the end of study.   
2.18.10.2. LLC orthotopic lung cancer model in C57BL/6 mice   
 
LLC cells, 5x105 cells/mouse in 100µl PBS, were systemically injected via the tail vein into eight 
C57BL/6 8-week-old female mice.  Non-contrast enhanced lung computed tomography (CT) was 
used to assess lung volumes of the mice at regularly intervals and the reduction in lung volume over 
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time was used as a surrogate marker for tumour volume.  Animals showing signs of distress or 
loss/gain of body weight or overwhelming lung disease were killed in accordance with Home Office 
regulations. 
 
2.19. Statistical Analysis 
 
All statistical analysis was undertaken in Prism 5 except the calculation of TCID50 values using the 
Reed-Muench method which was performed in Microsoft Excel.  EC50 values were determined from 
dose-response curves created using non-linear regression analysis.  Experiments with greater than 
two groups were analysed by either 1-way ANOVA with Newman-Keuls comparison post tests or 2-
way ANOVA with Bonferroni post tests depending on the number of variables.  Experiments with 
two groups were analysed either by unpaired t-test or 2-way ANOVA with Bonferroni post tests 
depending on the number of variables.  Survival data were represented in a Kaplan-Meier plot and 
log rank analysis was used to determine if differences between groups were significant.  In the 
Results Chapters 3-9, significance is depicted on graphs by stars; three stars (***) represent P < 
0.001, two stars (**) represent P < 0.01 and one star (*) represents P < 0.05.
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Chapter 3  
Differences between nude and wild-type murine syngeneic 
cancer models treated with systemically delivered Vaccinia 
virus 
3.1. Viral recovery from wild-type spleen and blood is greater at early time points 
when compared to nude mice 
 
In order to investigate which components of blood affect the systemic delivery of Vaccinia virus it 
was important to dissect out the previously observed differences between nude and 
immunocompetent BALB/c mice bearing CT26 flank tumours.  Accordingly, a series of experiments 
were undertaken to examine the temporal biodistribution of VVL15 in vivo in these mice. As shown 
in Figure 3.1a, there were no differences in the amount of virus detected in the plasma at any time 
points in nude and wild-type mice infected with VVL15.  However, there was significantly more viral 
DNA present in the blood cells of immunocompetent mice infected with VVL15 at 30 mins (P<0.05) 
and 3 hours (P<0.001) (Figure 3.1b).   
 
Furthermore, there was significantly more viral DNA isolated from the immunocompetent mouse 
spleens (Figure 3.1c) compared to their nude counterparts at 5, 10, 30 and 180 minutes (P<0.001 or 
P<0.01) in the mice infected with VVL15.  There was no significant difference between the models in 
terms of viral DNA isolated at later time points from either tumour or ovaries (Figure 3.1d&e).   
 
The main differences in the amount of viral DNA detected between the nude and 
immunocompetent models were in the spleen and whole blood cells.  These data (blood & spleen) 
taken together suggest there is a possible cellular component in the blood and spleen which is 
preferentially binding VVL15 in the immunocompetent model and considering the previous work in 
our group by James Tysome et al. (unpublished data, Chapter 1.5, Figure 1.4) it is likely these cellular 
components are monocytes/splenic macrophages. 
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Figure 3.1. Viral recovery from wild-type spleen and blood is greater at early time points when 
compared to nude mice.   
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Figure 3.1. Viral recovery from wild-type spleen and blood is greater at early time points when 
compared to nude mice.   
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(e) 
 
 
 
 
 
 
 
 
Figure 3.1. Viral recovery from wild-type spleen and blood is greater at early time points when 
compared to nude mice.  Either wild-type or nude BALB/c mice were injected with 1x106 CT26 cells 
in their right flanks.  Tumours were allowed to grow to 5-6mm diameter before one intravenous 
injection of 1x108 PFU VVL15.  Three mice in each group were culled at the following time points  
5mins, 10mins, 30mins and finally at 3 hours post injection.  All mice were killed by cardiac puncture 
with exsanguination and subsequently the tumours, ovaries and spleens were harvested.  DNA was 
extracted from all samples and qPCR performed to quantify viral DNA present.  Mean viral copy 
numbers per 1mcg total DNA loaded ± standard error of the mean (SEM) are displayed  (a) Plasma; 
there are no significant differences at any time point in viral DNA isolated between wild-type and 
nude samples (b) Blood cells; there is significantly more viral DNA isolated from wild-type blood cells 
compared to nude at 30mins (P<0.05) and 3 hours (P<0.001) post injection (c) Spleens; there is 
significantly more viral DNA isolated from wild-type spleen compared to nude at 5min (P<0.001), 
10mins, 30mins and 3hours post injection (P<0.01) (d) Tumours and (e) Ovaries; there are no 
significant differences at any time point in viral DNA isolated between wild-type and nude samples in 
either of these organs.  These are the combined results of two separate experiments.       
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3.2. Viral uptake in wild-type mouse macrophages is increased compared to those 
from nude mice ex vivo  
 
To investigate which blood cells accounted for this observed variation between the two different 
murine models in VVL15-infected mice a viral infection assay was performed on isolated 
subpopulations of either immunocompetent or nude mouse blood cells.  There was significantly 
more virus bound to monocytes (CD11b+ cells) from immunocompetent compared to nude mice 
(P<0.05) whereas there was no difference when lymphocytes or erythrocytes were compared (Figure 
3.2).  These results suggest that there is reduced monocyte activity in the nude mouse model 
resulting in less phagocytosis of virus compared to the immunocompetent model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Significantly more VVL15 was detected in macrophages from immunocompetent mice 
compared to those from nude mice. Pooled blood from either three wild-type or nude mice was 
separated by magnetic beads into lymphocytes, erythrocytes, and monocytes and then incubated 
with VVL15 at MOI 0.01 at room temperature for 30 minutes.  Subsequently DNA was extracted and 
viral DNA quantified by qPCR.  Mean viral copy numbers per cell ± SEM are displayed.  There is no 
statistical difference in viral DNA between wild-type and nude RBCs and lymphocytes, whereas there 
is statistically significantly more viral DNA isolated from wild-type mouse macrophages compared to 
nude mouse counterparts (P<0.05). 
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3.3. Phagocytosis of opsonised bioparticles is the same in nude and wild-type 
mouse macrophages  
 
Given the previous data in Figure 3.2 suggesting there was a difference in phagocytotic activity 
between nude and wild-type BALB/c mouse macrophages a general phagocytosis assay was 
undertaken.  There were no differences between nude and wild-type macrophages with respect to 
phagocytosis of fluorescein-labeled Escherichia coli K-12 BioParticles (Figure 3.3).  There might be 
differences in other forms of endocytosis or this observed difference could be virus-specific. 
 
 
 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
(b)    
    
 
 
 
 
 
 
Figure 3.3.  No difference in phagocytosis of Fluorescein-labeled Escherichia coli K-12 BioParticles 
by nude and wild-type mouse macrophages with and without IC87114.   
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(c)      
 
 
 
 
 
 
 
 
Figure 3.3.  No difference in phagocytosis of Fluorescein-labeled Escherichia coli K-12 BioParticles 
by nude and wild-type mouse macrophages with and without IC87114.  Bone marrow was 
extracted and pooled from either two nude or two wild-type BALB/c mice.  The macrophages were 
cultured ex vivo for seven days in medium containing macrophage colony stimulating factor until 
fully matured.  Cells were then pretreated with either IC87114 or medium for 2 hours,  after which 
cells were either stimulated with Lipopolysaccharide (LPS at 100ng ml-1) or left in medium for 1 hour 
and then opsonised E.coli particles from the Vybrant Phagocytosis Assay Kit (V-6694) were added for 
1 hour.  Macrophages were then harvested and analysed by FACS.  Data are presented as the mean 
percentage of the total macrophage population that phagocytosed opsonised beads ± SEM.  (a)  
There is no difference in the percentage of opsonised bioparticles that nude and wild-type mouse 
macrophages phagocytosed.  (b) & (c) The addition of IC87114 does not affect the ability of either 
(b) nude or (c) wild-type mouse macrophages to phagocytose opsonised E.coli particles.  The data 
presented are for LPS-stimulated macrophages.  There was no difference either in phagocytosis 
between nude and wild-type mouse macrophages treated without LPS (data not shown). 
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3.4. Summary of Chapter 3 
 
The main differences observed between nude and wild-type BALB/c mice bearing CT26 flank 
tumours subsequently infected with VVL15 were in the blood cells and spleen (Figure 3.1b&c).  It is 
reasonable to consider that there might be a cellular component in both the blood cells and spleen 
samples which might account for these differences.  Previous work in our group by James Tysome et 
al. (unpublished) has provided evidence that these cellular components are likely to be 
monocytes/splenic macrophages.  Figure 3.2 demonstrates that there was significantly more virus 
bound to monocytes (CD11b+ cells) from immunocompetent compared to nude mice.  These data 
further suggest that the difference between the nude and wild-type models is indeed macrophages, 
however there did not appear to be a general difference in phagocytosis between the models 
(Figure 3.3) but rather a virus-specific difference. 
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Chapter 4  
Macrophages are the key early cellular players in the 
clearance of systemically delivered Vaccinia virus 
4.1.  Depletion of macrophages enhances Vaccinia virus infection in tumours in 
vivo 
 
James Tysome et al. (unpublished data, Chapter 1.5, Figure 1.4) have previously shown that BALB/c 
mice bearing CT26 flank tumours pretreated with clodronate liposomes tended to have a higher 
tumour luminescence signal compared to PBS or liposome+PBS treated mice.  However this 
difference was not significant because there were too few mice in the control arm of the 
experiment.  Now, given the data from the previous experiments (Chapter 3) suggesting that 
monocytes/macrophages appear to be key early players in VVL15 clearance the clodronate liposome 
depletion experiment was repeated with appropriate numbers in each arm (n=5).  The results are 
illustrated in Figure 4.1, where the mice pretreated with clodronate liposomes had a significantly 
higher luminescence signal in their tumours compared to the controls (P<0.05 or P<0.01).  Thus 
depleting macrophages in the immune-competent model results in effective infection at the tumour 
site, similar to infection observed in the nude mice in the earlier experiment (unpublished data from 
James Tysome et al. Chapter 1.5, Figure 1.4).  Considering both this result and the previous results 
from Chapter 3 it appears that macrophages play a key role in the early clearance of systemically 
delivered VVL15 in immunocompetent BALB/c mice. 
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Figure 4.1. Macrophage depletion by clodronate liposomes significantly enhances the tumour 
luminescence signal in immunocompetent mice. 1x106 CT26 cells were subcutaneously injected into 
the right flank of fifteen BALB/c mice. When tumours reached approximately 100mm3, five mice 
received either 200l clodronate liposomes or 200l PBS liposomes or 200l PBS via intra-peritoneal 
(IP) injections at 144, 72 and 24 hours prior to all mice receiving one intravenous injection of 1x108 
PFU VVL15. Biodistribution of VVL15 was ascertained by In Vivo Imaging System (IVIS) under 
inhalation anesthesia from 5 minutes following IP injection of D-Luciferin (15mg ml-1). Mean 
luminescence values of tumours ± SEM are displayed.  Mice treated with VVL15 and clodronate 
liposomes have a significantly higher luminescence signal compared to the other two groups (P < 
0.05 or P < 0.01).    
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4.2.  Viral infection up-regulates expression of p110 delta at 3hrs in the wildtype 
mice   
 
Clodronate liposomes irreversibly deplete macrophage populations by inducing apoptosis and so 
potentially diminish any beneficial activity they might have in the tumour microenvironment 
unrelated to viral clearance.  This is particularly pertinent when considering that a successful 
strategy for the viral treatment of cancer is likely to involve both viral oncolysis and immune 
modulation.  In this context macrophages both in the immediate microenvironment and elsewhere 
are likely to be crucial in helping to effect the change from tumour tolerance to the development of 
anti-tumour immunity and so this necessitates a search for a novel, more selective and transient 
agent for enhancement of systemic delivery of VVL15.  Several lines of evidence have highlighted an 
important role for phosphatidylinositol 3-kinases (PI3K) [152-155] in macrophage phagocytosis and it 
maybe that this could account for the differences seen in viral uptake between nude and 
immunocompetent macrophages. 
 
It is also known that the class Ia p110 delta isoform is enriched in macrophages [184] and data from 
Chapter 3 together with work by James Tysome et al. (unpublished data, Chapter 1.5, Figure 1.4) 
suggest that splenic macrophages are crucial in the successful early clearance of VVL15 from the 
circulation.  In order to determine if the delta isoform could make an effective target, nude or 
immunocompetent mice bearing CT26 flank tumours were treated with either systemically delivered 
VVL15 or PBS.  They were then culled either directly after the viral/PBS injection or 3 hours later.  
Then their spleens were harvested and homogenised and delta isoform levels were quantified using 
qPCR.  Figure 4.2 shows the results, and there is significantly more p110 delta RNA at three hours in 
the splenocytes of immunocompetent mice treated with VVL15 compared to all other conditions 
(P<0.001).  This implies that there is a virally induced up-regulation of p110 delta RNA in splenocytes 
derived from immunocompetent mice but not nude, providing further clues as to the differences 
between the models and at least plausibly lending greater weight to the concept that splenic 
macrophages play a central role in VVL15 clearance.   
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Figure 4.2.  Systemic viral infection significantly increases p110 delta isoform RNA levels in the 
splenocytes of immunocompetent mice.  Either wild-type or nude BALB/c mice were injected with 
1x106 CT26 cells in their right flanks.  Tumours were allowed to grow to approximately 100mm3 
before either one intravenous injection of 1x108 PFU VVL15 or PBS via the tail vein.  Three mice in 
each group (Nude/PBS, Nude/VVL15, Immunocompetent/PBS and Immunocompetent/VVL15) were 
killed immediately after the tail vein injection or three hours later.  The spleens were harvested from 
all mice and homogenised, RNA was extracted and the amount of p110 delta RNA quantified by 
qPCR.  Data are presented as mean p110 delta transcription units per 2μg total RNA loaded ± SEM.  
There is significantly more p110 delta RNA at three hours in the immunocompetent mice treated 
with VVL15 compared to all other conditions (P<0.001).  
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4.3.  p110 delta protein expression is reduced in nude mouse macrophages 
 
Experimental data have shown that there are differences in the ability of nude and wild-type 
macrophages to bind VVL15 (Figure 3.2).  Furthermore after viral infection p110 delta expression at 
the RNA level is upregulated in immunocompetent splenocytes (Figure 4.2).  Figure 4.3 illustrates an 
experiment in which p110 delta protein expression was assayed by Western blot in either nude or 
wild-type mouse bone marrow-derived macrophages.  There appears to be no difference in p110 
delta protein expression in nude mouse macrophages compared to wild-type.  However small 
differences in expression of p110 delta would not be detected by this method.  Furthermore the 
p110 delta antibody, supplied by Santa Cruz Biotechnologies (sc-7176), varied somewhat between 
batches resulting in slightly different bands (this finding was confirmed in communications with 
Professor Vanhaesebroeck's group).  This inter-experimental variation can be seen in the western 
blots performed in this study (Figures 4.3, 6.6 & 9.5). 
 
Interestingly this experiment also demonstrates that there is more p110 delta protein expression in 
virally treated immunocompetent mouse macrophages compared to mock-treated.   This is 
consistent with the previous studies that have demonstrated that viral infection induces increases in 
PI3 kinase signalling [116, 143, 144] and also demonstrates that the observed virally induced up-
regulation of p110 delta RNA (Figure 4.2) translates to an increase in protein level.  This finding was 
confirmed in subsequent experiments performed in this study (Figure 9.5).  One limitation of this 
experiment was that nude macrophages were not treated with VVL15.  This would have been a 
useful comparison but was not performed due to an oversight by the author.  This occurred because 
the focus of the study at this point was changing from investigating the differences between nude 
and immunocompetent macrophages to the effects of p110 delta expression in wildtype 
macrophages alone.   
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Figure 4.3.  Expression of p110 delta isoform is reduced in nude macrophages. Bone marrow was 
extracted and pooled from either two nude or two wildtype BALB/c mice.  The macrophages were 
cultured ex vivo for seven days in medium containing macrophage colony stimulating factor until 
fully matured.  Nude mouse macrophages were immediately harvested for analysis of p110 delta 
expression whereas wild-type mouse macrophages were infected with VVL15 at MOI 5 or mock for 1 
hour.  After which the wild-type mouse macrophages were harvested and p110 delta protein 
expression was assessed by western blot.  There appears to be no difference in p110 delta isoform 
expression in nude mouse macrophages when compared to wild-type but there is more p110 delta 
isoform expression in the virally treated immunocompetent mouse macrophages. 
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4.4. Summary of Chapter 4 
 
Depletion of macrophages by clodronate liposomes improves the systemic delivery of VVL15 to the 
tumour site in wild-type BALB/c mice (Figure 4.1).  This provides further evidence that macrophages 
are the key early cellular players in the clearance of systemically delivered VVL15.  Clodronate 
liposomes are not an attractive agent for use in clinical trials as they irreversibly deplete 
macrophages.  PI3 kinases have established roles in phagocytosis in macrophages [152-155] and the 
class Ia p110 delta isoform is upregulated at the RNA and protein levels in wild-type mice after 
VVL15 infection (Figure 4.2 & 4.3).  These data suggest that blockade of PI3 kinases in general and 
class Ia p110 delta isoform in particular might be an appropriate method for enhancing VVL15 
systemic deliver in a pre-clinical model. 
 
Furthermore nude mouse macrophages appear to be less effective at taking up virus than wild-type 
ones probably because they fail to up-regulate their p110 delta transcription in response  to viral 
infection (Figure 4.2).  This reduction in p110 delta levels compared to wild-type might be a key 
difference when attempting to explain the relative reduction in viral uptake by nude mouse 
macrophages. 
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Chapter 5  
Inhibition of class 1a p110 delta and gamma isoforms 
reduces viral attachment to macrophages in vitro  
5.1.  Viral attachment to macrophages is markedly reduced after the inhibition of 
class Ia PI3 kinases 
 
Bone marrow-derived macrophages were pretreated with a panel of class 1 PI3 kinase inhibitors and 
a VVL15 attachment assay was performed.  All the inhibitors significantly reduced the amount of 
VVL15 attached to both wild-type (Figure 5.1a, P<0.001) and nude mouse macrophages (Figure 5.1b, 
P<0.01).  Interestingly although all the inhibitors reduced viral attachment in both nude and wild-
type mouse macrophages as before, the amount of virus attached to the untreated wild-type 
macrophages was greater than the untreated nude mouse macrophages.  Again supporting the idea 
that nude mouse macrophages are in some way less effective at taking up virus than wild-type 
counterparts. 
 
Unsurprisingly, PI-103 (a class 1a PI3 kinase alpha inhibitor) and TGX221 (a class 1a PI3 kinase beta 
inhibitor) both significantly reduced viral attachment.  However, both PI3 kinase alpha and beta 
isoforms are ubiquitously expressed in most cells, furthermore PI-103 is not a very specific alpha 
isoform inhibitor, as its actions are more similar to a pan-class 1 PI3 kinase inhibitor.  Thus alpha and 
beta isoforms are poor therapeutic targets in general due to the likehood of numerous off-target 
effects and PI-103 is specifically a poor choice for targeting the alpha isoform.  Similarly, wortmannin 
a pan-PI3 kinase inhibitor has far too many off-target effects [167].   
 
Figure 5.1a shows that delta and gamma PI3K inhibitors were the two most potent at selectively 
inhibiting macrophage activity and were almost as good as the pan inhibitor.  Additionally, class 1 PI3 
kinase delta and gamma are enriched in leucocytes cells and so blockade of either would likely have 
fewer (or at least more restricted) off-target effects compared to PI3 kinase alpha or beta.  In 
summary, macrophages appear to be the key cells involved in the clearance of systemically delivered 
VVL15 and inhibitors of PI3 kinase delta and gamma appear to be the most promising at blocking 
viral attachment to macrophages in vitro.  
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Figure 5.1. Selective inhibitors of p110 delta or gamma are almost as effective as the pan PI3 
kinase inhibitor, Wortmannin, in reducing the uptake of VVL15 by macrophages.  Bone marrow 
was extracted and pooled from either two wild-type or two nude BALB/c mice.  The macrophages 
were cultured ex vivo for seven days in media containing macrophage colony stimulating factor until 
fully matured.  Macrophages were pretreated for 2 hours with vehicle buffer or PI-103 ( a selective 
PI3k alpha inhibitor), TGX221 (a selective beta inhibitor), IC87114 (a selective p110 delta inhibitor), 
AS 604850 (a selective gamma inhibitor) or Wortmannin (a pan PI3k inhibitor) and then 
subsequently a viral attachment assay was undertaken.  None of the inhibitors were cytotoxic to 
either type of macrophage.  Mean viral copy numbers per macrophage plated ± SEM are displayed.  
(a) Wild-type macrophages;  all inhibitors are significantly different to vehicle buffer (P<0.001).  (b) 
Nude macrophages; All inhibitors are significantly different to vehicle buffer (for PI-103 P<0.001, for 
all other inhibitors P<0.01). 
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5.2.  Inhibition of p110 delta and gamma does not affect internalisation  
 
In section 5.1 it had been shown that selective class 1 p110 delta (IC87114) and p110 gamma 
(AS 604850) inhibitors markedly reduced VVL15 attachment to both wild-type and nude mouse 
macrophages.   These observations were confirmed in several further independent experiments 
illustrated in Figures 5.2a & 5.3a.  However, it was unknown how IC87114 or AS 604850 might affect 
internalisation of an attached virus in both nude and wild-type mouse macrophages.  With this in 
mind, internalisation assays were performed (Figures 5.2 b-c, 5.3 b & 5.4 b-c) which demonstrated 
that once the virus is attached to either a nude or wildtype mouse macrophage IC87114 or 
AS 604850 make no difference to the subsequent internalisation step(s).  Thus internalisation after 
attachment appears to occur in a p110 delta- and p110 gamma-independent manner, a finding 
which is consistent with previous work [143].  Furthermore the differences observed between nude 
and wild-type mouse macrophages appear to be restricted to viral attachment since when this is 
accounted for there is no statistically significant difference between viral internalisation in untreated 
wild-type and nude mouse macrophages (Figure 5.5). 
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Figure 5.2.  Selective inhibition of p110 delta reduces attachment of VVL15 to macrophages but 
does not affect internalisation of the virus.  Bone marrow was extracted and pooled from two 
wildtype (WT) BALB/c mice.  The macrophages were cultured ex vivo for seven days in media 
containing macrophage colony stimulating factor until fully matured.  Macrophages were pretreated 
for 2 hours with IC87114, a selective p110 delta inhibitor, or vehicle buffer and then subsequently a 
viral attachment assay was undertaken.  (a) VVL15 attachment assay, data are presented as mean 
viral copy numbers ± SEM;  the inhibitor treated group was statistically significantly different from 
untreated macrophages (P < 0.001) (b) & (c) VVL15 internalisation assay, data are presented as the 
mean percentage of the total attached virus that was internalised ± SEM;  macrophages were 
treated exactly as in the attachment assay but after the viral incubation phase at 4oC for 1 hour 
rather than harvesting them the macrophages were washed with PBS and then the inhibitor or 
vehicle buffer was reapplied for either 30mins or 60mins.  After which the macrophages were 
washed and the amount of virus present determined by qPCR.  There is no statistical difference 
between either group after (b) 30mins or (c) 60mins.     
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(a)   (b) 
 
 
 
 
 
 
 
Figure 5.3.  Selective inhibition of p110 gamma reduces attachment of VVL15 to macrophages but 
does not affect internalisation of the virus.  Bone marrow was extracted and pooled from two 
wildtype BALB/c mice.  The macrophages were cultured ex vivo for seven days in media containing 
macrophage colony stimulating factor until fully matured.  Macrophages were pretreated for 2 hours 
with AS 604850, a selective PI3 kinase gamma inhibitor, or vehicle buffer and then subsequently a 
viral attachment assay was undertaken.  (a) VVL15 attachment assay, data are presented as mean 
viral copy numbers ± SEM;  the inhibitor treated group was statistically significantly different from 
untreated macrophages (P < 0.01) (b) VVL15 internalisation assay, data are presented as the mean 
percentage of the total attached virus that was internalised ± SEM;  macrophages were treated 
exactly as in the attachment assay but after the viral incubation phase at 4oC for 1 hour rather than 
harvesting them the macrophages were washed with PBS and then the inhibitor or vehicle buffer 
was reapplied for 30mins.  After which the macrophages were washed and the amount of virus 
present determined by qPCR.  There is no statistical difference between either group. 
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Figure 5.4.  In nude mouse macrophages selective inhibition of p110 delta reduces attachment of 
VVL15 but does not affect internalisation of the virus.  Bone marrow was extracted and pooled 
from two nude BALB/c mice.  The macrophages were cultured ex vivo for seven days in media 
containing macrophage colony stimulating factor until fully matured.  Macrophages were pretreated 
for 2 hours with IC87114, a selective p110 delta inhibitor, or vehicle buffer and then subsequently a 
viral attachment assay was undertaken.  (a) VVL15 attachment assay, data are presented as mean 
viral copy numbers ± SEM;  the inhibitor treated group was statistically significantly different from 
untreated macrophages (P < 0.001) (b) & (c) VVL15 internalisation assay, data are presented as the 
mean percentage of the total attached virus that was internalised ± SEM;  macrophages were 
treated exactly as in the attachment assay but after the viral incubation phase at 4oC for 1 hour 
rather than harvesting them the macrophages were washed with PBS and then the inhibitor or 
vehicle buffer was reapplied for either 30mins or 60mins.  After which the macrophages were 
washed and the amount of virus present determined by qPCR.  There is no statistical difference 
between either group after (b) 30mins or (c) 60mins.     
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Figure 5.5.  There is no difference between viral internalisation in untreated wild-type and nude 
macrophages.  Bone marrow was extracted and pooled from either two nude or wild-type BALB/c 
mice.  The macrophages were cultured ex vivo for seven days in medium containing macrophage 
colony stimulating factor until fully matured.  Subsequently, a viral attachment and internalisation 
assay was undertaken.  Data are presented as the mean percentage of the total attached virus that 
was internalised ± SEM; there is no statistical difference between either group after (a) 30mins or (b) 
60mins.     
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5.3.  Class Ia p110 delta knock-in macrophages demonstrate a similar reduction 
in viral attachment to wildtype macrophages treated with IC87114  
      
Kinase inhibitors are renowned for having off-target effects, often affecting kinases other than their 
intended targets.  IC87114 is thought to be quite specific however it certainly could hamper other 
kinases [167].  Therefore there is a need to ascertain that the reduction in VVL15 attachment 
observed in section 5.2 is in fact due to IC87114 blocking p110 delta activity.  Accordingly, bone 
marrow-derived macrophages from transgenic p110 delta knock-in (this is a ‘kinase-dead’ 
inactivating mutation) mice were kindly provided by our collaborator Professor Vanhaesebroeck.  
(Unfortunately, there were no equivalent PI3 kinase gamma knock-in mice available at our 
institution).   Using these macrophages, together with matched C57BL/6 wild-type macrophages an 
attachment assay was performed.  Figure 5.6 shows that there is a similar significant reduction of 
VVL15 attachment to wild-type macrophages treated with IC87114 compared with both 
heterozygote and homozygote transgenic macrophages (P<0.01 or P<0.05 respectively).  These data 
suggests that the reduction in attachment seen in wild-type macrophages treated with IC87114 is 
due to selective p110 delta inhibition.  Therefore it is logical to suggest that p110 delta is involved in 
the process of virus binding to the macrophage.  Interestingly, there is no difference in the reduction 
in attachment between the heterozygote and homozygote p110 delta knock-in macrophages, 
implying that after a certain level of delta blockade VVL15 attaches to the cell in a p110 delta-
independent manner, a finding which is consistent with previous work [116, 143, 144]. 
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Figure 5.6.  p110 delta is important in viral attachment.  Bone marrow was extracted and pooled 
from either two wildtype BALB/c mice or four transgenic mice with p110 delta knocked in 
(heterozygous knock in [n=2], homozygous knock in [n=2]).  The macrophages were cultured ex vivo 
for seven days in medium containing macrophage colony stimulating factor until fully matured.  A 
viral attachment assay was performed immediately on the transgenic macrophages whereas the 
wild-type macrophages were pretreated for 2 hours with IC87114, a selective p110 delta inhibitor, or 
vehicle buffer and then subsequently a viral attachment assay was undertaken. Data are presented 
as mean viral copy numbers ± SEM.  Both heterozygote and homozygote delta knock in transgenic 
murine macrophages demonstrated a similar reduction in viral attachment to wild-type 
macrophages treated with IC87114, all groups were statistically significant from untreated wild-type 
macrophages (P < 0.05 or P < 0.01). 
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5.4.  Class II PI3 kinase C2β knock-in macrophages  do not show reduction in viral 
attachment when compared to wild-type macrophages 
 
There is evidence that the class 2 PI3 kinase C2β isoform is involved in both actin rearrangement and 
endocytosis [159].  Given this, it is possible that it might play a role in the attachment of VVL15 to 
macrophages.  Accordingly, bone marrow derived macrophages from transgenic mice with PI3 
kinase C2β knocked-in (kinase-dead) were obtained from our collaborator Professor 
Vanhaesebroeck.  Figure 5.7 illustrates the results from several attachment assays performed on 
these macrophages using matched background wild-type macrophages as controls.  There is no 
significant difference in the attachment of VVL15 between untreated wild-type and C2β knock-in 
macrophages.  Therefore it seems unlikely that PI3 kinase C2β plays a significant role in the 
attachment of VVL15 to macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7.  PI3 kinase C2β plays no role in the attachment of VVL15 to macrophages.  Bone 
marrow was extracted and pooled from either two wild-type BALB/c mice or two transgenic mice 
which were homozygous for PI3k C2β knock in.  The macrophages were cultured ex vivo for seven 
days in media containing macrophage colony stimulating factor until fully matured after which a  
viral attachment assay was performed.  Data are presented as mean viral copy numbers per 
macrophage plated ± SEM.  There was no statistical difference between the homozygous C2β knock 
in macrophages and wildtype ones after treatment with virus.   
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5.5 Summary of Chapter 5 
 
All class 1 PI3 kinases inhibitors reduce viral attachment in wild-type and nude macrophages (Figures 
5.1 & 5.2).  However p110 delta and gamma are less likely to have off target effects compared to  
alpha, beta and the pan inhibitor.  p110 delta or p110 gamma blockade does not affect 
internalisation of VVL15 (Figures 5.3 & 5.4) and differences between nude and wild-type 
macrophages appear restricted to viral attachment only (Figure 5.5).  p110 plays an important role in 
viral attachment to macrophages (Figure 5.6) and finally class II PI3 kinase C2β  does not affect viral 
binding (Figure 5.7). 
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Chapter 6  
The effect of p110 delta and gamma inhibition on viral 
cytotoxicity and replication in a panel of tumour cell lines 
 
It has been demonstrated that IC87114 and AS 604850 effectively reduce VVL15 attachment to 
macrophages in vitro, but what is not certain is whether or not the inhibitors have a direct cytotoxic 
effect on cancer cells.  MTS assay was performed using either IC87114 or AS 604850 on either CMT 
93 or CT26 murine cancer cell lines the highest concentration was 100μM (a hundred times the 
experimental concentration used in all the in vitro assays) and then there were nine 1:10 serial 
dilutions of either inhibitor.  Interestingly it was not possible to develop a dose response curve as 
there was only an effect on cell survival at the maximum concentration (100μM).  Thus it was not 
possible to calculate an EC50 value.  Figure 6.1 illustrates percentage of cells alive in the maximum 
concentration treatment groups compared to the untreated group, there is an approximate 20% 
reduction in the cell survival in both cell lines compared to untreated cells.  There is no statistically 
significant difference between the IC87114 or AS 604850 groups in either cell line.  Given that there 
was only an effect on cell survival at 100uM it is reasonable to suggest that at the in vitro experiment 
concentration, 1µM, the inhibitors will be having no effect on cell survival. 
 
However, the EC50 of IC87114 is 0.5μM [173] and for AS 604850 it is 250nM [167].  It is very odd and 
highly unlikely that a concentration of 100μM would have no effect at all on these cell lines.  It is 
technically very difficult to dissolve these kinase inhibitors into medium as they are very 
hydrophobic.  One possible reason for the discrepancy between reported EC50 values and this 
experiment is that the inhibitors were not present in the medium at the expected concentrations.  It 
may well be the case that the inhibitors were only partially dissolved when making the highest 
concentration and so the concentration of inhibitors was not in fact 100μM.  Thus all subsequent 
dilutions would also not be the desired concentrations.  Indeed it is possible little or no inhibitor was 
present in the final dilutions.  This is a very significant weakness of this particular experiment. 
 
  
 
 
 
Chapter 6 
84 
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(b) 
 
 
 
 
 
 
 
 
Figure 6.1.  IC87114 and AS 604850 are minimally cytotoxic when directly applied to CT26 and 
CMT93 cancer cell lines.  A MTS assay was performed on CT26 & CMT 93 cancer cell lines each of 
which were treated with either IC87114 (a selective p110 delta inhibitor)  or AS 604850 (a selective 
PI3k gamma inhibitor) at nine serial dilutions with a maximum concentration of 100μM (a hundred 
times the normal experimental concentration used in all the in vitro assays).  This concentration 
range was not sufficient to produce an EC50 value therefore data are presented as the mean 
percentage of cells alive in the maximum concentration treatment groups compared to the 
untreated group ± SEM.  There is approximately a 20% reduction in the cell survival in both cell lines 
compared to untreated cells.  There is no statistically significant difference between the IC87114 or 
AS 604850 groups in either cell line.  (a) CT26 cancer cell line (b) CMT 93 cancer cell line   
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6.1.  Pretreatment with IC87114 or AS 604850 does not affect the cytotoxicity of 
VVL15 in a panel of murine cancer cell lines  
 
Having established that IC87114 and AS 604850 are only marginally directly cytotoxic at high 
concentrations, it was then important to determine whether the addition of IC87114 or AS 604850 
with VVL15 on cancer cells lines might have a positive or negative additive or synergistic effect in 
terms of viral cytotoxicity.  Indeed the inhibitors may reduce the efficacy of VVL15 by preventing 
infection of the cancer cells.  Accordingly, MTS assays were undertaken after murine cancer cell lines 
had been pretreated with either IC87114 or AS 604850 or both.  In vivo the inhibitors would be given 
by oral gavage and then subsequently enter the blood stream.  Shortly after entering the circulation 
they would flow through the tumour capillary beds and enter tumour cells.  Residual non-absorbed 
inhibitors would then drain from the tumour microenvironment.  Mindful of this, the experiment 
was designed to mimic this in vivo scenario; cancer cell lines were pretreated for 2 hours with either 
inhibitor or both, allowing them to be absorbed into the tumour cells, and then the excess inhibitors 
were removed prior to viral infection.  However, it was also important to know if the persistence of 
inhibitors in the tumour microenvironment might have an effect on viral cytotoxicity.  To test this, 
another arm of the experiment was designed in which cancer cell lines were pretreated with 
inhibitors and excess inhibitors were not removed prior to viral infection, but instead remained in 
the supernatant for the entire 6-day experiment. 
 
Figures 6.2, 6.3 and 6.4 demonstrate that the addition of IC87114 or AS 604850 or both in 
combination were entirely neutral in terms of their effect on viral cytotoxicity.  It made no difference 
whether the cells were pretreated for 2 hours with subsequent removal of excess inhibitors or 
whether the inhibitors remained within the supernatant for the entire 6 day experiment. 
Admittedly, the reason for this observation might simply be a reflection of the fact that the cell lines 
do not express p110 delta or p110 gamma isoforms and so any length of treatment would have 
limited or no effect. 
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Figure 6.2.  The addition of IC87114 or AS 604850 alone or in combination on CT26 cells had no 
effect on viral cytotoxicity.  A MTS assay was performed on the CT26 cancer cell line.  500 CT26 cells 
per well were plated out on 96 well plates.  The cells were pretreated with either vehicle buffer, 
IC87114 (a selective p110 delta inhibitor), AS 604850 (a selective PI3k gamma inhibitor) or both at a 
concentration of 1μM.  Plates were either pretreated with the various inhibitors for 2 hours and 
then the supernatant was aspirated and fresh media without any inhibitors added before viral 
infection or cells were pretreated for 2hrs and then without aspiration of the supernatant viral 
infection was undertaken.  In experiments where the inhibitor or mock was not aspirated before the 
viral infection the inhibitor was present for the duration of the 6-day experiment.  Plates were 
infected with nine 1:10 serial dilutions of VVL15 with the highest multiplicity of infection (MOI) being 
100.  Plates were incubated for 6 days and then a MTS assay was performed.  All experiments were 
performed in duplicate.  (a) Mean EC50 values ± SEM of the various groups after pretreatment with 
inhibitors or mock for 2 hours with subsequent removal before viral infection.  (b) Mean EC50 values 
± SEM of the various groups after pretreatment with inhibitors or mock for 2 hours without 
subsequent removal and then viral infection.  There are no statistical differences between any of the 
groups in either (a) or (b). 
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(a)   (b) 
 
 
 
 
 
 
 
Figure 6.3. The addition of IC87114 or AS 604850 alone or in combination on CMT93 cells had no 
effect on viral cytotoxicity.  A MTS assay was performed on the CMT93 cancer cell line.  1x103 
CMT93 cells per well were plated out on 96 well plates.  The cells were pretreated with either 
vehicle buffer, IC87114 (a selective p110 delta inhibitor), AS 604850 (a selective PI3k gamma 
inhibitor) or both at a concentration of 1μM.  Plates were either pretreated with the various 
inhibitors for 2 hours and then the supernatant was aspirated and fresh media without any 
inhibitors added before viral infection or cells were pretreated for 2hrs and then without aspiration 
of the supernatant viral infection was undertaken.  In experiments were the inhibitor or mock was 
not aspirated before the viral infection the inhibitor was present for the duration of the 6 day 
experiment.  Plates were infected with nine 1:10 serial dilutions of VVL15 with the highest 
multiplicity of infection (MOI) being 100.  Plates were incubated for 6 days and then a MTS assay was 
performed.  All experiments were performed in duplicate.  (a) Mean EC50 values ± SEM of the various 
groups after pretreatment with inhibitors or mock for 2 hours with subsequent removal before viral 
infection.  (b) Mean EC50 values ± SEM of the various groups after pretreatment with inhibitors or 
mock for 2 hours without subsequent removal and then viral infection.  There are no statistical 
differences between any of the groups in either (a) or (b). 
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Figure 6.4. The addition of IC87114 or AS 604850 alone or in combination on 4T1 cells had no 
effect on viral cytotoxicity.  A MTS assay was performed on the 4T1 cancer cell line.  1x103 4T1 cells 
per well were plated out on 96 well plates.  The cells were pretreated with either vehicle buffer, 
IC87114 (a selective p110 delta inhibitor), AS 604850 (a selective PI3k gamma inhibitor) or both at a 
concentration of 1μM.  Plates were either pretreated with the various inhibitors for 2 hours and 
then the supernatant was aspirated and fresh media without any inhibitors added before viral 
infection or cells were pretreated for 2hrs and then without aspiration of the supernatant viral 
infection was undertaken.  In experiments were the inhibitor or mock was not aspirated before the 
viral infection the inhibitor was present for the duration of the 6 day experiment.  Plates were 
infected with nine 1:10 serial dilutions of VVL15 with the highest multiplicity of infection (MOI) being 
100.  Plates were incubated for 6 days and then a MTS assay was performed.  All experiments were 
performed in duplicate.  (a) Mean EC50 values ± SEM of the various groups after pretreatment with 
inhibitors or mock for 2 hours with subsequent removal before viral infection.  (b) Mean EC50 values 
± SEM of the various groups after pretreatment with inhibitors or mock for 2 hours without 
subsequent removal and then viral infection.  There are no statistical differences between any of the 
groups in either (a) or (b). 
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6.2.  IC87114 and AS 604850 do not affect viral replication in a panel of murine 
cancer cell lines 
 
Figures 6.2, 6.3 and 6.4 demonstrate that pretreatment with either IC87114 or AS 604850 or both 
has no effect on viral cytotoxicity whether the excess inhibitor is washed away prior to viral infection 
or not.  The next step was to assess whether or not pretreatment of the same cancer cells with 
IC87114 or AS 604850 or both had any effect on viral replication.  Given that no difference had been 
observed between pretreatment of cells with the inhibitors for 2 hours or for 6 days in terms of 
cytotoxicity, cells were only pretreated for 2 hours in this experiment, mimicking the in vivo 
scenario, as this reduced the complexity of the experiment and the cost. 
 
Figure 6.5 shows the results of this experiment.  The addition of either inhibitor or in combination 
has no effect on viral replication on a panel of murine cancer cell lines.   
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(a)  (b) 
 
 
 
 
 
 
 
 
                             (c) 
 
 
 
 
 
 
Figure 6.5.  The addition of IC87114 or AS 604850 alone or in combination on a panel of cancer cell 
lines had no effect on viral replication.  CT26, CMT 93, and 4T1 cell lines were plated in six well 
plates at 2x105 cells/well in 2ml of 5% DMEM.  Cells were left to adhere overnight and then 
pretreated with either vehicle buffer, IC87114 at 1μM, or AS 604850 at 1μM or both IC87114 & AS 
604850 at 1μM.  Two hours later the inhibitor/media was aspirated and fresh media applied.  Then 
the cells were infected with VVL15 at MOI 1.  Cells were then harvested at 24, 48, 72, and 96 hours 
after viral infection.  A TCID50 assay was performed using the harvested cell lysates and PFU ml
-1 was 
calculated using the Reed & Muench method [177].  Data are presented as PFU per cell ± SEM  (a) 
CT26 cells (b) CMT 93 (c) 4T1; there is no significant difference between any of the groups in any of 
the cell lines. 
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6.3. Expression of p110 delta isoform in a panel of cancer cell lines is much less 
than in bone marrow derived macrophages 
 
IC87114 and AS 604850 appear to similarly reduce viral attachment to macrophages (chapter 5) 
although IC87114 was slightly more potent (Figure 5.1a).  They also appear not to have any direct 
toxic effect on a panel of cancer cell lines.  Furthermore they appear to be entirely neutral in respect 
of viral cytotoxicity and replication on the same panel of cancer cell lines.  However there is 
increasing evidence from clinical trials that delta inhibition, rather than gamma, is a promising 
therapeutic target [185].  It is for this reason and the possibility that IC87114 might be marginally 
more effective at reducing viral attachment (Figure 5.1a) that the rest of this current study has 
focused on p110 delta inhibition rather than any of the other class 1 PI3 kinase isoforms as a means 
of reducing viral attachment to macrophages and potentially enhancing systemic delivery of VVL15. 
 
Accordingly, further experiments were set up examining the effect of pretreatment of KPC-derived 
cell lines DT 6606 and K 8484 and the murine head and neck cancer cell line SCCVII with IC87114 
only. MTS assay or viral replication assay were undertaken.  As had been previously shown with the 
other tested cell lines the pretreatment of IC87114 for 2 hours had no positive or negative effect on 
either viral cytotoxicity or replication (data not shown).  This additional work was carried out by Mr 
Ka Lok Choi as part of his MSc course work.  It was carried out under the direction and supervision of 
the author of this study. 
 
All the results so far have demonstrated that IC87114 has no effect on the tested murine cancer cell 
lines with or without the addition of VVL15.  These observations are further supported by the results 
of a Western blot examining p110 delta protein levels in these cell lines demonstrating minimal or 
absent expression (Figure 6.6).  This result could explain why there has been no observed effect of 
pretreatment of these cell lines with IC87114 for either 2 hours or 6 days. 
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Figure 6.6. p110 delta expression is low or absent in a panel of cancer cell lines.  Expression of p110 
delta isoform by Western blot assay.  Demonstrating the relative lack of expression of p110 delta 
isoform in CT26, CMT93, 4T1, K8484 and DT6606 when compared to murine bone marrow-derived 
macrophages.  
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6.4.  Summary of Chapter 6 
 
IC87114 and AS 604850 are only marginally directly cytotoxic at 100μM and at experimental 
concentrations will have no direct effect on cell survival (Figure 6.1).  Neither have any effect on viral 
cytotoxicity or replication on CT26, CMT 93, or 4T1 cell lines (Figures 6.2, 6.3, 6.4 & 6.5).  Tested 
separately IC87114 does not affect the viral cytotoxicity or replication in SCC VII, DT6606 or K8484 
cell lines (data not shown).  This is not surprising as there is minimal or no expression of p110 delta 
isoform in any of the tested murine cancer cell lines (Figure 6.6).   
 
The focus of the rest of the study will be on IC87114 as it appears to be slightly more effective at 
reducing viral attachment to macrophages (Figure 5.1a) and there is increasing evidence from 
clinical trials that p110 delta inhibition might be the more promising therapeutic target [186, 187] 
rather than p110 gamma inhibition.  
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Chapter 7  
Optimisation and biodistribution of p110 delta inhibitor in 
vivo  
7.1. Pretreatment with higher doses of IC87114 results in significantly more virus 
in the tumour compared to virus alone in vivo    
 
Before any animal studies could occur the optimal in vivo dose of IC87114 needed to be ascertained.   
IC87114 has not been given previously in combination with VVL15.  However there have been 
several studies (Sadhu et al[173] and Durand et al[188]) which have used IC87114 at different 
concentrations and delivery methods.  Given that the mice would subsequently have intra-venous 
injections, and given that IC87714 is orally available [189] it was deemed the that oral administration 
was least traumatic and thus ideally the preferable route in this study.  Also a once daily regime is 
required under our institution’s Home Office Animal Licence.  Sadhu et al[173] had used a twice daily 
IP dose of 32mg kg-1 and Durand et al[188] had used a twice daily oral gavage dose of 25mg kg-1.  
Neither group used any viruses in combination with their IC87114 administrations.  The combined 
daily doses were 50mg kg-1 and 64mg kg-1 which were used as the midpoint of a range of doses of 
IC87114 for this study.  Accordingly the initial doses tested in this study were 25mg kg-1, 50mg kg-1, 
and 75mg kg-1 by oral gavage.  It was decided to administer these doses three hours prior to VVL15 
systemic delivery in BALB/c mice bearing CT26 flank tumours.  This timing was based on the in vitro 
data in Chapter 5 that showed that there was a reduction in viral attachment to macrophages after 
three hours of incubation with IC87114 and a pharmacokinetics study performed in Rats 
demonstrating that the time to maximum plasma concentration after oral administration of IC87114 
was 4hrs [189].  
 
An initial dose escalation study was undertaken which is illustrated in Figure 7.1.  The 25mg kg-1 dose 
was not significantly different from the vehicle control group and therefore was discounted 
immediately from further consideration (Figure 7.1a).  Both 50mg kg-1 and 75mg kg-1 doses of 
IC87114 were statistically significantly different from vehicle buffer alone (Figure 7.1b & c) at various 
time points.  Admittedly the 75mg kg-1 dose group was statistically different from control at more 
time points than the 50mg kg-1 dose group.  However, based on these initial data and bearing in 
mind the high cost of IC87114 it was decided to use the 50mg kg-1 dose for future work and it was 
used in the experiment illustrated in Figure 8.1.  But, in time, the dose escalation study was repeated 
and it was found that when data were combined from both studies (n=8 per group in combined 
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data) that the 75mg kg-1 dose group was most consistently statistically different from vehicle buffer 
alone (Figure 7.2c).  Indeed when the data were combined the 50mg kg-1 group was not statistically 
significantly different from the vehicle buffer group (Figure 7.2b).  After this repeat study had been 
analysed all subsequent in vivo studies used 75mg kg-1 as the optimised inhibitor dose.  One further 
dose escalation study was undertaken after this using 75mg kg-1 and the combined results for all 
three experiments (n=11 per group in combined data) clearly show that the 75mg kg-1 dosing 
produces consistently higher tumour luminescence compared to control (Figure 7.3). 
 
Interestingly, the peak tumour luminescence was always observed at day 3 and 5 after a single viral 
treatment irrespective of pretreatment with or without IC87114 or clodronate liposomes (Figure 
4.1).  This appears to be an intrinsic viral characteristic and plausibly mirrors the peak viral 
replication seen at 72 hours in vitro with subsequent decline by day 7, in all likehood due to a 
developing anti-viral immunity. 
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Figure 7.1. Initial experiment demonstrating that there is increased tumour luminescence in 
BALB/c mice bearing CT26 flank tumours after pretreatment with 50mg kg-1 and 75mg kg-1 
IC87114.  Four BALB/c mice bearing CT26 flank tumours received either one of the various doses of 
IC87714 (25mg kg-1, 50mg kg-1 or 75mg kg-1) or vehicle buffer three hours before one intravenous 
injection of 1x108 PFU VVL15.  Biodistribution of VVL15 was ascertained by In Vivo Imaging System 
(IVIS) under inhalation anesthesia from 5 minutes following intra-peritoneal (IP) injection of D-
Luciferin (15mg ml-1). Mean luminescence values of tumours ± SEM are displayed.  There was no 
significant difference between the group pretreated with 25mg kg-1 and the no inhibitor group.  
There was significantly more signal detected from the group pretreated with 50mg kg-1 IC87114 at 
day 5 (P<0.01) compared to the no inhibitor group.  There was significantly more signal detected 
from the group pretreated with 75mg kg-1 IC87114 at days 1, 3 and 5 (P<0.001 at day 1 and P<0.05 at 
days 3 & 5) compared to the no inhibitor group.   
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Figure 7.2. Combined results demonstrating that there is increased tumour luminescence in 
BALB/c mice bearing CT26 flank tumours after pretreatment with only 75mg kg-1 IC87114.  These 
are the combined results of two experiments.  Eight BALB/c mice bearing CT26 flank tumours 
received either one of the various doses of IC87714 (25mg kg-1, 50mg kg-1 or 75mg kg-1) or vehicle 
buffer three hours before one intravenous injection of 1x108 PFU VVL15.  Biodistribution of VVL15 
was ascertained by IVIS under inhalation anesthesia from 5 minutes following IP injection of D-
Luciferin (15mg ml-1). Mean luminescence values of tumours ± SEM are displayed.  There was no 
significant difference between the group pretreated with 25mg kg-1 and the no inhibitor group.  
There was no significant difference between the group pretreated with 50mg kg-1 and the no 
inhibitor group.   There was significantly more signal detected from the group pretreated with 75mg 
kg-1 IC87114 at days 1, 3, 4 and 5 (P<0.05) compared to the no inhibitor group.  
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Figure 7.3  Confirmation that pretreatment with 75mg kg-1 IC87114 is the optimal dose for 
enhancing the tumour luminescence signal in BALB/c mice bearing CT26 flank tumours.  These are 
the combined results of three experiments.  Eleven BALB/c mice bearing CT26 flank tumours 
received either 75mg kg-1 IC87714 or vehicle buffer three hours before one intravenous injection of 
1x108 PFU VVL15.  Biodistribution of VVL15 was ascertained by IVIS under inhalation anesthesia from 
5 minutes following IP injection of  D-Luciferin (15mg ml-1). Mean luminescence values of tumours ± 
SEM are displayed.  There was significantly more signal detected from the group pretreated with 
75mg kg-1 IC87114 at days 1, 3, 4 and 5 (P<0.01 at day 1 and P<0.05 at days 3, 4, & 5).  
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7.2. p110 delta inhibition enhances viral recovery in vivo from tumours whilst 
there is minimal off-target viral recovery 
 
The dose escalation studies demonstrated that there was increased viral luminescence from the 
tumours in IC87114 treated mice particularly at days 3 and 5.  The viral recovery from the tumours in 
the biodistribution study illustrated in Figure 7.4 is consistent with these finding.  The group treated 
with IC87114 had more virus recovered from their tumours than the controls particularly on days 3 
& 5 mirroring the previous results seen in the imaging studies (Figures 7.1, 7.2 & 7.3).  The 
differences observed in viral recovery in tumours between the treated and non-treated groups were 
not statistically significant but there was a general trend for the IC87114 group to have more viruses 
recovered from the tumour tissues at all time points (Figure 7.4a).  There are several reasons for 
this, firstly each experiment only had 3 mice in each group and even with the combined data there 
are only 9 mice per time point per group (Figure 7.4 a, b & c).  These are relatively low numbers and 
so there is the possibility of considerable inter-mouse variation.  Moreover, TCID50 was used to 
quantify viral recover and this technique has a margin of error of up to a power of ten.  One way to 
standardise these systemic errors would be to perform one much larger experiment with 10 mice in 
each group.  This would be a massive and costly undertaking that would be difficult to justify as the 
data from the multiple dose escalation studies clearly demonstrate a statistically significant increase 
in the luminescence signal from the IC87114 group compared to virus alone (Figure 7.1-7.3).   
     
The off-target viral recovery in the brain, ovaries, and liver were similar between IC87114 and VVL15 
alone groups.  The differences between the groups were not statistically significant and were of 
much less magnitude compared to the levels seen in the tumour (data not shown).  However, there 
were occasional spikes in viral recovery in the lungs and spleen (Figures 7.4 b & c respectively), and 
this possibly represents trapped blood in these filtering organs during viraemic episodes rather than 
productive parenchymal infection especially as the thymidine kinase-deleted VVL15 replicates poorly 
in normal cells [175]. 
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(a) (b) 
 
 
 
 
 
 
 
 
   (c) 
 
 
 
 
 
Figure 7.4.  Increased viral recovery from tumours of mice pretreated with IC87114 at later time 
points.  Biological time point study of VVL15 in BALB/c mice bearing CT26 flank tumours after 
pretreatment with 75mg kg-1 IC87114 or vehicle buffer alone.  When tumours reached 5-6mm in 
diameter, 15 mice received either 75mg kg-1 of IC87714  or vehicle buffer three hours before one 
intravenous injection of 1x108 PFU VVL15. Biodistribution of VVL15 was ascertained by TCID50 after 
three mice were culled at each time point per group.  Data are presented as mean PFU per gram of 
tissue harvested ± SEM.  There was a trend for more virus to be recovered in the tumour tissues in 
mice pretreated with IC87114 at later time points whereas the off target recovery was similar 
between groups and of much less magnitude. Tissues: (a) Tumours, (b) Lungs, (c) Spleen.  These are 
the combined results of three separate experiments with a total of 9 mice per time point per group.  
Viral recovery from liver, ovary, and brain was also performed.  There was minimal amounts of virus 
detected at these sites and there was no difference between mice pretreated with IC87114 or 
vehicle buffer alone (data not shown).  
 
 
3hrs Day 1 Day 3 Day 5 Day 7
100
102
104
106
108 No Inhibitor + VVL15
IC87114 + VVL15
Spleen
Time
P
F
U
 /
 g
3hrs Day 1 Day 3 Day 5 Day 7
100
102
104
106
108
1010
1012
No Inhibitor + VVL15
IC87114 + VVL15
Tumours
Time
P
F
U
 /
 g
3hrs Day 1 Day 3 Day 5 Day 7
100
102
104
106
108
1010 No Inhibitor + VVL15
IC87114 + VVL15
Lungs
Time
P
F
U
 /
 g
Chapter 7 
101 
 
7.3. Pretreatment of KPC mice with IC87114 enhances the viral delivery to 
spontaneous orthotopic pancreatic cancers  
 
It has been previously shown that the pretreatment of IC87714 enhanced the tumour luminescence 
in BALB/c mice bearing flank tumours (Figures 7.1, 7.2 & 7.3).  Preclinical models of human cancer 
are all to a certain extent poor representations of human disease.  Immune-competent mice bearing 
syngenic flank tumours are certainly useful but do not represent clinical disease as well as a 
spontaneous orthotopic pancreatic cancer model.    KPC mice are conditional heterozygote mutants 
for both mutant Kras and P53 genes in pancreatic tissue.  The Cre recombinase is under a pancreatic-
specific promoter and causes the expected “1LoxP” recombination events in the KPC (triple mutant) 
mice [178, 179].  These mice reliably develop spontaneous orthotopic pancreatic cancers by about 
two and half months of age [178], which recapitulates the pathogenesis of human pancreatic cancer 
including its histological structure.  Using this more representative model, three mice were 
pretreated with IC87114 or vehicle buffer respectively and then systemically infected with VVL15.  
There was a clear trend towards improved viral delivery to the tumour in the IC87114 group but it 
was not statistically significant (Figure 7.5).  Again it is likely this is due to inter-mouse variation 
within each group and the small sample size.  Bearing this in mind, six more KPC mice were 
pretreated with either IC87114 or vehicle buffer and then infected with VVL15.  These mice were 
then culled on day 3 after viral infection, which correlated with the highest luminescent signal from 
the treated group in the study in Figure 7.5, and their tumours harvested and prepared for 
immunohistochemical analysis with staining for the Vaccinia viral coat protein.  They were semi-
qualitatively assessed by a histopathologist who was blinded to the treatment (Dr Yaohe Wang).  
Figure 7.6 illustrates these results; there are more positively staining tumour cells in the IC87114-
treated group compared to control.  This evidence lends further weight to the conclusion that 
pretreatment with IC87114 may enhance systemic delivery of VVL15 in a spontaneous orthotopic 
model of cancer as well as in syngeneic flank tumour models.    
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Figure 7.5. Pretreatment with IC87114 enhances the tumour luminescence signal in KPC mice.  
Previous work has established that by two and half months old KPC mice have pancreatic tumours 
[178].  Accordingly, 2.5 month old KPC mice were pretreated with either 75mg kg-1 IC87714 (n=3) or 
vehicle buffer (n=3) three hours before one intravenous injection of 1x108 PFU VVL15.  
Biodistribution of VVL15 was ascertained by IVIS under inhalation anesthesia from 5 minutes 
following IP injection of D-Luciferin (15mg ml-1). Mean luminescence values of tumours ± SEM are 
displayed.  Mice pretreated with IC87114 tend to have a more intense signal from pancreas tumours 
compared to the vehicle buffer group. 
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Figure 7.6.  Pretreatment with IC87114 and subsequent systemic VVL15 administration increased 
the number of tumour cells infected in KPC mice.  Previous work has established that by two and a 
half months old KPC mice have established pancreatic tumours [178].  Accordingly, 2.5 month old 
KPC mice were pretreated with either 75mg kg-1 IC87714 (n=3) or vehicle buffer (n=3) three hours 
before one intravenous injection of 1x108 PFU VVL15.  Mice were then culled on day 3 after the viral 
infection and their tumours prepared for immunohistochemical examination using Vaccinia viral coat 
protein primary antibody (a) & (b) Photographs of H&E stained tumour cross sections with 
immunohistochemical staining for Vaccinia viral coat protein from mice.  The stained tumour cells 
are marked with arrows.  (a) Pretreated with vehicle buffer (b) Pretreated with IC87114. (c)  Semi-
quantification of strongly staining tumour cells in randomly selected high-power fields of x200 
magnification.  The number of tumour cells immunoreactive for Vaccinia coat protein were manually 
counted in each random x200 magnification field.  Data are presented as number of positive staining 
tumour cells per random x200 magnification field ± SEM.  There is a statistically significant difference 
between the group pretreated with IC87114 and the group pretreated with vehicle buffer (P<0.05).  
The stained tumour cells are marked with arrows. 
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7.4.  Summary of Chapter 7 
 
The optimised dose of IC87114 for in vivo studies is 75mg kg-1 three hours prior to systemic injection 
of VVL15 (Figures 7.1, 7.2, & 7.3).  This dosing schedule gives a peak tumour luminescent signal on 
days 3 and 5 after viral infection, which correlates with peak signal observed when depleting 
macrophages using clodronate liposomes (Figure 4.1).  Biological time point studies examining 
tumours demonstrated a clear trend towards increased viral recovery in IC87114-treated mice with 
limited off target effects (Figure 7.4). 
 
There is enhanced signal from orthotopic tumours in KPC mice pretreated with IC87114 (Figure 7.5), 
this finding was supported by semi-quantitative immunohistochemical analysis demonstrating 
pretreated KPC mice had increased numbers of virally infected tumour cells (Figure 7.6).  IC87114 
pretreatment appears to be a potential method for enhanced systemic delivery of VVL15 in a 
spontaneous orthotopic model of cancer as well as in syngeneic flank tumour model.    
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Chapter 8  
Anti-tumour efficacy of the optimised regime in murine 
syngeneic cancer models  
8.1. IC87114 enhances the anti-tumour efficacy of systemically delivered VVL15 in 
vivo in BALB/c mice bearing CT26 flank tumours 
 
The optimised dose of IC87114 was used in a therapeutic regime of three doses of VVL15 in BALB/c 
mice bearing CT26 flank tumours.  The first dose of VVL15 was given intravenously once the average 
tumour volume of the mice reached 100mm3, preceded by either oral gavage of IC87114 or vehicle 
buffer.  The subsequent treatments were given three days and five days later respectively.  Mice 
treated with the optimised regime had statistically smaller tumours at the end of the experiment 
than the other groups (Figure 8.1a) and this reduction in tumour volume conferred a significant 
survival advantage (Figure 8.1b).   
 
Most importantly there is a clear statistical difference between the virally infected groups.  The 
IC87114 pretreated group had on average a smaller tumour burden and survived longer than the 
group pretreated with vehicle buffer.  However, the group treated with VVL15 alone is not 
statistically different from the other control groups. In previous experiments the immune-competent 
mice treated with single therapy VVL15, appeared to have virus within their tumours (Figures 3.1, 
4.1, 7.1-7.4) but this experiment demonstrates that these viruses do not establish effective infection 
(this is consistent with previous work in our group on systemic delivery of VVL15 in immune-
competent mice) without pretreatment with IC87114.  Admittedly, even with this pretreatment the 
mice's tumours in Group D (IC87114 + VVL15) did eventually start to increase in size and the mice 
died but VVL15 is a thymidine kinase-deleted virus and is far less efficacious than other Vaccinia 
viruses, armed with immune modulating transgenes, being developed within our group. 
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Figure 8.1.  The optimised regime significantly reduces the tumour burden and improves survival 
in BALB/c mice bearing CT26 tumours.  Forty mice were subcutaneously injected in their shaved 
right flank with 1x106 CT26 tumour cells.  When the tumours had reach approximately 100mm3 the 
mice were randomly sorted into four groups; Group A, B, C and D.  Mice were pretreated with either 
vehicle buffer (Groups A & C) or IC87114 at 50mg kg-1 (Groups B & D) by oral gavage three hours 
before receiving either an intravenous injection of 1x108  PFU VVL15 (Groups A & D) or PBS (Groups 
B & C).  This treatment was commenced on day 8 post tumour implantation and repeated on days 11 
and 13.  (a) Tumour volumes; data are presented as mean tumour volumes in mm3 ± SEM.  There is 
significantly less tumour burden in the group pre-treated with IC87114 compared to all other 
groups.  Specifically, Group D compared to Group A at days 11 & 13 (P<0.001).  Group D compared 
to Group B at days 11 & 13 (P<0.001).  Group D compared to Group C at day 11 (P<0.001).  (b)  
Survival analysis; data are represented in a Kaplan-Meier plot.  Mice pre-treated with IC87114 
(Group D) survived significantly longer than all the other groups.  Specifically, Group D compared to 
Group A (P<0.01).  Group D compared to Group B (P<0.01).  Group D compared to Group C (P<0.05).   
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8.2. 4T1 is an orthotopic breast cancer model in BALB/c mice that reliably 
metastasizes 
 
The second model that has been developed is an orthotopic breast cancer model in BALB/c mice 
bearing 4T1 mammary tumours.  4T1 cells are derived from a spontaneously arising murine 
mammary tumour [181].  After reviewing the range of doses that have been used in the literature 
[180-183], 1x105 4T1 cells in 50μl PBS were injected orthotopically into the left lower thoracic 
mammary gland.  Table 8.1 illustrates the results of histological analysis of this model at three time 
points (day 8, 16 and 20).  There are lung metastases (3/3 at day 16, 3/4 at day 20) after day 16 in 
this model.  Admittedly one mouse in the day 20 group, despite having an extensive primary tumour, 
did not have lung metastases.  However some degree of inter-mouse variation in metastasis pattern 
is expected and when the mice in both day 16 and 20 groups are taken together the lung metastasis 
rate after day 16 was 85%.  This represents a fairly reliable preclinical metastatic model. 
 
Time point (days) Sample Percentage of samples with cancer 
9 Tumour 100% 
 Liver 0% 
 Lungs 0% 
 Spleen 0% 
16 Tumour 100% 
 Liver 33% 
 Lungs 100% 
 Spleen 0% 
20 Tumour 100% 
 Liver 25% 
 Lungs 75% 
 Spleen 0% 
 
Table 8.1.  Orthotopically implanted 4T1 cells in BALB/c mice reliably metastasize by day 
16.  10 BALB/c mice had 1x105 4T1 cells in 50μl PBS injected orthotopically into the left lower 
thoracic mammary gland.  Mice were then monitored for any signs of distress and culled at nine 
(n=3), sixteen (n=3), and twenty days (n=4) post tumour injection.  The tumours, livers, lungs and 
spleen were harvested, embedded and fixed.  The samples were histologically examined for tumour 
cells by a pathologist (Dr Yaohe Wang).  The results are displayed as the percentage of the total 
number of samples which were positive for tumour cells.   
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8.3. IC87114 enhances the anti-tumour efficacy of systemically delivered VVL15 in 
vivo in BALB/c mice bearing orthotopic 4T1 tumours 
 
Having established that BALB/c mice bearing orthotopic 4T1 tumours was a reliable preclinical model 
(section 8.3) an efficacy study was undertaken using it.  The optimised dose of IC87114 was used in a 
therapeutic regime of three doses of VVL15.  The first dose of VVL15 was intravenously given once 
the average tumour volume of the mice reached 80mm3, preceded by either IC87114 or vehicle 
buffer.  The subsequent treatments were given three days and five days later respectively.  There 
were statistically smaller tumours in the optimised regime compared to all other groups (Figure 
8.2a) and this reduction in tumour volume conferred a significant survival advantage (Figure 8.2b).  
These results are the same as was demonstrated in the previous study (Figure 8.1). 
 
Most importantly, as before there is a clear statistical difference between the two groups that were 
infected with VVL15 (Groups A & D).  The optimised regime group had on average a smaller tumour 
burden and survived longer than the group treated with VVL15 alone.  Indeed, as in Figure 8.1a the 
group treated with virus alone is not statistical different from the other control groups. Admittedly, 
as before (Figure 8.1), this reduction in tumour burden in the optimised group was only transient 
and eventually the mice's tumours in Group D (IC87114 + VVL15) did start to increase in size. 
 
These data together with the previous work strongly suggest that transient attenuation of 
macrophage function by the use of a selective p110 delta isoform inhibitor, IC87114, is an effective 
strategy for enhancing the systemic delivery of VVL15.  
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Figure 8.2.  The optimised regime significantly reduces the tumour burden and improves survival 
in BALB/c mice bearing orthotopic 4T1 tumours.  Thirty-six BALB/c female mice had 1x105 4T1 cells 
in 50μl PBS injected orthotopically into the left lower thoracic mammary gland.  When the tumours 
had reach approximately 80mm3 the mice were randomly sorted into four groups; Group A, B, C and 
D.  Mice were pretreated with either vehicle buffer (Groups A & C) or IC87114 at 75mg kg-1 (Groups 
B & D) by oral gavage three hours before receiving either an intravenous injection of 1x108 PFU 
VVL15 (Groups A & D) or PBS (Groups B & C).  This treatment was performed on days 12, 15, and 17 
after tumour implantation.  (a) Tumour volumes; data are presented as mean tumour volumes in 
mm3 ± SEM.  There is significantly less tumour burden in the group pre-treated with IC87114 
compared to all other groups.  Specifically, Group D compared to Group A at days 16 & 19 (P<0.05 & 
P<0.001 respectively).  Group D compared to Group B at day 16 & 19 (P<0.001).  Group D compared 
to Group C at days 16, 19, & 21 (P<0.001).  (b)  Survival analysis; data are represented in a Kaplan-
Meier plot.  Mice pre-treated with IC87114 (Group D) survived significantly longer than all other 
groups.  Specifically, Group D compared to Group A (P<0.05).  Group D compared to Group B 
(P<0.01).  Group D compared to Group C (P<0.01).   
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8.4. IC87114 enhances the anti-tumour efficacy of systemically delivered VVL15 in 
vivo in KPC mice 
 
After the promising results in section 7.3 (Figures 7.5 & 7.6) an efficacy study was undertaken using 
KPC mice.  The optimised dose of IC87114 was used in a therapeutic regime of three doses of VVL15.  
The first dose of VVL15 was given once the mice had reached two and half months old as it has been 
previously shown that by this age the mice will reliably have pancreatic cancer [178].  The 
subsequent treatments were given three days and five days later respectively.  Figure 8.3 illustrates 
that the mice treated with optimised regime had a significant survival advantage compared to the 
untreated KPC mice (P<0.001) and those mice treated with IC87114 alone (P<0.001).  At the time of 
these experiments mice were not imaged using IVIS system after treatment nor were their organs 
assessed for viral recovery after culling.  This was due to an oversight on the part of the principle 
investigator in this study.  
 
Breeding KPC mice is a time-consuming exercise and usually considerably less than 25% of each litter 
have the appropriate genotype.  As a result it has been difficult to breed enough mice for all the 
necessary control arms.  Disappointingly, it was not possible during the time of this study to recruit 
any mice to the VVL15 alone group.  However mice treated, by our collaborator Professor Thorsten 
Hagemann (Barts Cancer Institute, London, UK), with IP VVL15 did not have significantly different 
survival compared to untreated mice (data not shown).  This suggest, at least,  that mice treated 
with VVL15 alone might not survive as long as mice treated with the optimised regime. 
 
Presented in Figure 8.3 are the survival results for 11 mice that were recruited into the optimised 
regime arm, 10 mice recruited into the IC87714 alone treatment arm and the survival data of 15 
untreated KPC mice supplied by our collaborator Professor Thorsten Hagemann (Barts Cancer 
Institute, London, UK).  These preliminary data demonstrate that the optimised regime is at least 
better in terms of survival than no treatment at all or treatment with IC87114 alone.  Indeed, when 
compared to the previous two preclinical models (Figures 8.1 & 8.2) the optimised regime greatly 
increases the number of days the mice survives for compared to untreated ones.  This implies that 
potentially pretreatment with IC87114 and then treatment with VVL15 maybe a very effective 
treatment strategy in pancreatic cancer.    
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Figure 8.3.  The optimised regime improves survival in KPC mice bearing spontaneous orthotopic 
pancreatic tumours.  Previous work has established that by 2.5 months old KPC mice have 
established pancreatic tumours [178].  Accordingly, 2.5 month old KPC mice were pretreated with 
IC87114 at 75mg kg-1 by oral gavage three hours before receiving either an intravenous injection of 
1x108 PFU VVL15 or PBS.  This treatment was performed on days 0, 3 and 5.  Mice were then 
monitored for signs of distress and culled if necessary in accordance with Home Office regulations.  
Survival of all mice was recorded from the first treatment.  The untreated mice data was the kind gift 
of our collaborator Professor Thorsten Hagemann (Barts Cancer Institute, London, UK) and 
represents a separate experiment in which 15 KPC mice were monitored from 2.5 months old and 
their survival recorded.  Survival analysis; data are represented in a Kaplan-Meier plot.  Mice pre-
treated with IC87114 and then systemic VVL15 survived significantly longer than the untreated mice 
and mice treated with IC87114 alone (P<0.001).   
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8.5.  Summary of Chapter 8 
 
Systemic delivery of VVL15 after pretreatment with IC87114 reduces the tumour burden and 
improves the survival compared to virus alone (and all other control groups) in two preclinical cancer 
models (Figures 8.1 & 8.2) and is superior in terms of survival in a third (Figure 8.3).  This suggests 
that transient attenuation of macrophage function by the use of a selective p110 delta isoform 
inhibitor, IC87114, is an effective strategy for enhancing the systemic delivery of VVL15.  
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Chapter 9  
Mechanisms by which optimised regime achieves superior 
oncolytic potency 
9.1. IC87114 increases Rho A levels in bone marrow-derived macrophages in vitro 
 
Previously it had been shown that up-regulation of Rho A, by use of a constitutively active mutant, 
reduces viral entry by between 50-70% [116, 144] and given that the class 1A p110 delta isoform 
inversely regulates Rho A activity [190] an inhibitor of p110 delta would be another way of achieving 
this.  Accordingly an experiment was undertaken to quantify the amount of activated (GTP-bound) 
Rho A induced in macrophages by a viral attachment assay at various time points.  Bone marrow-
derived macrophages were either pretreated with IC87114 or vehicle buffer after which they were 
infected with either VVL15 or mock infection.  The results of this experiment are illustrated in Figure 
9.1.   
 
Firstly, as has been reported earlier the addition of either IC87114 alone [190] or virus increases 
activated Rho A levels [116, 143, 144].  Furthermore, there is a clear statistically significant increase 
in activated Rho A levels in the group pretreated with IC87114 with subsequent viral infection 
compared to the untreated group (No Inhibitor + Mock) at all time points (Figure 9.1a, P<0.001).  
Interestingly when IC87114 + VVL15 group was compared to IC87114 + Mock (Figure 9.1b) there was 
more activated Rho A in the mock treated group compared to the virally treated group at time point 
0 minutes (P<0.001) whereas the opposite was true at 30 minutes post infection (P<0.001).  It is 
possible that initially viral infection may, to some extent, dampen the effect of IC87114 on activated 
Rho A levels whereas at the later time point the presence of virus drives continued high levels of Rho 
A.  
 
Finally when comparison is made between the two groups which were virally infected but differed in 
being either pretreated with IC87114 or vehicle buffer, the IC87114 group has statistically 
significantly higher levels of activated Rho A at time points at 3 mins (P<0.01), 12mins (P<0.05) and  
30mins (P<0.001).  Given that up-regulation of Rho A reduces viral attachment [116, 143, 144] and 
that Rho A is regulated by p110 delta isoform [190], it is plausible that the differences seen between 
the IC87114 + VVL15 and No Inhibitor + VVL15 in this study are in large part due to the increased 
levels in activated Rho A seen in the IC87114-treated macrophages.   
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Figure 9.1.  Active Rho A is significantly increased in macrophages after pretreatment with IC87114 
and subsequent viral infection.  Bone marrow was extracted and pooled from two wild-type BALB/c 
mice.  The macrophages were cultured ex vivo for seven days in medium containing macrophage 
colony stimulating factor until fully matured.  Macrophages were pretreated for 2 hours with vehicle 
buffer or IC87114 at 1μM and then a viral attachment assay was undertaken.  Macrophages were 
infected with VVL15 at a MOI 5 or mock infected.  Macrophages were then harvested at 0, 3, 6, 12 
and 30 minutes after commencement of viral attachment assay.  Subsequently, total Rho A and 
activated GTP-bound Rho A levels were quantified using commercially available ELISA and G-LISA kits 
respectively from Cytoskeleton Inc.  Data is presented as the mean percentage of the total Rho A 
that was activated (GTP-bound) ± SEM.  IC87114 + VVL15 group is statistically significantly different 
at all time points to the No Inhibitor + Mock infection group (P<0.001).  IC87114 + VVL15 group is 
statistically significantly different at 0 mins and 30mins to the IC87114 + Mock infection group 
(P<0.001).  IC87114 + VVL15 group is statistically significantly different at 3 mins (P<0.01), 12mins 
(P<0.05) and  30mins (P<0.001) to the No Inhibitor + VVL15 group.       
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9.2.  ROCK inhibition in combination with  IC87114 returns viral attachment to 
levels seen in untreated macrophages in vitro  
 
It is already known that IC87114 increases the levels of Rho A by inhibiting p110 delta isoform [190].  
Data from section 9.1 suggests that reduction in VVL15 attachment to bone marrow derived 
macrophages might be mediate through increased levels of Rho A.  To investigate this further a viral 
attachment assay was performed using a panel of inhibitors potentially important in viral 
attachment and entry (Figure 9.2).  As has been reported earlier the addition of IC87114 alone 
significantly reduces viral attachment.  Interestingly the addition of a Rho-associated protein kinase  
(ROCK) inhibitor, that acts to reduce Rho A levels, in combination with IC87114 returns viral 
attachment to levels seen in untreated macrophages.  These data support the idea that increased 
levels of Rho A play a role in reduced viral attachment (previously reported in other cell systems 
[116, 143, 144]).  A ROCK inhibitor alone does not have any effect on viral attachment and this has 
also previously been reported in another cell system [144].  Rho A is part of the Rho GTPase family, 
another member of which is Rac1.  Conversely to Rho A, increased levels of Rac1 have been shown 
to increase levels of viral infection and reduced levels of Rac1 have been shown to lead to reduced 
viral infection [116, 143, 144].  It is unsurprising then that NSC23766 (a Rac1 inhibitor) also 
significantly reduces viral attachment to macrophages.       
 
Previously in Figure 5.1, it had been shown that PI3 kinase alpha inhibition led to reduced viral 
attachment, however this was using PI-103 which has wider pan class I PI3 kinase inhibitor activity 
whereas when a more PI3 kinase alpha specific inhibitor was used, A66, there was no reduction in 
viral attachment.  This is cogent as the pre-dominant class I PI3 kinases in macrophages are p110 
delta and p110 gamma isoforms.    Furthermore Cytochalasin D (inhibitor of actin polymerisation) 
and Nocodazole (inhibitor of polymerisation of microtubules) had no effect on viral attachment.  
This was unsurprising as viral attachment assay was performed at 4oC but it does, at least, suggest 
that viral attachment can occur independent of actin or microtubule polymerisation. 
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Figure 9.2.  The addition of a ROCK inhibitor to IC87114 treated macrophages results in viral 
attachment similar to untreated macrophages.  Attachment assay of VVL15 on murine bone 
marrow derived macrophages.  Bone marrow was extracted and pooled from two wildtype BALB/c 
mice.  The macrophages were cultured ex vivo for seven days in media containing macrophage 
colony stimulating factor until fully matured.  Macrophages were pretreated with vehicle buffer or 
IC87114 (selective p110 delta inhibitor) or IC87114 in combination with Y-27632 (Rho-associated 
protein kinase inhibitor) or NSC23766 (Rac1 inhibitor) or Cytochalasin D (inhibitor of actin 
polymerisation) or Y-27632 alone or Nocodazole (inhibitor of polymerisation of microtubules) or A66 
(PI3K p110α inhibitor) and then subsequently a viral attachment assay was undertaken.  Data are 
presented as mean viral copy number per macrophage plated ± SEM.  In the IC87114 and NSC23766 
groups there was a statistically significant reduction in viral attachment compared to the untreated 
group (P<0.05).  There was a statistically significant reduction in viral attachment in IC87114 and 
NSC23766 groups when compared to the IC87114 in combination with Y-27632 group (P<0.05).  
There was no significant difference between the untreated and IC87114 in combination with Y-
27632 groups nor was there any significant difference between either untreated or IC87114 in 
combination with Y-27632 groups and any of A66, Cytochalasin D, Y-27632 alone, or  Nocodazole 
groups.  
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9.3.  Pretreatment with IC87114 reduces the localisation of Vaccinia virus to the 
spleen after systemically delivered VVL15 in vivo 
 
In vitro IC87114 acts by possibly increasing Rho A levels with resultant reduction in viral attachment 
to macrophages and in vivo IC87114 reduces the early clearance of VVL15 from mice bearing 
syngeneic tumours.  Indeed if IC87114 pretreatment does reduce viral attachment to macrophages 
in vivo, thus reducing systemic clearance of VVL15, a key area for this to occur should be in the red 
pulp of the spleen where one would expect to observe fewer virions associated with splenic 
macrophages.   
 
To investigate this hypothesis mice were treated with virus alone or the optimised regime and then 
three hours later their spleens were harvested and prepared for immunohistochemical examination 
for Vaccinia virus coat protein.  As shown in Figure 9.3, there was far more viral coat protein 
immunoreactivity associated with the spleens of mice treated with virus alone compared to the 
group treated with IC87114 and virus (Figure 9.3c).  This provides further evidence that in part the 
mechanism by which IC87114 improves effective infection of the tumour site by VVL15 is by 
reducing clearance of VVL15 by splenic macrophages in the red pulp of the spleen.   
 
Previous data suggested that there is a virally induced up-regulation of p110 delta RNA in 
splenocytes derived from immunocompetent BALB/c mice three hours following viral infection 
(Figure 4.2) and that this viral induced up-regulation is subsequently translated into p110 delta 
protein (Figure 4.3).  Therefore separate sections were cut from the fixed histological blocks from 
the experiment illustrated in Figure 9.3 so that immunohistochemical examination for p110 delta 
expression could be undertaken.  The total amount of p110 delta protein expression in the red pulp 
of the spleens did not appear to be effected by either pretreatment with IC87114 or viral infection 
(Figure 9.4).  It is not surprising that IC87114 did not reduce p110 delta protein levels as it affects 
delta isoform function rather than physically depleting the protein.  Also the PI3 kinase staining is 
not specific to macrophages but rather includes other cells such plasma cells.  This could result in the 
virally induced increase in p110 delta isoform in macrophages being missed as all the strongly 
staining cells within the red pulp of the specimens were counted for the quantification of the p110 
delta expression.   
 
However, an in vitro experiment was performed where macrophages were pretreated with either 
IC87114 or vehicle buffer before being infected with VVL15 after which the macrophages were 
harvested and p110 delta protein expression was assessed by western blot (Figure 9.5).  Viral 
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infection alone appears to increase the amount of p110 delta protein detected (consistent with 
previous finding in Chapter 4, Figure 4.3) whereas addition of the IC87114 alone does not affect 
levels of p110 delta protein however this is expected as IC87114 does not physically deplete p110 
delta.  Interestingly, pretreating the macrophages with IC87114 appears sufficient to prevent the 
virally induced up-regulation of p110 delta protein.  As IC87114 inhibits the function of p110 delta 
this suggests that one function of p110 delta in viral infection is to up-regulate its own expression.   
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Figure 9.3.  Wildtype BALB/c mice bearing CT26 tumours treated with the optimised regime had 
significantly less Vaccinia virus coat protein in their spleens.  Wildtype BALB/c mice bearing CT26 
flank tumours received 1x108 PFU VVL15 intravenously three hours after either receiving vehicle 
buffer or IC87114 (75mg kg-1) by oral gavage.  These mice were then killed at three hours after viral 
infection and their spleens prepared for immunohistochemical examination using Vaccinia virus coat 
protein primary antibody.  (a) & (b) Photomicrographs of haematoxylin-stained spleen cross sections 
with immunohistochemical staining for Vaccinia viral coat protein.  Arrows mark the virally infected 
cells. (a) Pretreated with vehicle buffer. (b) Pretreated with IC87114. (c)  Semi-quantification of 
strongly staining cells in randomly selected high-power fields of x200 magnification.  The number of 
cells immunoreactive for Vaccinia coat protein were manually counted in each random x200 
magnification field.  Data are presented as number of positive staining cells per random x200 
magnification field ± SEM.  There is a statistically significant difference between the groups 
(P<0.001). 
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Figure 9.4.  There is no difference in p110 delta protein expression in wildtype BALB/c mice 
bearing CT26 tumours pre-treated with either vehicle buffer or IC87114 then intravenous VVL15 or 
PBS.  Wildtype BALB/c mice bearing CT26 flank tumours received either 1x108 PFU VVL15 or PBS 
intravenously three hours after either receiving vehicle buffer or IC87114 (75mg kg-1) by oral gavage.  
These mice were then killed at three hours after viral/mock infection and their spleens prepared for 
immunohistochemical examination using murine p110 delta protein primary antibody.  (a)-(c) The 
slides show macrophages in the red pulp of the spleen staining strongly for p110 delta. (a)  
Pretreated with vehicle buffer then infected with VVL15. (b)  Pretreated with IC87114 then infected 
with VVL15. (c)  Pretreated with vehicle buffer and then infected with mock. (d)  Quantification of 
strongly staining cells in the red pulp; random high-power fields (roughly equivalent of x40 
magnification of a conventional microscope), all within the red-pulp were identified and a manual 
'point-and-click count' of all the strongly stained cells was undertaken.  Data are expressed as the 
mean number of strongly positive cells per mm2 of analysed tissue ± SEM.  There is no statistical 
difference between any of the groups. 
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Figure 9.5.  Expression of p110 delta isoform is increased by viral infection.  Expression of p110 
delta isoform by Western blot assay in bone marrow derived macrophages. Bone marrow was 
extracted and pooled from two wildtype BALB/c mice.  The macrophages were cultured ex vivo for 
seven days in media containing macrophage colony stimulating factor until fully matured.  
Macrophages were then pretreated with either IC87114 at 75mg kg-1 or vehicle buffer for 2 hours 
before being infected with VVL15 at MOI 5 or mock for 1 hour.  After which the macrophages were 
harvested and p110 delta protein expression was assessed by western blot.  Viral infection alone 
increases the amount of p110 delta protein detected whereas addition of the IC87114 alone or in 
conjunction with VVL15 does not appear to alter the amount of p110 delta protein detected.  This 
experiment was designed by the author of this study but was undertaken by Dr. Rathi Gangeswaran.      
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9.4.  IC87114 reduces the anti-viral immunity stimulated by systemically 
delivered VVL15 in vivo 
 
Inhibition of p110 delta by IC87114 is known to have a range of effects on T cell biology and cytokine 
production in both mice and humans [186, 191-193].  Accordingly investigations were undertaken to 
examine whether pretreatment with IC87114 affected subsequent anti-viral or anti-tumour 
immunity induced by VVL15 infection.  Figure 9.6 illustrates an ex vivo interferon gamma assay 
performed on splenocytes derived from BALB/c mice bearing CT26 tumours.  This demonstrated that 
splenocytes derived from the mice treated with the optimised regime developed similar anti-tumour 
IFN gamma responses to all the other groups tested (Figure 9.6a).  However, the splenocytes derived 
from the IC87114 + VVL15 group did have reduced levels of IFN gamma after stimulation with the 
viral protein B8R when compared to splenocytes from the group treated with virus alone (Figure 
9.6b).  Thus pretreatment with IC87114 appears to reduce in magnitude the subsequent 
development of an anti-viral response.  This potentially could mean that aside from the effect 
IC87114 has on macrophages at an early time point it has a separate more lasting effect that leads to 
reduced anti-viral immunity and to the establishment of an effective infection of the tumours 
leading to the observed improvement in efficacy compared to virus alone.  
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Figure 9.6. IC87114 attenuates anti-viral immunity but has no effect on anti-tumour immunity.  
Interferon gamma assay on splenocytes derived from BALB/c mice bearing CT26 tumours.  Fifteen 
mice were subcutaneously injected in their shaved right flank with 1x106 CT26 tumour cells.  When 
the tumours had reached approximately 100mm3 the mice were randomly sorted into four groups; 
Group A, B, C and D.  Mice were pretreated with either vehicle buffer (Groups A & C) or IC87114 at 
75mg kg-1 (Groups B & D) by oral gavage three hours before receiving either an intravenous injection 
of 1x108 PFU VVL15 (Groups A & D) or PBS (Groups B & C).  The mice were then left for fourteen days 
after which they were killed and their spleens harvested.  Splenocytes from each group were 
incubated with either mitomycin treated CT26 cells or B8R protein ex vivo and then an interferon 
(IFN) gamma ELISA was performed.  Data are presented as mean IFN gamma concentration (pg ml-1) 
± SEM.  (a)  Anti-tumour immunity; Splenocytes were stimulated with mitomycin treated CT26 cells, 
there was no statistically significant difference between any of the groups  (b) Anti-viral immunity; 
Splenocytes were stimulated with B8R protein, there was more IFN gamma detected in Group A (No 
Inhibitor + VVL15) compared to all other groups (P<0.05).     
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9.5. Summary of Chapter 9 
 
It has been shown previously that increased levels of activated Rho A reduce VVL15 infection [116, 
143, 144].  IC87114 increases Rho A levels in macrophages (Figure 9.1).  A ROCK inhibitor in 
combination with IC87114 increases viral attachment to levels seen in untreated macrophages 
(Figure 9.2).  Whereas a Rac1 inhibitor decreases viral attachment (Figure 9.2).  Thus the increased 
levels of Rho A induced by the pretreatment of IC87114 might be a plausible mechanism by which 
viral attachment to macrophages is reduced.  Whereas ROCK inhibition alone or PI3 kinase alpha 
inhibition have no effect on viral attachment and re-arrangements of actin or microtubules do not 
appear to be required for viral attachment (Figure 9.2). 
 
In vivo, IC87114 pretreatment reduces the amount of VVL15 coat protein associated with 
macrophages in the red pulp of the spleen whereas p110 delta protein levels are unaffected (Figures 
9.3, 9.4 & 9.5).  Furthermore anti-viral immunity is reduced by pretreatment with IC87114 (Figure 
9.6).  Thus, in vivo, a potential functional mechanism for the observed improved efficacy is that the 
pretreatment with IC87114 reduces viral clearance in the red pulp of the spleen whilst reducing the 
magnitude of the developing anti-viral immunity leading to improved effective infection of the 
tumour site with the observed enhancement of efficacy.   
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Chapter 10  
Discussion 
10.1. Macrophages appear to be the key early cellular player in the clearance of 
systemically delivered Vaccinia virus 
  
The origins of this study arose from the attempts to understand why for a given dose of systemically 
delivered VVL15 it was possible to establish effective infection in syngenic flanks tumours in nude 
but not in immunocompetent mice.  Working on the premise that athymic mice would lack the 
necessary T cells to activate macrophages in the context of a viral infection, depletion of CD4+ T cells 
using GK1.5 was undertaken in the immunocompetent mice.  However, this did not lead to effective 
infection of the tumour site (James Tysome et al, unpublished).  Observations by the same workers 
that Vaccinia virus coat protein was closely associated with immunocompetent macrophages in the 
red pulp of the spleen at early time points (3 & 8 hours) after systemic viral infection whilst not in 
nude spleens lead to speculation that the macrophage might be the key difference between the 
mice models.  Further work by James Tysome et al(unpublished) depleting macrophages using 
clodronate liposomes improved the systemic delivery of VVL15 to the tumours to levels observed in 
the nude mice.  Investigations in this study depleting macrophages using clodronate liposomes have 
confirmed these findings (Figure 4.1).   
 
There is clear evidence from this study that macrophages in the spleen are key players in the early 
clearance of VVL15 (Figures 3.1, 7.4 & 9.3).  There is also reported evidence that lung macrophages 
play a crucial role in the clearance of intra-nasally delivered VV infection [194].  In this study it was 
observed in both In Vivo Imaging System (IVIS) studies (data not shown) and biodistribution studies 
(Figure 7.4) that VV was detected at early time points in the lungs.  Therefore it is reasonable to 
suggest that as well as the spleen the lungs may be an important site for early clearance of VV by 
macrophages.  However, in all the biodistribution experiments performed in this study there was 
minimal or no viral recovery from liver samples (data not shown).   The endothelial gaps in the liver 
are approximately 100nm wide allowing extravasation of Adenovirus [97] but VV dimensions are 
350nm by 250nm [112, 113].  So, unlike Adenovirus, VV is not cleared in significant quantities by 
Kupffer cells in the liver, the other major site of microbial clearance.   
  
The differences between splenic, and potentially lung, nude and immunocompetent macrophages 
specifically appears to be due to their relative abilities to take up VVL15.  Figure 3.1 demonstrate 
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that there is a marked increase in the amount of VVL15 quantified from whole blood cells and spleen 
extracts derived from immune-competent compared to nude mice.  Subsequent investigation of the 
factors that differed with respect to viral infection within nude and immune-competent blood 
identified that monocyte/macrophages appeared to be the only variable component (Figure 3.3).  
Although, there does not appear to be a general difference in phagocytosis between nude or 
immune-competent macrophages as opsonised Escherichia coli K-12 BioParticles were phagocytosed 
similarly (Figure 3.4).   
 
Interestingly, there do appear to be differences in the way that nude and immunocompetent 
macrophages respond to VVL15 infection.  Figure 4.2 demonstrate that there is virally induced up-
regulation of transcription of class 1a p110 delta isoform in the immunocompetent splenocytes but 
not nude ones.  Finally it also seems that the difference between athymic and wild-type 
macrophages is specifically to do with viral attachment as once this had been accounted for there 
was no difference in their abilities to internalise VVL15 (Figure 5.5).   
 
In summary there do not appear to be, nor has there been reported in the literature, gross 
differences between nude and immunocompetent macrophages.  Rather there appears to be a 
subtle, possibly, Vaccinia virus specific differences in viral attachment, which could be explained by 
comparatively low expression of p110 delta protein in nude macrophages.  Potentially this low level 
of p110 delta could lead to higher levels of Rho A consequently meaning that less virions attach to 
the nude macrophage.  There is nothing described in the literature in respect of this and admittedly 
this difference could be explained also by a T cell-mediated action on macrophages absent in the 
nude setting.  Despite these uncertainties what is clear from this work is that macrophages appear 
to be the key early player in the systemic clearance of Vaccinia virus.  
 
10.2. Class I p110 delta inhibition significantly reduces viral attachment to 
macrophages in vitro        
 
Viral attachment to macrophages is reduced by inhibitors of all class 1 PI3 kinase isoforms (Figure 
5.1).  The p110 alpha and beta inhibitors target these ubiquitously expressed isoforms and the pan 
inhibitor lacks specificity [167] thus these inhibitors are more easily excluded from further 
consideration.  Whereas p110 delta and gamma are enriched within leucocytes and are effective at 
reducing viral attachment to macrophages (Figure 5.1).  As was the case with nude macrophages 
perturbation of either p110 delta or gamma makes no difference to internalisation of the virus once 
the attachment has been accounted for (Figures 5.2 & 5.3). 
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With respect to IC87114 the reduction in viral attachment appears to be a specific p110 delta effect 
as transgenic p110 delta knocked in mice were similarly effected compared to treated wildtype 
macrophages.  However, VVL15 clearly attaches to the macrophage in a p110 delta independent 
manner as well (Figure 5.6) since virus attaches to homozygous p110 delta knocked in macrophages, 
a feature consistent with previous work [116, 143, 144].  In terms of the literature the finding that 
either selective p110 delta or gamma inhibition reduces viral attachment to macrophages is entirely 
novel.  Certainly workers have blocked PI3 kinase signalling before, using a class 1 PI3 kinase pan-
inhibitor, with a resultant reduction in Vaccinia virus infection in vitro.  But this has been shown 
mainly in HeLa cells and never in macrophages nor using a isoform-specific PI3 kinase inhibitor [116, 
143, 144, 195].   
 
Inhibition of either p110 delta or gamma or in combination appears to be entirely neutral on a panel 
of murine cancer cells lines in terms of both cytotoxicity and viral replication (Figures 6.1-6.5).  This is 
unsurprising though given the fact that these cell lines either do not express p110 delta protein or do 
so in very low levels (Figure 6.8).  It potentially would have been attractive to select either p110 
delta or gamma inhibitors based on ones superior direct tumour cytotoxicity.  However the main 
reason for focussing exclusively on p110 delta inhibition for the rest of this study was the evolving 
evidence from the literature that p110 delta inhibition shows more promise as a therapeutic 
intervention than does inhibition of p110 gamma [185, 196-200].  Interestingly though, most of this 
evidence is in haematopoietic malignancies, where the efficacy appears to be mainly mediated 
through immune modulation, rather than a direct anti-tumour effect, resulting in a less tumour 
permissive microenvironment [196].  It was this potential effect, aside from p110 delta inhibition's 
effect on viral attachment to macrophages, that lead to IC87114 being selected for further study.  
Admittedly, there was a financial consideration as well since both inhibitors are very costly to 
purchase and the subsequent investigations would all involve expensive in vivo studies therefore 
given the limited resources available a single agent had to be selected.   
 
10.3. Class Ia p110 delta inhibition is a promising strategy for the enhancing of 
systemically delivered Vaccinia virus in vivo      
 
The observed in vitro reduction in viral attachment to macrophages translated into a statistical 
significant improvement in viral delivery to the target tumour sites.  In Vivo Imaging System (IVIS) 
proved to be the most reliable method for assessing effective tumour infection as viral recovery 
studies and TCID50 have far too many potential variations or errors.  Repeated IVIS studies have 
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demonstrated that a dose of 75mg/kg of IC87114 most consistently enhances the systemic delivery 
of VVL15 to the tumour site. (Figures 7.1-7.3).  However TCID50 method of assessing viral infection 
played a crucial role in quantifying low levels of infection in vivo that could not be detected by the 
IVIS method in the off target organs.  Fortunately the optimised regime had very few off-target 
effects (Figure 7.4). 
 
The optimised regime has demonstrated improved efficacy in two murine syngenic models of cancer 
(Figures 8.1 & 8.2) and improved survival in a third (Figure 8.3).  Importantly these models vary in 
both histological type and site of growth potentially meaning that this optimised approach could 
have a wide therapeutic range.   In the two models in which tumour volume was measured there 
was a reduction in the rate of growth of the tumours and in all three efficacy studies there was a 
survival advantage in animals treated with IC87114 and VVL15.  Clearly pretreatment with IC87114 
at 75mg/kg enhances the systemic delivery of VVL15 conferring reduced tumour burden and a 
survival advantage, and these are entirely novel findings.  
 
10.4. The potential mechanism by which p110 delta inhibition reduces Vaccinia 
virus attachment and improves efficacy 
 
Figure 10.1 summarises the potential signaling pathway involved in the attachment of VV to a 
macrophage.  Izmailyan et al. [195] have recently suggested that VV associates with 
glycosaminoglycans and laminin on the cell membrane inducing the recruitment of integrins such β1 
with subsequent recruitment of CD98 and activation of PI3 kinase signalling with resultant endocytic 
internalisation of VV.  Others however have implicated EGFR as a key protein involved in the 
induction of intracellular signalling leading to viral attachment and internalisation [144].  The results 
from this current study have not elucidated any further potential transmembrane proteins involved 
in the attachment of the VVL15.  However, investigations have clearly shown that the inhibition of 
p110 delta reduces viral attachment to macrophages, which is a novel finding.  Certainly, what has 
been shown before is that VV induces PI3 kinase activity and the addition of a non-specific PI3 kinase 
inhibitor effectively reduces VV attachment and infection [116, 143, 144].     
 
Also it is known that the RhoGTPases are required for VV attachment and that these regulate PAK1 
which is in turn essential for endocytic entry of the virus [143, 144].  What is also clear is that up-
regulation of Rho A reduces viral attachment [116, 143, 144] and that Rho A is regulated by p110 
delta isoform [190].  Results from this study support these finding.  Figure 9.1 clearly shows that the 
addition of IC87114 and VVL15 leads to increased levels of Rho A and Figure 9.2 demonstrates that 
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the addition of a ROCK inhibitor (which will decrease Rho A levels) concurrently with IC87114 leads 
to levels of viral attachment seen in untreated macrophages.  Taken together these data strongly 
suggest that the viral reduction seen with pretreatment with IC87114 is mediated through Rho A 
levels. 
 
This study focussed exclusively on viral attachment because internalisation assays had demonstrated 
that IC87114 did not affect internalisation once the amount of attached virus had been accounted 
for (Chapter 5).  All the attachment assays were performed at 4oC and no effect was seen when 
inhibitors of rearrangements of either actin or microtubules were applied (Figure 9.2).  This is not 
surprising since these rearrangements require energy that is not available at 4oC.  However in the 
literature there is evidence that inhibitors of actin rearrangement prevent viral infection and up-
regulation of either RhoGTPases or PAK1 cannot overcome this.  Viral attachment can occur in the 
context of inhibition of RhoGTPases by up-regulation of PAK1.  However PI3 kinase inhibition 
prevents viral attachment and it cannot be overcome by either up-regualtion of RhoGTPases or 
PAK1.  These observations suggest that class 1 PI3 kinases have multiple inputs into this pathway 
which are both up and downstream of the RhoGTPases and PAK1 [116, 143, 144].  Finally it should 
be noted that the majority of this work has been undertaken in HeLa cells with only one study 
investigating VV entry in dendritic cells [117].  This is the first time that this mechanism for viral 
attachment has been suggested for macrophages. 
 
Functionally, the reduced viral attachment to macrophages in vitro results in vivo in less VV coat 
protein associated with macrophages in the red pulp of the spleen (Figure 9.3) and this leads to 
effective infection of the tumours (Chapter 7) and clearly this also plays a role in the observed 
superior efficacy (Chapter 8).  Interestingly there is plenty of evidence that inhibition of p110 delta 
has an immune modulating effect [186, 191-193, 196].  Data presented in Figure 9.6 suggests that 
pretreatment with IC87114 appears to reduce anti-viral immunity presumably this helps to facilitate 
improved infection of the tumour sites and contributes to the observed improved efficacy.  This 
reduction in anti-viral immunity may simply be a reflection of the fact that macrophages are 
important antigen presenting cells in the context of early stage Vaccinia infection and there is less 
virus-macrophage interaction as a result of p110 delta inhibition.  It is interesting that there is no 
observed reduction in anti-tumour immunity (Figure 9.6), and this might be because only three 
doses of IC87114 were used and this is not sufficient to dampen the anti-tumour response.  However 
recent work by Ali et al[186] showed that inhibition of p110 delta can break the tumour induced 
immune tolerance in the tumour microenvironment, in part by reducing the number of Treg cells 
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and increasing CD8+ T cells.  So it might be that p110 delta inhibition does not reduce anti-tumour 
immunity. 
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Figure 10.1.  Proposed functional mechanism for Vaccinia virus attachment to a macrophage.  
Vaccinia virus binds to one or more transmembrane proteins such as glycosaminoglycans and 
laminin, with subsequent integrin and CD98 recruitment [195] or it could bind EGFR [144] and/or 
other unknown proteins.  After which there is class 1a p110 delta activation with subsequent 
RhoGTPase activation and then p21 activated kinase 1 (PAK1) recruitment leading to pre-fusion 
attachment of VV to the macrophage [116, 143, 144]. Given that all of the various attachment 
experiments in this study have been performed at 4oC this proposed mechanism must also occur at 
4oC.  It is well known that viral/cell membrane fusion and/or macropinocytosis/endocytosis are 
energy requiring processes and do not occur at such low temperatures.  But clearly viral attachment 
and the blocking of viral binding can occur at this cold temperature.  Maybe this is because the 
attachment process requires little or no energy or indeed the process may release pre-stored energy 
that is sufficient for the binding.    
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10.5. Safety issues  
 
IC87114 is not being developed for clinical use, but another compound called idelalisib (previously 
known as GS-1101 or CAL 101) has been successfully through phase 1 trial in chronic lymphocytic 
leukaemia (CLL).  It was well tolerated with no known dose-limiting toxicities and only 7% of 
recruited patients stopped their treatment due to adverse effects [201].  A subsequent phase 3 trial 
in CLL has demonstrated impressive efficacy [199] and a further phase 2 trial in relapsed indolent 
lymphoma was very promising [200].  Vaccinia virus has been used in the worldwide eradication of 
smallpox and as such has had millions of doses given with a very few side effects.  More recently a 
strain of VV called JX-594 has been used in a dose escalation study in patients with solid cancers.  In 
that study,  JX-594 was well tolerated with the most common side effect being a mild flu-like illness 
[35].  Thus although no such study has been performed in man to date it seems at least reasonable 
to suggest that the combination of Vaccinia virus and a p110 delta inhibitor would be well tolerated 
in cancer patients. 
 
10.6. Potential applications of this novel strategy  
 
Obviously a potential application of this strategy of p110 delta blockade for the enhancement of 
systemically delivered Vaccinia virus would be in the treatment of solid based cancers.  There is 
recent published evidence that p110 delta inhibition may have efficacy in not just haemopoietic 
malignancies but also solid cancers [186, 187].  And that this effect is mediated through an immune 
modulation that may well be beneficial to concurrent VV infection leading to a synergistic 
improvement in tumour rejection and clearance.  In this context it is most likely that the p110 delta 
inhibition would be used to enhance the delivery of a Vaccinia virus with therapeutic transgenes for 
immune therapy and initially this combination would probably be used in a clinical trial in patients 
who have failed conventional therapy.  Lung cancer could be a particular disease which might 
respond well to this strategy.  It is well known that there are resident lung macrophages and it has 
been shown that depleting them worsens the severity of unattenuated Vaccinia virus infection when 
delivered intra-nasally in mice [194].  Clearly these same macrophages may also play a role in the 
early clearance of systemically delivered VVL15 preventing them reaching their target tumours.  
Furthermore, during the IVIS biodistribution studies (Chapter 7) it was observed that there was an 
increased lung luminescence signal at early time-points (day 0, 1 - data not shown) in mice 
pretreated with IC87114.  However this study did not demonstrated any effective infection of lung 
parenchyma.  Taken together this data suggests that pretreatment with IC87114 may well enhance 
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the anti-tumour effect of intravenously delivered VVL15 in lung cancer.    An appropriate preclinical 
orthotopic lung cancer model in C57BL/6 mice using Lewis lung cancer cells (LLC) has been optimised 
as part of this study and potentially could be used to test this hypothesis in the first instance 
(Appendix A.2). 
 
Another potential application of this strategy could be in combination with surgery.  The patient 
could have their primary disease resected and then an intravenous administration of Vaccinia virus 
(after a pretreatment with a p110 delta inhibitor) could be used to eradicate any micro-metastatic 
deposits.   
 
Finally, NSC23766, a Rac1 inhibitor, was shown to reduce the VV attachment to macrophages (Figure 
9.2).  Although NSC23766 has been used extensively in preclinical studies there is no Rac1 inhibitor 
being used in clinical trials at present nor has there been.  Despite this, given the promising data in 
this study, Rac1 inhibition could be used in the future as an alternative to p110 delta inhibition as a 
means to enhancing the systemic delivery of VV. 
 
10.7. Conclusions 
 
The macrophage appears to be the key player in the early clearance of Vaccinia virus from immune 
competent mice.  Inhibition of class 1a p110 delta isoform is an efficient method of reducing the 
viral attachment to macrophages in vitro and the addition of the p110 delta inhibitor is entirely 
neutral in terms of viral cytotoxicity and replication on a panel of cancer cell lines in vitro.   The in 
vivo studies demonstrate that the optimized regime of IC87114 and VVL15 has limited off target 
effects which are similar to VVL15 alone whilst having statistical significantly superior efficacy in 
terms of both tumour burden and survival in two preclinical murine models of cancer.  Pretreatment 
with IC87114 appears firstly to increase Rho A levels within macrophages resulting in reduced viral 
attachment and secondly it appears to reduce the anti-viral immune response in combination these 
effects appear to account for the improved efficacy observed.  
 
10.8. Future direction  
 
More work needs to be done to understand the exact functional mechanism by which pretreatment 
with IC87114 both reduces viral attachment and modulates the immune response to the viral 
infection.  Focus may need to shift to idelalisib as this is the p110 delta inhibitor currently being used 
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in clinical trials.  Ultimately the hope would be to commence clinical trials using this strategy for the 
enhancement of systemic delivery of Vaccinia virus in patients with solid cancers.
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Appendix A  
Optimisation of further tumour models for future anti-
tumour efficacy studies 
Sections 8.1-8.3 illustrate the results from two efficacy studies using the optimised regime. Further 
work has been undertaken to identify other preclinical cancer models which could be used to test 
the optimised regime, two of these models are reported below.  
A.1.  C57BL/6 mice bearing CMT93 flank tumours  
 
Figure A.1 shows the results of four C57BL/6 mice bearing syngenic CMT93 flank tumours.  CMT93 is 
a murine colorectal carcinoma. These cells form tumours which grow far more slowly than the CT26 
flank tumours in BALB/c mice.  The median survival for untreated mice bearing CMT93 tumours is 25 
days compared to 14 days for mice bearing CT26 tumours.  Thus this alternative flank model could 
be used to investigate whether the optimised regime is effective in a less aggressive cancer model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1.  Assessment of a slower growing syngeneic flank tumour model.  Four C57BL/6 mice 
were injected in their shaved right flank with 5x106 CMT93 cells in 100 μl PBS.  Mice were then 
monitor for any signs of distress and tumour volumes were regularly recorded.   Data are presented 
as mean tumour volumes in mm3 ± SEM  
0 5 10 15 20 25 30
0
200
400
600
800
Time (days)
T
u
m
o
u
r 
v
o
lu
m
e
 (
m
m
3
)
Appendix A 
150 
 
A.2.  Lewis Lung Cancer (LLC) is a suitable orthotopic model of lung cancer in 
C57BL/6 mice 
 
The final model that has been developed is an orthotopic lung cancer model using systemically 
delivered Lewis Lung Cancer (LLC) cells in C57BL/6 mice.  LLC are a very aggressively growing lung 
cancer that when delivered systemically is reliable model.  However, compared to the C57BL/6 CMT 
93 model described it is much more aggressive with mice dying from day 14 onward and none 
surviving beyond day 25 (Figure 8.4).  In this respect it is much more akin to the BALB/c CT26 model.  
Computed tomography (CT) appears to be a reasonably practical method for following the lung 
cancer progression and because it is a very aggressive model with mice unlikely to last beyond 3 
weeks the radiation dose delivered to the mice will not be therapeutic.   
 
 
 
 
 
 
(a) 
 
 
 
 
 
 
 
 
 
(b) 
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(c) 
 
 
 
 
 
 
 
 
 
Figure A.2.  LLC orthotopic lung cancer model in C57BL/6 mice.  Eight C57BL/6 mice were injected 
systemically with 5x105 LLC cells via the tail vein.  Computed tomography (CT) of the lungs was used 
to assess lung volumes of the mice at regularly intervals and the reduction in lung volume over time 
was used as a surrogate marker for tumour volume.  (a) Minimal lung disease; computed 
tomography image of a mouse's lungs ay day 7 after IV administration of LLC cells.  (b)  Extensive 
disease; computed tomography image of a mouse's lungs ay day 19 after IV administration of LLC 
cells.  (c) Tumour volume growth; data are presented as mean tumour volumes in mm3 ± SEM.  The 
first mouse died on day 14 after the tumour injection and none survived beyond day 25.  
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Appendix B  
Publications associated with this work 
B.1.  Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles  
 
Appendix B 
153 
 
 
 
 
 
 
 
Appendix B 
154 
 
 
 
 
 
 
Appendix B 
155 
 
 
 
 
 
 
Appendix B 
156 
 
 
 
 
 
Appendix B 
157 
 
 
 
 
 
Appendix B 
158 
 
 
 
 
 
Appendix B 
159 
 
 
 
 
 
Appendix B 
160 
 
 
 
 
 
Appendix B 
161 
 
 
 
 
 
 
Appendix B 
162 
 
 
 
 
 
Appendix B 
163 
 
 
 
 
 
Appendix B 
164 
 
 
 
 
 
Appendix B 
165 
 
 
 
 
 
Appendix B 
166 
 
 
